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This research aims to investigate the application of medical biotechnology with regard to the 
detection and treatment of hospital-associated infection. Various strategies focused on the 
implementation of biological detection agents and biotherapeutics are discussed, with 
particular emphasis placed on surface-anchoring technologies. This thesis is presented in the 
alternative format, consisting of published research papers embedded within the text. An 
extended introduction precedes each publication and a reflective commentary accompanies 
each research paper. For the purpose of continuity, all figure captions and references are in 
keeping with the body of the text. 
 
Part A concerns the detection of residual sources of transmissible infection, via the 
utilisation of an enzymatic detection agent, capable of modelling clinical surface 
contamination post sterilisation.  Chapter 1 details the development of a current clinical 
biosensor, focused on modification of polymeric substrates via plasma activation. Covalent 
immobilisation facilitated enhanced proteinaceous surface retention, alongside retention of 
biological activity, potentially providing a more stringent assessment of hospital sterilisation 
measures. Chapter 2 (unpublished) investigates the possibility of protein engineering for 
further development of the aforementioned biosensor. This research focuses on genetic 
modification of the detection agent and subsequent covalent conjugation to a fluorescent 
reporting system, with the intention of quantifying surface contamination in the clinical 
setting.  
 
Part B focuses on the development of potential biological therapeutics for the treatment of 
infection. Chapter 3 aims to provide the theoretical background to the proceeding research in 
the form of a review paper. Chapter 4 concerns the utilisation of surface-anchored, polymeric 
nanoparticles as delivery vectors for bacteriophage, facilitating the controlled delivery of the 
antimicrobial cargo at an elevated temperature associated with chronic wound infection. 
Chapter 5 is presented as an extension of the preceding research, detailing the use of a 
synergistic enzybiotic cocktail as oppose to bacteriophage, in an attempt to alleviate certain 
regulatory concerns.  
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Part A:   Detection of Infection 
 
“Problems are the price of progress. Don't bring me anything but trouble. Good news weakens 
me”. 
 
Charles F. Kettering – Engineer, inventor of the electrical starting motor. 
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Chapter 1: Study into the Kinetic Properties and Surface Attachment 
of a Thermostable Adenylate Kinase  
1.1 Introduction 
The aim of this research concerns the effective modelling of surface contamination within the 
clinical setting, focused on eliminating cross contamination through improperly sterilised 
surgical equipment. Despite the best efforts of clinicians and technical staff worldwide, the 
complete eradication of surface contamination, specifically proteinaceous contamination, can 
prove challenging owing to the resilient nature of certain hospital-associated infectious 
agents. This research aims to model particularly surface adherent species through utilisation 
of a thermostable enzyme, the activity of which can be monitored in order to quantify 
simulated protein contamination as a function of surface anchoring strategies. The overall 
intention being the provision of a more stringent assessment of hospital sterilisation 
measures through the development of a current clinical biosensor.  
 
1.1.1 Hospital Sterilisation Efficacy 
The importance of rigorous and efficient cleaning of reusable surgical equipment cannot be 
underestimated. The Centers for Disease Control and Prevention (CDC) has published a set of 
guidelines for the disinfection and sterilization of healthcare equipment, detailing the 
mandatory cleaning procedures required for a variety of tools and equipment 1. However, 
there are certain pathogens which are resistant to common sterilization techniques; the most 
relevant in this case being prions.  
 
Prions are exceptionally stable, extracellular misfolded proteins formed by the post-
translational modification of a normal host encoded glycoprotein into an abnormal isoform. 
Prions replicate by converting cellular proteins into the corresponding infectious conformers. 
A recent study has utilised cryomicroscopy in order to deduce the structure of the infective 
prion protein, which has eluded scientists for decades as a result of its poor solubility and 
tendency towards aggregation 2. Whilst the exact mechanism of prion replication remains 
unknown, it is believed that it is solely a conformational change in the protein that brings 
about the infectious nature of the newly formed isoform, rather than covalent modification 3.  
 
 Part A: Chapter 1  
4 
 
Prions are associated with a range of fatal, neurodegenerative diseases including Creutzfeldt-
Jacob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomnia and 
kuru. Prion diseases can be inherited or sporadic, whilst the most concerning in terms of 
transmission through accidental exposure is termed acquired or iatrogenic. The iatrogenic 
form of prion disease can be contracted through contact with infected tissue. From 1970 to 
2015, 85 such cases have been reported in the UK following procedures such as dura mater 
implants, corneal transplants and administration of human-derived growth hormone and 
human gonadotrophin 4. There have also been six cases worldwide of iatrogenic CJD 
transmission as a result of insufficient cleaning of surgical tools (neurosurgical instruments 
and depth electrodes) 5. Whilst this may seem like a low incidence rate, evaluation of clinical 
disinfection measures has demonstrated inadequacy in preventing the transmission of prion 
agents, meaning the potential threat of exposure remains a cause for concern 6. Furthermore, 
there have been a number of incidents whereby the transmission of CJD via surgical 
equipment was suspected. Whilst there have been no confirmed reports of iatrogenic 
transmission as a result of these incidents, the associated repercussions were significant. 
Entire operating theatres were shut down, patients were sent elsewhere for emergency 
surgery, ambulances were diverted and hundreds of neurosurgical patients were contacted 
and informed of the risk (albeit very low) of having contracted prion disease 7.  As a result, 
the UK Department of Health published a set of guidelines in 2012 detailing the appropriate 
measures required in order to prevent the spread of CJD within the healthcare setting, largely 
owing to the fact that conventional decontamination methods (treatment with formalin or 
ethylene oxide, autoclaving and irradiation) are ineffective 8. To date, the characteristic 
presentation of human prion disease can only be definitively confirmed post mortem via the 
identification of plaques within the brain tissue of those affected. Thus, the need to eliminate 
the risk of transmission both in terms of the unnecessary spread of infectious disease, and the 
economic and social implications associated with any potential or suspected risk of infection 
must be addressed and ultimately eliminated.  
 
1.1.2 Enzymes 
Enzymes are proteins found in abundance in living cells, capable of catalysing biochemical 
reactions. They consist of a sequence of amino acids joined in a specific order, dictated by the 
genetic code responsible for cellular enzyme synthesis, resulting in a complex protein 
structure. The nature of this amino acid sequence gives rise to unique enzymatic properties 
characteristic of the class and activity of each individual enzyme. Enzymes are classified 
according to the type of reaction they catalyse, for example transferase, cyclase, reductase, 
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oxidase etc. 9. Owing to their complex structure, enzymes are capable of exhibiting innate 
specificity for certain substrate molecules both in terms of chemo/ stereoselectively as well 
as enantiomeric and regioselective properties. The way in which this is achieved is typically 
accounted for by either; the lock and key model (first described by Fisher in 1894, detailing 
how a certain enzyme is specific for a certain substrate, which fits exactly in the enzyme’s 
active site), or by the induced fit model (stating that protein geometry changes during 
substrate binding in order to accommodate the substrate molecule) 10. As biological catalysts, 
enzymes have a complex 3D structure which results in small clefts or pockets specific for a 
certain substrate, known as the enzyme’s active site. Like all catalysts, enzymes are capable of 
increasing the rate of a reaction without being consumed in the process. This is achieved by 
the ability of the enzyme to lower the activation energy required for the formation of the 
intermediate transition state, allowing more molecules to successfully react. An enzyme does 
not affect the thermodynamics of a reaction, nor does it affect the position of equilibrium, 
that is to say the rate of reaction is enhanced in both directions. This is in agreement with the 
second law of thermodynamics as the difference in the Gibbs free energy between the 
reactants and the products is unchanged; it is solely the transition state which is affected. 
 
1.1.3 Enzyme Kinetics 
One of the most effective ways to investigate the mechanism of an enzyme-catalysed reaction 
is to establish the rate of reaction as a function of enzyme activity. This is known as enzyme 
kinetics. It concerns the rate of product formation over time as a function of enzyme and 
substrate concentration under specific, predefined conditions. By deducing how and why the 
rate of product turnover is limited by the system, it is possible to calculate key parameters 
allowing quantifiable determination of enzyme activity. 
 
1.1.3.1 The Michaelis - Menten Model 
In 1903 Victor Henri highlighted the importance of the formation of an enzyme substrate 
complex as a key step in catalysis. This idea was taken forward in 1913 by German 
biochemist Leonor Michaelis, and Canadian pathologist Maud Menten. They postulated that 
the enzyme [E] and substrate [S] combine in a reversible manner to form the enzyme 
substrate [ES] complex, which is subsequently converted into product [P]. This gave a 
generalised reaction scheme for enzyme-catalysed product formation:  
 







Scheme 1 - The enzyme-catalysed conversion of substrate into product via an intermediate 
enzyme-substrate complex. k1, k-1, k2 represent rate constants for each step. 
 
 
Note that there is no k-2 value; this results from the fact that the model takes into account the 
initial rate of reaction, therefore in the absence of any significant amount of product, it can be 
assumed that there is no reversal from product to the enzyme substrate complex. In order to 
mathematically describe the changes occurring in an enzyme-catalysed reaction it is 





 = - k1 [E][S]+ k-1[ES] + k2[ES]   (1) 
𝑑[S]
𝑑𝑡








 = k2[ES]      (4) 
 
The law of conservation must then be applied, relating enzyme activity to general catalysis, 
implying that the overall enzyme concentration does not change (i.e. the catalyst is not used 
up during the reaction). Rather, it exists in two forms; as free enzyme and enzyme bound to 
substrate in the intermediate complex: 
 
                                                                                                                                                 
                                                                                                                                                       (5)      
 
Michaelis and Menten applied the assumption that the enzyme substrate complex exists in 
rapid equilibrium with the free enzyme and substrate 11. This holds true provided that k2 is 
[E
0
] = [E] + [ES] 
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much smaller than k-1, such that a thermodynamic equilibrium exists whereby the 
concentration of the enzyme substrate complex is not perturbed to a significant extent via 
breakdown (through k2) to release product.  
 
                 k1 [E][S] = k-1 [ES]                                                             (6) 
 
Hence, equation (3) then simplifies to: 
 
        
𝑑[ES]
𝑑𝑡
 = k1 [E][S]- k-1[ES] 
 
Combining the law of conservation (5) with the equilibrium approximation (6) provides a 





 = k1 [(E0) – (ES)][S]- k-1[ES] 
 
 
Solving for [ES]:                                                    






The rate of product formation is reliant upon k2 as shown in equation (4), thus combining (4) 
and (9):  
 


































This is commonly referred to as the Michaelis constant and is effectively an equilibrium 
constant for the enzyme substrate complex. Often, it is used as a measure of the affinity an 
enzyme has for its substrate as it describes the dissociation of substrate from enzyme. A 
higher KM value indicates a lower affinity for substrate (weak binding), whereas a low KM 
value indicates tight binding.  
 




Vmax = k2 [E0] 
 
Vmax refers to the point at which all enzyme molecules are bound as enzyme substrate 
complex. This correlates to the maximum velocity possible under any given set of conditions. 
It is a theoretical value rarely seen in experimental data but can be found via various 
graphing and software techniques. Equation 13 is a fundamental equation, derived according 
to a specific set of assumptions outlined by scientists at the turn of the 20th century (which is 
still very much in use today), in order to calculate key parameters relating enzyme activity to 
a wide range of reaction conditions. 
 
1.1.3.2 The Briggs - Haldane Model  
One of the major limitations of the Michaelis-Menten model is the assumption that k2<<k-1. 
This is not the case for a number of enzymes. Indeed, there are cases where k2>k-1 and where 
k2 and k-1 are comparable. In cases such as these it is impossible to omit k2 from the 
differential, thereby changing the meaning of KM. This is not to say that the model is rendered 
invalid, rather it just prevents KM being considered dissociation constant or a measure of 
substrate affinity. However in 1925 George Edward Briggs and John Burdon Sanderson 
 (12) 
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Haldane provided an alteration to the standard Michaelis-Menten model in a publication 
entitled ‘A Note on the Kinetics of Enzyme Action’ 12. Rather than making assumptions based 
on the nature of the rate constants, they derived a complementary model in which they 
describe the enzyme substrate complex as being in a ‘steady state’. This term assumes that 
the concentration of the enzyme substrate complex does not change; the rate of formation is 
equal to the rate of breakdown 13. This can be expressed as: 
 
k1 [E][S] = k-1 [ES]+k2[ES] 
 
Combining the law of conservation (5) with the new steady state assumption (14) gives rise 





  = k1 [(E0) – (ES)][S]- k-1[ES] – k2[ES]              
 
          = k1 [(E0) – (ES)][S]- (k-1 + k2)[ES]                
 
          = k1 (E0) – (k1[S] + k-1 + k2)[ES]                   
 
Solving for [ES]:                                                  
[ES] =  
𝑘1[E0] [S] 




The rate of product formation remains reliant upon k2 as shown in equation (4), thus 
combining (4) and (18):  
 
𝑣 =  
𝑘1[E0] [S] 𝑘2





























Where:                                                             





This combination of rate laws is often still referred to as the Michaelis-Menten constant 
despite the fact that it is actually a deviation from the model first put forward by Michaelis 
and Menten in 1913. It can be seen from this equation that KM can only be considered equal to 
the dissociation constant of the enzyme substrate complex when k2<<k-1 (i.e. only when the 
equilibrium approximation becomes the limiting case of the steady state assumption). 
Despite the change in derivation, the overall rate equation looks exactly the same with the 
sole exception of a change in meaning of KM: 
  
 





  Vmax = k2 [E0] 
 
The Briggs-Haldane model is now widely accepted as a general rate law for simple one 
substrate enzyme kinetics, whilst the Michaelis-Menten model is associated with cases where 
there are clear measureable differences in rate constants (k-1 and k2). An additional case has 
been put forward by Van Slyke and Cullen which invokes the converse assumption that 
k1<<k2. Following the previous derivations, this produces a KM value equal to k2/k1, however 
this is only applicable in certain cases 14. 
 
1.1.3.3 Multisubstrate Reactions  
Both the Michaelis-Menten and the Briggs-Haldane models accounts for simple, uninhibited, 
one substrate binding enzyme kinetics. However, many enzymes bind more than one 
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substrate often resulting in the release of more than one product. There are three key models 
that describe the kinetic behaviour of such enzymes; random sequential, ordered sequential 
and the ping pong mechanism (the former being of particular importance to this research) 15. 
The process whereby an enzyme binds to more than one substrate without any organised 

















When considering the rate equation for a random bi bi sequential mechanism, the system 
becomes much more complex. Alongside the maximum velocities (Vmax) for the overall 
forward and reverse reactions, each reversible step has its own Michaelis-Menten constant 
associated with it (KMA, KMB, KMC, KMP, KMQ).  Unlike single substrate reactions, a reaction 
involving two substrates will proceed via an intermediate transitory complex prior to 
formation of the enzyme substrate complex. Therefore the initial binding of substrate A can 
be characterised by a pure dissociation constant. This differs from the Michaelis-Menten 
constant for substrate A and so is referred to as KD. The entire rate equation is shown in 
equation 22, where Ke is the equilibrium constant for the overall reaction.  
 
 
𝑣 =  
𝑉1 𝑉2 ([𝐴][𝐵] – 
[𝑃][𝑄]
𝐾𝑒  )
𝐾𝐷𝐴𝐾𝑀𝐵𝑉2  +  𝐾𝑀𝐵𝑉2[𝐴] + 𝐾𝑀𝐴𝑉2[𝐵] +
𝐾𝑀𝑄𝑉1[𝑃]
𝐾𝑒
 +  
𝐾𝑀𝑃𝑉1[𝑄 ]
𝐾𝑒
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Whilst a rate equation such as the one above may initially appear complex and extensive, it 
may be simplified by applying certain assumptions and limitations to the system. If the rapid 
equilibrium assumption is made, so that the breakdown of the ternary complex (EAB.EPQ) is 
slower than the return to the reactants, the V2 and product terms may be omitted from the 
equation. Secondly, if the rate of formation of the ternary complex is not limited by substrate 
concentration and only initial velocities are considered, the overall rate equation simplifies to 
simple one substrate Michaelis-Menten kinetics.  
 
1.1.3.4 Sigmoidal Kinetics  
In some cases a typical rate vs. substrate concentration graph for an enzyme-catalysed 
reaction will display a sigmoidal curve (as opposed to the predicted hyperbolic curve). A 
possible explanation for this type of behaviour relates to cooperativity. True cooperativity is 
defined as a reflection of the equilibrium binding of substrates to both the free enzyme and 
the enzyme substrate complex. It is characterised by a change in binding affinity of one 
substrate as a direct consequence of the binding of another 17. This can be a positive effect 
(the binding of one substrate increasing the affinity for the second substrate), or a negative 
effect (the affinity for the second substrate is decreased as a result of the binding of the first 
substrate). An extension of the Michaelis-Menten model aimed at expressing the concept of 
cooperativity was presented by Archibald Hill in 1910 18; his modification to the standard 
model is presented in equation (23), where n is the Hill constant: 
 
 






It should be noted that the Hill constant does not directly correspond to the number of 
substrate binding sites within an enzyme; rather, it is a measure of the degree of 
cooperativity, often calculated as a non-integer value 19. Whilst the Hill equation has been 
widely used in order to model cooperativity in enzymatic systems (its use has been reviewed 
elsewhere 20), there are certain limitations associated with its use. Owing to its derivation, the 
Hill equation does not provide a physically realistic reaction scheme, as it is limited 
predominantly to modelling positive cooperativity and hence is only linear over a restricted 
range of substrate concentrations 21,22. Nonetheless, sigmoidal response curves are often 
successfully fitted to the Hill equation (provided no further information is required regarding 
reaction mechanism).  
(23) 
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A second possible explanation for the appearance of sigmoidal kinetics arises as a result of a 
multisubstrate reaction involving two or more of the same substrate. A two substrate, 
enzyme-catalysed reaction, following a random binding sequence can display sigmoidal 
kinetics without exhibiting true cooperativity. This occurs when the formation of the 
intermediate containing both substrates (EAB) is formed faster than the individual binding of 
the second substrate (EB). Meaning the affinity of the initial enzyme substrate complex (EA) 
for the second substrate (B) is greater than the affinity of the free enzyme (E). This results in 
a ‘switching on’ of the sigmoidal part of the graph; initially the reaction proceeds via the 
standard binding mechanism, until the concentration of (EA) builds up to such an extent that 
the velocity of the reaction increases, owing to an increase in affinity for the second substrate 
(B) 23.  
 
1.1.4 Enzyme Inhibition 
The activity of an enzyme may be inhibited by a number of factors owing to the sensitivity of 
enzymes to external reaction conditions, such as temperature, ionic strength and pH, 
alongside specific molecules capable of interrupting enzyme activity. There are two distinct 
classes of enzyme inhibitor: reversible and irreversible 24. Irreversible inhibitors covalently 
and irreversibly modify part of the enzyme (usually the active site) via the formation of 
adducts, rendering the enzyme permanently inactive. This is not to be confused with enzyme 
inactivation, which involves the destruction of protein structure as a result of changes in 
temperature or pH. Reversible inhibition may include competitive, non-competitive and 
uncompetitive inhibition, all of which have been discussed extensively elsewhere 25.  
However, a noteworthy form of inhibition surrounds the ability of a participating substrate 
(or an enzyme-catalysed product) to affect the overall rate of reaction. 
 
Substrate inhibition is often considered a strange phenomenon. However, there appears to be 
some highly significant biological reasoning behind its existence. Enzymes are often found to 
be inhibited by their own substrate, although it is a common misconception that this arises 
from “using artificially high substrate concentration in a laboratory setting” as pointed out by 
Reed et al 26. In fact, the ability of substrate molecules to regulate enzyme activity may arise 
as a result of specially evolved biochemical behaviour, tailored toward metabolic/ signalling 
control mechanisms. In terms of kinetic analysis, substrate inhibition is characterised by a 
sudden decline in the rate of reaction after a certain substrate concentration has been 
reached.   
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Another important biochemical control mechanism is the ability of an enzyme-catalysed 
product to inhibit further enzyme activity via a negative feedback loop. This kind of inhibition 
can also play a crucial role in metabolic and signalling pathways, an example of which is 
exhibited by the enzyme aspartate kinase 27. Kinetically, this type of inhibition also presents 
itself as a decrease in the rate of reaction at a specific substrate concentration. However, 
unlike substrate inhibition, product inhibition can be overcome by a drastic increase in 
substrate concentration. This occurs as the substrate can eventually out-compete the 
inhibitor (the product) at high concentrations. 
 
1.1.5 Enzymes as Biosensors  
Immobilisation is an effective way to exploit the catalytic properties of certain enzymes, not 
only does it allow the recovery of the enzyme, it also allows separation from the products 
and/or reactants. Enzymes may be immobilised according to a number of different strategies 
including covalent attachment, bio-affinity binding, crosslinking and encapsulation. The pros 
and cons of each method have been discussed elsewhere 28. The potential to exploit the 
specificity of biological catalysts has driven the development of enzyme-based biosensors for 
a range of applications from health care to agriculture 29.  
 
1.1.5.1 Adenylate Kinase 
The enzyme adenylate kinase (AK) is a phosphotransferase enzyme which catalyses the 
reversible formation of adenosine diphosphate (ADP) from adenosine triphosphate (ATP) 




Scheme 2 – Adenylate kinase catalysed ADP formation.  
 
ATP is considered the main form of cellular energy, therefore this interconversion of 
nucleoside phosphates is essential for sustaining life. By exploiting the necessity for all forms 
of life to carry this enzyme, AK has been widely used in the detection and monitoring of 
surface contamination. An interesting development in the utilisation of AK as a biomarker for 
surface contamination involves evaluating bacterial presence in the hygiene industry 30. ATP 
ATP      +      AMP                                   2ADP 
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production can be monitored via a coupled system using a secondary enzyme, luciferase and 
its substrate luciferin (D-LH2). The mechanism of which is shown in Scheme 3 31. 
 





Scheme 3 – Luciferase-catalysed bioluminescent formation of oxyluciferin from luciferin (D-
LH2) and ATP, resulting in the emission of a photon from the singlet excited state. 
 
 
The decay from the singlet excited state of oxyluciferin back to the ground state is 
responsible for the observed emission of light in the form of bioluminescence, although there 
has been a number of conflicting theories regarding which tautomer (keto or enol) is 
responsible 32. However, a theoretical study conducted by Song et al 33, using molecular 
dynamics and quantum-mechanics/molecular-mechanics methods, under conditions 
mimicking the physiological excited state (oxyluciferin bound to luciferase), has shown that 
the keto to enol isomerisation is unlikely to occur within the lifetime of the excited species. 
They also suggested that the acquisition of a proton from a neighbouring lysine side chain (in 
order to facilitate tautomerisation) is unlikely owing to the potential charge stabilization 
offered by surrounding water and/or protein groups. Thus, they argue that the keto tautomer 
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is likely the emitting species. Regardless of the exact reaction pathway, as a result of this 
process it is possible to quantitatively correlate light output to ATP concentration. This has 
been exploited in the food processing industry by the chemically driven lysis of potential 
microbial contaminants. This results in the release of microbial AK, which is then exposed to 
its substrate (ADP) and coupled to the luciferase/ luciferin system. It is then possible to 
quantify the number of microbial cells present via evaluation of ATP turnover 30.  
 
1.1.5.2 Thermostable Adenylate Kinase 
Thermostable enzymes have been employed in a number of new and novel technologies, 
largely owing to the fact that many other enzymes will denature (lose their structural 
integrity rendering them inactive), at relatively low temperatures. The isolation and 
purification of a thermostable AK (tAK) from the archaebacterium Sulfolobus acidocaldarius 
(S. acidocaldarius) in 1993, paved the way for the significant development of surface 
contamination detection within the healthcare setting 34. The archaebacterium from which 
tAK is isolated is an extremophile found growing in volcanic springs at temperatures between 
75 – 80 °C. The corresponding tAK isolated from this thermophile exhibits a temperature 
optimum of around 90 °C and is stable to very low pH 35. It exists as a 69 kDa trimer with 
highly conserved nucleotide binding sites. Figure 2 shows the crystal structure of tAK (PDB 












Figure 2 Crystallographic ribbon plot of two AK trimers isolated from S. acidocaldarius. 
 
tAK catalyses a multisubstrate, multiproduct reaction in a random bi bi sequential fashion, as 
previously described in Section 1.1.2.3 37.  The reaction scheme specific to AK can be seen in 
Figure 3 38.  




Figure 3 Random bi bi sequential reaction scheme for AK. 
 
However, as previously mentioned when looking at the kinetics of such a system, they can 
simplify to the one substrate, Michaelis-Menten model provided that certain limitations are 
established.  
 
1.1.5.3  WASHtAK 
The novelty of tAK surrounds its ability to withstand extreme conditions, rather than the 
specific reaction it catalyses. tAK is currently used in the clinical setting as a model for highly 
surface adherent species commonly associated with surface contamination. Owing to the 
highly resilient nature of tAK, it can be used to model the cleaning efficacy of reusable 
surgical equipment post disinfection. Alongside tAK, there are other protein-based structures 
which are also resistant to high temperatures and low pH (two common methods of 
disinfection within hospitals) 39. An example of which are prions; protease resistant, 
transmissible glycoproteins responsible for a range of transmissible spongiform 
encephalopathies (as discussed in Section 1.1.1) 40. tAK is employed in the clinical setting as 
WASHtAK, patented by BIOtAK® 41. The technology behind this device is detailed in a paper 
entitled “Quantitative measurement of the efficacy of protein removal by cleaning 
formulations; comparative evaluation of prion-directed cleaning chemistries”, which 
highlights how protein removal is modelled by tAK as an indicator of cleaning efficiency 42. 















E •  MgATP
E •  AMP
E •  MgADP
E •  ADP
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WASHtAK comprises of a polymer based support with tAK physisorbed to its surface. It is 
placed into the clinical disinfection washer alongside any surgical equipment to be sterilised. 
Post washing, it is removed and exposed to its substrate, ADP. Any ATP produced is detected 
using the luciferase based coupling system. Light emitted post wash cycle correlates directly 
to the amount of tAK remaining on the stick, indicating the efficacy of sterilisation of the 
surrounding surgical equipment 43.  
 
1.2 Extended Methodology 
1.2.1 Plasma Polymerisation 
The use of plasma technology for the modification of surfaces has been extensively reviewed 
and employed in recent years 44-46. Plasma technology including etching, deposition and 
polymerisation are currently utilised for a variety of applications including within the 
medical, automotive, aeronautical and environmental sectors 47-50. Plasma is capable of both 
removing and depositing material onto a surface, which offers the possibility of custom 
surface design suited to specific requirements, including sterilised platforms for use in 
medical devices, functionalised surfaces for biomolecule immobilisation (e.g. for use in 
biosensors), activated surfaces for electrochemical applications (such as supercapacitors) 
and plasma polymerised thin films for use as coatings (protective, anti-reflective, drug 
release etc.) 51-58. 
 
Plasma discharge polymerisation involves the generation of high energy chemical species 
(ions, electrons and radicals), both in the solid and the gas phase via application of an 
external electric field, which combine to form stable covalent linkages. Polymerisation occurs 
as a result of chemical reactions within the energetic plasma species; between the plasma and 
the surface and between the surface active groups to form large, complex polymeric units. 
Figure 4 WASHtAK. Copyright ©2017 BIOtAK Ltd. 
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Poly-recombination of the previously generated excited species may occur in the solid or the 
gas phase. Whilst low pressure plasma systems favour polymerisation in the solid phase (i.e. 
at the surface, owing to the low collision rate in the gas phase), increasing the pressure 
encourages polymer formation in the gas phase 59. The difference in properties of the 
resultant polymer films can be substantial, a detailed study of which has been carried out by 
Saboohi et al 60.  Regardless of their difference in physical and chemical characteristics, these 
newly generated polymeric architectures should not be confused with conventional polymers 
(consisting of repeat monomer units). Plasma polymerised structures often consist of 
fragmented and rearranged monomers with a high degree of branching and crosslinking 





Plasma polymerisation offers a number of advantages over conventional surface modification 
methods: it can be achieved at ambient temperature (cold plasma – not in thermal 
equilibrium), it is a solvent free process (which has the advantage of facilitating subsequent 
biomolecule immobilisation) and the deposition is largely a controllable process. Parameters 
associated with the generation of plasma, such as pressure, excitation method, excitation 
source, flow rate and reactor geometry can be tailored in order to achieve the desired 
properties of the polymer 63.  
 
Figure 5 Schematic showing the difference between a conventional polymer and a plasma 
polymer comprised of the same starting material. Reprinted from 61 with permission from 
Elsevier, Copyright ©2016. 
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1.2.2 Bioluminescence  
Luminescence concerns the emission of light in the absence of thermal radiation, i.e. as a 
consequence of anything other than heat (as oppose to incandescence). This term 
encompasses phenomenon including photoluminescence, chemiluminescence, 
radioluminescence and bioluminescence. Bioluminescence, first formally observed by 
Aristotle ca. 300 BC, occurs within a living organism, resulting in the emission of light from an 
electronically or vibrationally excited species 64,65. Biocatalysis of a chemical reaction is often 
an exothermic process, whereby the excess energy is retained within the system and 
converted from chemical potential energy into electronic excitation energy, rather than being 
released as heat (as with exergonic reactions). This gives rise to the transition of a reaction 
intermediate into the excited state. The subsequent relaxation to the ground state proceeds 
in the same manner as fluorescence and other forms of photoluminescence (excluding 
phosphorescence) 66. Bioluminescent emission of light is very efficient, often exhibiting high 
quantum yields and therefore high emission intensities. The firefly luciferase/ luciferin 
system is one of the most efficient (relative to other forms of bioluminescence), with a 
quantum yield of 41 ± 7.4% at pH 8.5 67. The process of bioluminescence can be monitored 
using a luminometer which has several advantages over other analytical techniques.  
Luminometry is far more sensitive than both adsorption and fluorescence spectroscopy, and 
is capable in many cases of measuring femtomole quantities. Luminescent light from chemi- 
or bioluminescence is monochromatic, it is emitted as a result of a single reaction, therefore 
wavelength selectors/ filters are not required. There is also a much smaller background light 
contribution in luminometry and samples can be measured over a vast concentration range 
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A thermostable adenylate kinase (tAK) has been used as model protein contaminant on 
surfaces, so used because residual protein after high temperature wash steps can be detected 
at extremely low concentrations. This gives the potential for accurate, quantitative 
measurement of the effectiveness of different wash processes in removing protein 
contamination. Current methods utilise non-covalent (physisorption) of tAK to surfaces, but 
this can be relatively easily removed. In this study, the covalent binding of tAK to surfaces 
was studied to provide an alternative model for surface contamination. Kinetic analysis 
showed that the efficiency of the enzyme expressed as the catalytic rate over the Michaelis 
constant (kcat/KM) increased from 8.45 ± 3.04 mM-1 s-1 in solution to 32.23 ± 3.20 or 24.46 ± 
4.41 mM-1 s-1 when the enzyme was immobilised onto polypropylene or plasma activated 
polypropylene respectively. Maleic anhydride plasma activated polypropylene showed 
potential to provide a more robust challenge for washing processes as it retained significantly 
higher amounts of tAK enzyme than polypropylene in simple washing experiments. Inhibition 
of the coupled enzyme (luciferase/luciferin) system used for the detection of adenylate 
kinase activity was observed for a secondary product of the reaction. This needs to be taken 
into consideration when using the assay to estimate cleaning efficacy.  
 
Keywords: Thermostable Adenylate Kinase, Kinetic Parameters, Plasma Deposition, Cleaning 
Efficacy, Enzyme Inhibition. 
 
 





Efficient modelling of protein attachment to surfaces has generated wide interest within the 
scientific community over the years, largely owed to the significant number of implications 
this phenomenon is responsible for. Perhaps one of the most clinically relevant implications 
is the residual protein contamination of surgical equipment post cleaning and disinfection. 
Equipment such as endoscopes and other reusable tools are subject to vigorous disinfection 
cycles within the clinic; however, there are certain biological species which are resistant to 
such cleaning processes. An example of which are prions, protease resistant, transmissible 
glycoproteins responsible for a range of transmissible spongiform encephalopathies 
including Creutzfeldt-Jacob disease (CJD) 40. Therefore evaluation of proteinaceous surface 
contamination has become paramount in preventing the spread of disease within the 
healthcare setting. This has led to specific review and revision of processes for cleaning 
surgical instruments in the health service in England 69. A current clinical model aimed at 
quantifying residual protein presence post disinfection utilises a thermostable adenylate 
kinase (tAK) enzyme, so used due to the resilient nature of the enzyme drawing potential 
comparison to equally resilient species such as prions.  
 
The enzyme adenylate kinase (AK) is a phosphotransferase enzyme which catalyses the 
reversible formation of adenosine triphosphate (ATP) and adenosine monophosphate (AMP) 











Scheme 4 tAK catalysed ATP formation. 
 
The isolation and purification of a thermostable AK (tAK) from the archaebacterium 
Sulfolobus acidocaldarius in 1993, paved the way for the significant development of 
proteinaceous surface contamination detection within the healthcare setting 34. The 
ATP AMP 2ADP + 
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archaebacterium from which tAK is isolated is an extremophile found growing in volcanic 
springs in temperatures between 75 – 80 °C. The corresponding tAK isolated from this 
thermophile demonstrates a temperature optimum of around 90 °C and is stable to very low 
pH 35. The novelty of tAK lies with its ability to withstand extreme conditions, tAK is currently 
in use in the clinical setting (WASHtAK 41) as a model for highly surface adherent species 
commonly associated with residual surface contamination. The technology behind this device 
is detailed in a previous paper, which highlights that protein removal is modelled by tAK as 
an indicator of cleaning efficiency 42. Briefly, in this system tAK is physisorbed to a 
polypropylene strip and is placed into a surgical equipment washer to undergo the standard 
disinfection cycle that reusable surgical equipment is subject to. Post wash cycle the 
polypropylene strip is removed and the residual tAK is exposed to its substrate (ADP) which 
is then converted to ATP. Subsequently the ATP concentration is measured via a well-known 
coupled enzymatic reaction involving a standard preparation of luciferase and its substrate 
luciferin. This assay has been extensively optimised over the years in order to accurately 
determine ATP concentration as a function of light output 70. Ultimately the system relies on 
the excitation of luciferin to a higher energy level using ATP, the decay from this excited state 
to the ground state then leads to the generation of light in the form of bioluminescence. The 
full mechanism of bioluminescence emission from the luciferase/ luciferin assay has been 
published elsewhere 31. 
 
Previous studies on AK isolated from Sulfolobus acidocaldarius (in conjunction with the 
luciferase method of quantification) have been largely studied at high temperatures close to 
the optimum. One such study conducted at 70 °C reported a KM value of 0.7 mM with ADP as 
the substrate in the presence of 5 mM MgCl 34. The study also reported a kcat/KM (catalytic 
capacity) value of 2.8 x105 M-1 s-1 based on a calculated theoretical Vmax value.  The kinetic 
properties of this specific AK at 25 °C, which would be the case where it used for daily 
monitoring of cleaning efficacy, are absent in the literature both in solution and bound to 
surfaces. As such there is no direct comparison or evaluation of the effect on activity when 
the enzyme is restricted to a solid support, such as it is in its current clinical application.  
 
There are a number of ways in which proteins can bind to surfaces, both the prevention and 
promotion of such a phenomenon has been vastly studied highlighting the effects of protein 
conformation/ orientation, hydrophobicity/hydrophilicity, electrostatic nature of the 
support, binding temperature/ pH and the structural stability of the protein in question 71,72. 
The prevention of protein attachment to surfaces is of particular importance when 
considering the anti-fouling properties of a range of materials including, but not limited to 
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biosensors, surgical equipment/ medical devices, food containment and industrial 
equipment, the significance of which has been  reviewed elsewhere 73.  
 
Plasma activated materials have generated considerable interest in terms of functionalising 
solid supports to promote protein attachment to surfaces, and this may be useful if one 
wishes to accurately model the removal of tightly adhered proteins, including prions. The 
highly energized state of plasma has the potential to modify the outermost layer of a polymer 
surface by deposition of various functional groups. The successfully deposited functional 
groups (which can vary from amines to carboxyl groups depending on the monomer used), 
can then go on to react with a variety of species which would otherwise remain unreactive 
towards the inert polymer support. Not only does plasma deposition provide a 
predominantly solvent free alternative to wet chemistry, which in turn reduces the amount of 
chemical waste, it is also a largely ‘controllable’ process, meaning surface modification can be 
achieved homogeneously with the final composition tailored towards the intended 
application 74. Numerous biomolecules have been successfully anchored onto polymer 
supports following plasma activation of the surface, many of which have been reviewed 
elsewhere 63. Plasma activation of surfaces to improve coating has been used on a large scale 
in the automotive industry, and this suggests that such processes should be scaleable if 
required for high volume applications. 
 
One of the main concerns when considering the possibility of utilising surface bound proteins 
is the apparent loss of activity when restricting biologically active species to a solid support. 
Random attachment (disregarding the orientation of the protein) can often result in the 
modification of critical resides within the protein structure, which can directly affect the 
overall stability of the complex. This in turn can have repercussions in terms of accessibility 
of the protein in question, often as a result of steric hindrance affecting access to particular 
biologically active sites within the protein structure. One must also consider the impact of 
utilising potentially charged functional groups (such as those commonly found in lysine and 
aspartic acid residues), the masking or complete removal of such a charge can have 
detrimental effects in terms of protein stability 75. An advantage of using a thermostable 
adenylate kinase which is largely resistant to extreme pH, is the resilient nature of the 
protein itself, tAK is essentially a stable protein, reducing its capacity to denature when 
anchored to a solid support, thus increasing the ways in which immobilisation can be carried 
out.  
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To date, there have been no studies carried out evaluating the kinetic behaviour of tAK and 
the subsequent coupled luciferase system when considering surface binding. This report aims 
to detail the catalytic activity and surface binding properties of tAK when immobilised onto a 
solid support, with the intention of potentially providing a more robust challenge for use in 
cleaning process validation and modelling. .  
 




tAK was obtained from the Technology Development Group, Public Heath England (PHE - 
Salisbury UK). Its isolation, expression in Escherichia coli and purification has been detailed 
previously 42,43. Mucin from porcine stomach was purchased from Sigma-Aldrich (Poole, 
Dorset, UK). ATP Reagent (luciferase/ luciferin/ divalent metal ions and stabilisers), Diluent 
C (reconstitution solution for ATP Reagent), tris-EDTA buffer, ADP and ATP standard 
solutions were all purchased from BioThema (Sweden).  
 
AMP, ethanol, maleic anhydride and preformed phosphate buffered saline (PBS) tablets (pH 




Generation of an ATP Standard Curve 
 
ATP standard solutions were prepared via serial dilution from stock (0.01 mM) to give a 
range of concentrations from 1 x10-3 mM to 1 x10-8 mM, diluted in tris-EDTA buffer. 100 µl of 
ATP standard was added to each well of a white 96 well polystyrene microtitre plate. 
Luminescence output was recorded for 3 s using the bioluminescence module on a BMG 
Labtech Spectrastar plate reader. ATP Reagent (standard preparation of luciferase, luciferin, 
magnesium ions and stabilisers) was prepared via reconstitution with Diluent C at room 
temperature, 30 µl was injected after 3 s using the inbuilt injector system. Luminescence 
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tAK in Solution 
 
ADP standard solutions were prepared via serial dilution from stock (0.2 mM) to give a range 
of concentrations from 0.1 mM to 0.0016 mM, diluted in tris-EDTA buffer. An 8 ng/µl tAK 
standard solution was serial diluted from stock (2.32 µg/µl) using a solvent system consisting 
of 80% water, 20% ethanol and 0.1% hog mucin to give a range of tAK concentrations – 4, 2,  
1, 0.5 ng/µl 43,76. 100 µl of ADP standard was added to each well of a white 96 well 
polystyrene microtitre plate.  ATP Reagent was prepared as before and a 2 component 
injection system was used; 10 µl tAK and 30 µl ATP Reagent were mixed and luminescence 
output was monitored for 5 s prior to injection and continued for a further 55 s at 25 °C post 
injection. This was performed in triplicate for each enzyme concentration.  
 
Adsorption of tAK to Polypropylene Surface 
 
A 0.8 ng/µl tAK standard solution was serial diluted from stock as before to give the same 
range of tAK concentrations. 50 µl of tAK was added to each well of a white 96 well 
polypropylene microtitre plate. This was allowed to dry down at 37°C for 2 h with agitation. 
30 µl ATP Reagent was then added to each well. ADP standard solutions were prepared via 
serial dilution from stock to give the same range of concentrations diluted in tris-EDTA 
buffer. Luminescence output was recorded for 5 s prior to the injection of 100 µl ADP and 
continued for a further 55 s post injection at 25 °C. This was repeated in triplicate for each 
concentration of enzyme with each concentration of ADP.   
 
Plasma Activation of Polypropylene Surface 
 
Plasma deposition was carried out using a plasma reactor unique to the research group as 
previously detailed 77. White 96 well polypropylene microtitre plates were placed inside the 
plasma reactor chamber; 0.1 g maleic anhydride was added to the Young’s flask, before being 
reduced to 10-3 mbar pressure. The flask then underwent three freeze thaw cycles using 
liquid nitrogen in order to remove any water. The plasma was ignited and pulsed at a duty 
cycle of 1 s (on) / 40 ms (off) with a peak power of 40 W input for 10 min. tAK was added  to 
the plasma deposited maleic anhydride microtitre plates immediately after deposition (at 37 
°C with agitation for 2 h). Successful deposition was confirmed with Fourier-Transform 
Infrared Spectroscopy (FT-IR) (Figure 1 Supplementary Information). A peak at 1788 cm-1 
represents the carbonyl stretching frequency of the newly deposited anhydride moieties.  It is 
likely that the primary amines found in a number of amino acid residues within tAK can go on 
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to react with the anhydride ring retained within the deposited maleic anhydride present on 
the modified polymer surface 77. A potential mechanism for the reaction of tAK with plasma 




Inhibition experiments were undertaken using AMP and luciferase. A concentration of             
1 x10-5 mM ATP was chosen based on previous experiments as this concentration of ATP 
produces light output in the mid-range of the experimental setup. The AMP concentration 
was varied from 1 mM to 1 x 10-4 mM. 100 µl of each ATP/AMP solution was added to each 
well of a white 96 well polypropylene microtitre plate, luminescence output was monitored 
for 5 s prior to the injection of 30 µl of ATP Reagent. The reaction was further monitored for 
55 s at 25 °C, and again performed in triplicate.  
 
Washing Experiments  
 
Washing experiments were performed after immobilisation of tAK by pipetting 100 µl of 
either water or PBS buffer into each well followed by manual swirling of the plate before 
removal via pipette. This was repeated three times for each well.  
 
Figure 6 Putative reaction scheme showing the reaction between plasma deposited maleic 
anhydride on polypropylene with tAK. 
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A standard curve was produced in order to quantify the initial rate of reaction of subsequent 
tAK experiments to ATP concentration for use in kinetic parameter calculations. The 
standard curve is shown in Figure 7 demonstrating a linear correlation between light output 
and ATP concentration. From this graph it was possible to relate ATP concentration to the 
rate of light production when considering the enzyme-catalysed formation of ATP. 
 
 
The kinetic properties of the tAK enzyme as evaluated following physical adsorption 
onto polypropylene 
 
Different concentrations of tAK were immobilised under standard conditions (80% water, 
20% ethanol, 0.1% mucin, reacted for 2 h at 37 °C with agitation) Data is shown as relative 
light units (Figure 8). The initial rate of reaction was calculated between 5 and 15 s by means 
of tangents and plotted as a function of ADP concentration, as shown in Figure 9. 


























Equation y = a + b*
Adj. R-Square 0.9999
Value Standard Error
B Intercept 9.08212 0.02784
B Slope 0.97624 0.00776
Figure 7 ATP standard curve used to correlate light output to ATP concentration in 
tAK experiments.  
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 Figure 9 Comparison of initial rate of reaction (RLU s-1) when using a high tAK concentration 
(A) and for lower tAK concentrations (B) adsorbed to polypropylene. Tangents were fitted 
according to a linear fit function within Origin graphing software between 5 and 15 s. 








  5ng tAK





Figure 8 Luminescence output (RLU) plotted as a function of tAK concentration over time. 
This figure shows the reaction of tAK adsorbed to polypropylene using a substrate 
concentration of 0.1 mM ADP. Data is shown as Relative Light Units (RLU) with error bars 
representing standard deviation. The data is an average of at least three independent repeats. 
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Table 1 Summary of the fitting values and the standard error for 20, 10 and 5 ng of tAK from 




A curious observation is the apparent drop in initial rate at a concentration of 0.05 mM ADP 
when using the highest concentration of tAK (40 ng). A possible explanation for this could be 
product inhibition, which is outcompeted at high substrate concentrations. This trend was 
not seen when lowering the concentration of tAK. The curves were fitted to the Hill equation 
(1), using a non-linear curve fit function generated within Origin graphing software, the 
fitting values for Figure 9B are shown in Table 1.  The Hill equation is a slight modification of 
the traditional Michaelis-Menten equation, allowing for a certain degree of cooperativity 
(represented by the n value) in a multi-substrate reaction. tAK binds two molecules of ADP in 
a random bi bi sequential fashion 37, meaning there is an increased likelihood of cooperativity. 
This phenomenon is also predicted due to the sigmoidal nature of curve.  
 
𝑣 =  
𝑉𝑚𝑎𝑥 [S]
𝑛
𝐾 +  [S]𝑛
 
 
The Michaelis-Menten equation (2) was employed in order to quantify enzyme activity, which 
normally accounts for simple one substrate binding kinetics, however random sequential 
kinetics will simplify to the Michealis-Menten model provided that k2<<k-1, which has been 
confirmed as being the case for AK 78, whereby the dissociation of bound nucleotides has 
been shown to be the rate limiting step. Vmax values were obtained via extrapolation and 
again produced using Origin graphing software, they were then compared with the standard 
curve in order to quantify maximum rate of reaction in terms of moles per litre per second of 
ATP produced. kcat values were then calculated based on the molecular weight of tAK (69 
kDa). 
tAK (ng) Adjusted R-Squared 
Value 
Vmax (RLU s-1) KM (mM) n value 
20 0.942 7420.79 ± 4355.85 0.028 ± 0.020 1.60 ± 0.63 
10 0.939 3619.22 ± 1371.42 0.023 ± 0.011 1.97 ± 0.94 
5 0.998 2024.45 ± 147.18 0.027 ± 0.003 1.73 ± 0.21 
(1) 









 tAK Bound to Plasma Deposited Maleic Anhydride on Polypropylene 
 
In an attempt to increase the binding and retention of tAK to polypropylene, maleic 
anhydride was coated using a plasma deposition method. Deposition was carried out under 
conditions previously optimised for maximum surface retention of functional groups 79. Initial 
rate data for 40 ng and 5 ng tAK is shown in Figure 10, and again the reduction in rate of 
reaction is present at mid-range ADP concentrations. This was mirrored for all tAK 
concentrations.  
 
The decrease in rate of reaction in the mid-range of ADP concentrations presented when tAK 
was covalently bound to the surface of the polymer was not seen when considering tAK in 
solution and was only observed at high tAK concentration when adsorbed to the polymer 
surface. This may suggest some form of inhibition caused by the restriction of the anchored 
enzyme, possibly as a result of a decrease in the rate of diffusion due to obstructed access to 
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Figure 10 Initial rate of reaction (RLU s-1) plotted as a function of ADP concentration for 
two tAK concentrations covalently bound to maleic anhydride deposited onto 
polypropylene. 
(2) 
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the enzyme’s active site, or as a result of steric hindrance. However the difficulty in assessing 
this hypothesis lies with the use of a coupled system. Whilst the apparent decrease in rate of 
reaction may be as a result of the anchoring of the enzyme to a surface, it may equally be due 
to interference from the luciferase system. It has long been known that luciferase can be 
inhibited by AMP if the concentration of AMP reaches a concentration whereby it 
outcompetes  ATP, a decrease in luminescence will be observed due to inhibition 70. Whilst 
this is not seen in solution when using the same concentration of reactant, it could be 
possible that due to a change in the rate of diffusion of nucleotides away from tAK in its 
anchored state (AMP being smaller and thus potentially diffusing away faster than the larger 
ATP molecules), the inhibition effect is enhanced. 
 
Inhibition Studies  
 
The inhibition of luciferase by various AMP concentrations was investigated in order to 
assess whether the coupled system can indeed be inhibited by a secondary product of the 
primary reaction in question. Figure 11 shows the initial rate of light production when 
utilising luciferase to turn over ATP whilst increasing the concentration of AMP. From the 
standard curve a concentration of 1 x10-5 mM ATP should give an initial rate of reaction of 
around 16000 RLU s-1.  Therefore it has been shown that even a very small amount of AMP 
can inhibit the coupled system involved in monitoring tAK activity.  
 























Figure 11 Effect of AMP concentration on initial rate of reaction in the luciferase catalysed 
turnover of ATP. 
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To avoid this effect impacting on the measurement of tAK activity during assessment of wash 
processes it is important that a large excess of ADP is used to ensure that it outcompetes any 
AMP for binding to the enzyme. This approach has been used in previous studies looking at 
the use of tAK to monitor wash efficacy in different settings 41,43,76. In addition, the reaction 
that luciferase catalyses can also be self-inhibiting, that is to say that two of the primary 
products formed in the production of light from ATP (oxyluciferin and dehydroluciferyl-
adenylate) are both competitive inhibitors of luciferase 80. Table 2 shows a summary of the 
calculated kinetic parameters.  
 
Table 2 Summary of calculated kinetic parameters for tAK in solution and bound to activated 
and non-activated surfaces. The previously highlighted deviations from the hyperbola in the 
initial rate data (e.g. when using 0.05 mM ADP) were omitted from the calculations.  
 
 kcat  (s-1) KM (mM) kcat/KM  (mM-1 s-1) 
 
Solution 0.138 ± 0.040 0.017 ± 0.003 8.45 ± 3.04 
Adsorbed to 
Polypropylene 
0.855 ± 0.029 0.027 ± 0.003 32.23 ± 3.20 
Plasma Activation of 
Polypropylene 
0.558 ± 0.182 0.024 ± 0.011 24.46 ± 4.41 
 
The results presented here show that in terms of activity and catalytic efficiency tAK 
performs best when adsorbed to polypropylene. The data shows a large increase in the kcat 
with six and four-fold increase for tAK immobilised to polypropylene and maleic anhydride 
derivatised polypropylene respectively. A small increase in the KM is also observed for the 
immobilised enzyme. This is consistent with an increase in the turnover number observed in 
other enzymes immobilised onto surfaces 81,82. 
 
Removal of tAK during simple wash experiment 
 
Simple wash experiments were conducted to evaluate whether the maleic anhydride 
treatment of the polypropylene altered the retention of the enzyme. For tAK absorbed onto 
polypropylene, even simple washing removed significant amounts of bound enzyme, between 
97.4 and 97.5% of the surface bound protein was removed with water or PBS. This is 
consistent with previous studies using the tAK enzyme as a model for assessing washing 
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performance. In these studies, tAK removal is biphasic with the majority of the enzyme being 
rapidly (<5 min) removed by water or cleaning formulations and subsequent protein removal 
being very slow (>2 h). The ability of the assay system to measure protein removal over a 
greater than 5-log dynamic range means that it is possible to model such removal with 
formulations that affect the slow-phase of tAK removal 41.   With tAK covalently bound to 
maleic anhydride modified polypropylene which had been plasma deposited onto the 
polymer support, only 16.5 and 68% of the surface bound protein was removed when 
washed with water and PBS respectively, thus demonstrating a higher degree of surface 
















Enhancing the binding capacity of the surface for retention of the tAK enzyme provides a 
more challenging comparison for evaluating cleaning products or approaches which have 




In conclusion this study has highlighted the importance of methods for the evaluation of 
hospital cleaning procedures related to reusable surgical equipment. Whilst the current 
system in use (WASHtAK) provides a reasonable method of assessing washing efficacy, it has 
been shown that modification of the surface contamination model with tAK may provide a 
model with greater ability to differentiate between effective cleaning and decontamination 
processes such as those required to remove exceptionally adherent molecules such as prions. 
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Figure 12 Effect of different washing strategies on the surface removal of tAK physisorbed to 
a polypropylene surface (A) and covalently bound to a polypropylene surface (B). 
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There may be scope to develop this system based on optimising the immobilisation of tAK 
through the use of plasma activation of surfaces, or by improving the detection reagents in 
order to remove any inhibition of signal output. The use of maleic anhydride plasma 
modification of polypropylene to improve the binding of proteins and to reduce desorption 
form materials, may have additional value in the study of biofilm communities which adhere 
to surfaces and for a variety of biotechnology processes that depend on immobilised enzymes 
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Supplementary Figure 1 FT-IR spectra showing retention of the anhydride functionality, 
demonstrated by the presence of a carbonyl peak at 1780 cm-1, confirming successful plasma 
deposition of maleic anhydride.  





















 Polypropylene - Maleic Anhydride
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1.4 Additional Research 
Additional research was carried out following the publication of the research article in order 
to evaluate other methods of covalent surface attachment of the tAK enzyme. Experiments 
were undertaken in order to establish the effect of a spacer arm when investigating protein 
immobilisation. This was achieved via plasma deposition of allylamine and subsequent 
reaction with glutaraldehyde.  
 
1.4.1 Materials and Methods 
1.4.1.1 Plasma Deposition of Allylamine 
Plasma deposition of allylamine was carried out according to the protocol detailed in Section 
1.3.4, conditions were optimised according to a study by Chen et al 83 and deposition was 
characterised by FT-IR.  Briefly, 1 ml allylamine was added to the Young’s flask, before being 
reduced to 0.5 mbar pressure. The plasma was ignited and set to continuous wave of 10 W 
input and adjusted for zero reflected energy for 30 min. A needle valve was used to restrict 
the entry of allylamine vapour into the reaction chamber. A clear colour change was observed 











1.4.1.2 Activation of Plasma Deposited Allylamine 
Prior to addition of tAK to the plasma deposited allylamine microtitre plates, 100 µl of 2.5% 
glutaraldehyde solution in H2O was added to each well and allowed to react for 1 h at 37 °C, 
(according to the protocol laid out by Vartiainen et al 84). Each well was washed thrice with 
100 µl of H2O to remove any unreacted glutaraldehyde. tAK was then added to the activated 
plates and activity was monitored according to Section 1.3.4, with a slight modification in the 
Figure 13 Colour change from blue to pink following plasma polymerisation of 
allylamine. 
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buffer, which was changed from tris-EDTA to PBS in all of the stock preparation in order to 
remove any amine-containing components.  
 
1.4.2 Results and Discussion 
1.4.2.1 Plasma Deposition of Allylamine 
Successful deposition was confirmed via FT-IR (Figure 14) with the primary amine N-H 
stretching frequency observed at 3205 cm-1 and the N-H bending frequency at 1638 cm-1. The 
peak at 1715 cm-1 could indicate the presence of an amide. The bands observed between 
2100 cm-1 and 2260 cm-1 may be attributed to species such as C≡N and C≡C, present as a 
result of fragmentation of the monomer structure 85. These peaks can be used as a reference 
when undertaking plasma deposition. The harsher the deposition conditions, the higher the 
degree of fragmentation.    
 
1.4.2.2 Activation of Plasma Deposited Allylamine 
Following plasma deposition, the surface amine groups were reacted with glutaraldehyde in 
order to provide anchor sites for the subsequent immobilisation of tAK, both of which rely on 
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Figure 14 FT-IR spectra of allylamine (AA) plasma deposited onto polypropylene (PP) 
as a function of power input.  
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the formation of a Schiff base or imine in order to achieve covalent attachment. Figure 15 
shows a possible reaction pathway for glutaraldehyde activation and subsequent tAK 
immobilisation; however it is difficult to determine the exact mechanism in this case, as 
glutaraldehyde can exist as a variety of structures in aqueous solution 86.  
 
 
The stability of the Schiff base has been called into question on numerous occasions owing to 
the possibility that it will break down in solution to reform the amine and aldehyde. The 
stability of the imine may be enhanced at elevated pH or by subjection to reductive amination 
 
Figure 15 Reaction of plasma deposited allylamine with glutaraldehyde and subsequent tAK 
immobilisation. 
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using sodium cyanoborohydride. However experiments were undertaken without further 
modification to the imine in order to establish whether successful immobilisation had taken 
place. The reaction of glutaraldehyde with the allylamine deposited support was again 























The peak at approximately 3400 cm-1 can be attributed to the O-H stretching frequency from 
residual water (used to wash off unreacted glutaraldehyde). As previously mentioned, there 
appears to be a certain degree of fragmentation of the allylamine, producing a range of peaks 
at around 2300 cm-1. The spectrum for allylamine activated polypropylene and 
glutaraldehyde (AA-PP-Glu) shows a missing peak at 1723 cm-1 (previously attributed to the 
possibility of an amide). The peak at 1640 cm-1 could indicate the presence of remaining 
primary amines. However, the C=N stretching frequency for an imine is normally found at 
1628 cm-1 so it is possible that a new imine peak is overlaid with any residual amine 
presence. Noteworthy also is that the shift in wavenumber for a protonated imine has been 
reported to exist at around 1738 cm-1 where there are a distinct lack of peaks in the 
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Figure 16 FT-IR spectra of plasma deposited allylamine on polypropylene (PP-AA) and 
plasma deposited allylamine reacted with glutaraldehyde (PP-AA-Glu). 
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glutaraldehyde spectrum 87. Therefore, it may be that the imine deprotonates in solution 
(provided that Schiff base formation is indeed the mechanism of glutaraldehyde conjugation).  
 
1.4.2.3 tAK Immobilisation 
Preliminary experiments were carried out evaluating the strength of the immobilisation of 























From the graph it can be seen that using a H2O wash results in minimal surface removal of 
tAK with just 13.4% removed, the lowest of all washing experiments. However, when looking 
at the endpoint value of 7990 RLU for the glutaraldehyde activation without washing, this is 
significantly lower than the parallel experiment using tAK adsorbed to a polypropylene plate 
with an endpoint of 171457 RLU. This generates a difference in initial rate of 152 RLU s-1 for 
glutaraldehyde activation compared to 3795 RLU s-1 for the parallel adsorption experiments. 
As such, it could be argued that the degree of surface protein removal as a result of washing is 
Figure 17 Effect of different washing strategies on the surface removal of tAK covalently 
bound to a polypropylene surface, plasma deposited with allylamine and activated with 
glutaraldehyde. 
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merely a function of initial surface protein concentration. Although a smaller proportion of 
protein is removed from the surface using a glutaraldehyde spacer linkage, less protein was 
successfully bound to the surface initially. Owing to the poor retention of tAK onto the plasma 
activated polymer, this system was not taken forward for full kinetic analysis.  
 
1.5 Conclusion and Future Work  
The research presented in this chapter demonstrates the possibility of covalent surface 
attachment of a thermostable protein with increased surface retention post washing. This 
offers the benefit of potentially providing a more challenging assessment of current clinical 
sterilisation protocols. Arguably, one of the key findings of this research surrounds the 
possibility of covalent anchoring of the tAK enzyme onto a solid support without the loss of 
activity. Entropic confinement of a protein can often result in a change in protein structure, 
and in many cases, resulting in complete loss of function. The utilisation of plasma as a means 
of activating surfaces may assist in preventing protein denaturation as discussed in section 
1.2.1. However, there is a fundamental consideration which, if addressed, would enhance the 
capacity of this technology to effectively model residual surface contamination. The surface 
binding of tAK (either through adsorption or covalent attachment) should be directly 
correlated to the surface binding of the relevant infectious agents. It would be more accurate 
to draw conclusions regarding sterilisation efficacy based on residual tAK presence (or lack 
thereof), if protein concentration could be directly correlated to the pathogens associated 
with the spread of infectious disease. Whilst it is commonly accepted that species such as 
prions are exceptionally surface adherent and resistant to almost all forms of sterilisation, 
there has been little research into the exact extent of their resilience in terms of comparison 
to alternative proteinaceous species (such as tAK), which can safely be used for modelling 
purposes.  
 
In terms of future development of this technology, alongside correlating the model system to 
the reality, there are a number of considerations which could potentially improve the current 
biosensor. Firstly, a change in polymer support may offer enhanced surface adhesion. For 
example, changing to a more hydrophobic polymer may facilitate hydrophobic interactions 
between the surface and specific amino acid residues within the protein (such as tyrosine or 
phenylalanine). Secondly, it would be of interest to investigate the use of a spacer arm 
further. In terms of the allylamine/ glutaraldehyde system it may be possible to reduce the 
imine in order to stabilise the system in aqueous solution, as previously mentioned. Removal 
of the luciferase/ luciferin coupled system would avoid any inhibitory effects which have 
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shown to affect the observed tAK activity. This concept was taken further as part of this 
research and is discussed in Chapter 2. Finally, the utilisation of plasma for direct inactivation 
of prions has received considerable attention in recent years. Studies conducted by von 
Keudell et al demonstrated complete prion inactivation in vitro using low pressure Ar/O2 
plasma 88. Similarly, Baxter et al conducted in vivo experiments which showed complete 
elimination of prion infectivity through radio frequency gas plasma treatment of 
contaminated surgical instruments 89.   The development of plasma induced inactivation of 
prions as an alternative to the current and often ineffective sterilisation strategies, could offer 
a more efficient method of surface decontamination. As such, it may be possible to use tAK as 
a real time sensor in order to analyse the efficacy of plasma decontamination within the 
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Chapter 2: Site-Directed Mutagenesis of a Thermostable Adenylate 
Kinase for Biosensor Development  
2.1 Introduction 
The research presented in this Chapter encompasses the genetic modification of tAK and 
subsequent selective conjugation to a fluorescent reporter system. The overall aim is focused 
on the direct fluorescent detection of tAK activity in real time. As detailed in Chapter 1, the 
luciferase-catalysed turnover of ATP appears to be subject to product inhibition. This 
potentially arises from secondary products of the tAK-catalysed reaction and additional 
products from the luciferin/ ATP reaction. Theoretically, removing the coupled system would 
provide a singular enzymatic system, capable of quantifying ATP concentration as a function 
of fluorescence output. This has added benefits in enabling direct detection without the 
addition of substrates, for example for use in wound dressings. It also opens up the potential 
to develop new sensors for purine nucleotides (ADP, AMP and ATP) and their derivatives.    
 
This concept relies on the functionalisation of tAK via introduction of site-specific cysteine 
residues located adjacent to the substrate binding positions. tAK, in its native form does not 
contain any cysteine residues, therefore subsequent thiol-mediated conjugation will facilitate 
specific binding, avoiding other conserved amino acids. N-(1-Pyrene)maleimide was chosen 
as the fluorophore pair for conjugation via Michael addition to two cysteine residues per 
protein. tAK comprises three major domains, two of which are involved in substrate binding 
(LID and NMP domains) and one relatively rigid domain which is not involved in catalysis 
(CORE). Exploiting the conformational change in the protein structure upon substrate 
binding (closure of the LID domain to form the closed structure), results in an increase in the 
proximity of the conjugated pyrene ligands which facilitates π - π stacking interactions. These 
interactions shift the fluorescence intensity from monomer to excimer emission, producing 
an observable change in the fluorescence spectrum. Hence, substrate binding (and indirectly, 
product formation) can be monitored according to the change in fluorescence at specific 































2.2 Protein Synthesis 
Cellular protein synthesis controls and regulates the production of functional polypeptides, 
via the precise assembly of individual amino acids from their corresponding nucleotide 
sequence a. The genetic code responsible for the structure and function of a protein is 
transcribed from deoxyribonucleic acid (DNA), into messenger ribonucleic acid (mRNA) and 
translated into the fully formed protein by ribosomal subunits (Figure 2). The predefined 
amino acid sequence and the subsequent peptide folding give rise to unique proteins with 
specific functions and activities 1.  
                                                             
a Nucleotide base pairs consisting of cytosine (C), guanine (G), adenine (A) and thymine (T) 
make up the structure of DNA. 3 bases form a codon; each codon corresponds to a specific 
amino acid.  
Figure 1 Schematic showing tAK conjugated to pyrene ligands via attachment to mutant 
cysteine residues (shown as –SH moieties). Substrate (ADP) binding results in a conformational 
change in the protein (LID closure), facilitating π- π stacking interactions resulting in a change 















The process of gene expression, in terms of protein biosynthesis, is a highly regulated process 
which takes place in both eukaryotic and prokaryotic cells, although there are slight 
differences in the mechanism of polypeptide construction. In prokaryotic cells transcription 
and translation occur simultaneously, the ribosomes are smaller, mRNAs are relatively short 
lived and the initiation and termination sites (the point at which the ribosome attaches and 
detaches from the mRNA) are different 2. The longer time scale and additional steps involved 
in eukaryotic biosynthesis (such as mRNA translocation from the cytoplasm), offers a greater 
degree of control in protein construction, including additional opportunities to modify the 
intended protein structure. Proteins can be modified either at the genetic level, via alteration 
of the DNA sequence, or post-translationally by covalent modification of amino acids.   
 
2.2.1 Site-Directed Mutagenesis  
The specific sequence of amino acids constituting a protein dictates the intrinsic properties of 
the protein itself, including stability, activity and versatility. Whilst nature has refined the 
process of protein biosynthesis through evolutionary development of the required molecular 
machinery, the intentional modification of proteins has been of interest to scientists for 
Figure 2 Schematic showing eukaryotic DNA transcription via splicing into mature mRNA 
in order to remove non-coding introns and ligate exons. The mature mRNA is then exported 
from the nucleus into the cytoplasm, where it is then translated into individual amino acids 
constituting the final protein structure. Copyright © 2010 Nature Education. 
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decades. The alteration (via insertion, deletion or substitution) of base pairs in the DNA 
sequence, and the resultant modification of single, or multiple amino acids can provide 
valuable insight into gene/ protein function, protein-protein interactions and structure-
function relationships 3. Exploiting intentional genetic changes in the structure of a protein 
provides an effective strategy for the development of various investigative tools, including 
probing the genetic causes of disease, determining the process of cellular signalling and 
providing insights into the mechanisms involved in protein folding. Furthermore, 
modification of an otherwise specific amino acid sequence often results in a change in the 
properties of the resulting protein 4. An early example of this is the substitution of a single 
amino acid (methionine) in subtilisin, for a non-oxidizable amino acid (such as serine, alanine 
or leucine). This substitution prevents subtilisin inactivation via oxidation, thus increasing its 
potential for commercial use (predominantly for use in detergents) 5. Genetic engineering 
offers a vast array of benefits in terms of protein applications, for example, improved 
biosensor sensitivity, enhanced specificity and reduced immunogenicity of therapeutic 
proteins, and an extension in shelf life of protein-containing food products 6-8.  
 
In order to intentionally modify the amino acid sequence of a protein at the genetic level, the 
DNA sequence must be altered so that it codes instead for an ‘edited’ version of the protein in 
question. Such events occur naturally in the form of alternative mRNA splicing 9,10, however 
synthetic gene alteration is referred to as mutagenesis, which can be random or directed. 
Early examples of mutagenesis involved the random insertion of mutations into the genome 
via exposure to chemical mutagens such as ethyl methanesulfonate 11. However, the potential 
advantages offered by site-specific changes to the primary protein structure, drove the 
development of rational design and site-directed mutagenesis 12.   
 
Site-directed mutagenesis, first reported in 1978 by Michael Smith 13 (who later received the 
Nobel Prize for his work in this area), involves the introduction of predefined changes to a 
section of DNA, corresponding to an alteration in the amino acid sequence. This method has 
been significantly adapted and improved in recent years, predominantly owing to the 
discovery and advancement of the polymerase chain reaction (PCR) 14-16. PCR is a 
fundamental technique which has revolutionised molecular biology; illustrated by the fact the 
two key scientists responsible for its development (Kary Mullis and Har Gobind Khorana), 
both received Nobel Prizes in their respective fields.  PCR involves the in vitro exponential 
amplification of DNA sequences via thermal cycling, in order to produce billions of copies of 
the target DNA strand 17. There are a number of commercially available kits for introducing 
mutations into double stranded DNA (plasmid DNA), which are widely used. Mutagenesis in 
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the context of this report will refer to double stranded DNA modification from this point 
onwards, in order to remain relevant to the research presented in the Experimental Section. 
Additionally, the steps involved in mutagenesis (as detailed in the following Sections) largely 
refer to the QuickChange® Lightning Mutagenesis Kit (Stragene, La Jolla, CA, USA) which was 
used in this research.  
 
2.2.1.1 Primer Design  
Site-directed mutagenesis relies on the design and selection of synthetic oligonucleotide 
primers; short, synthetic sequences of nucleotides, complementary to opposite strands of the 
vector, containing the desired mutations. Primers anneal to the section of template DNA to be 
amplified and direct the replication process. In plasmid mutagenesis this results in the 
synthesis of copies of the entire plasmid rather than just the mutated DNA section. There are a 
number of considerations to take into account when designing primers, such as: 
 
 Primers should be between 25 and 45 nucleotides long. 
 They should have a high guanine/ cytosine content (at least 40%). 
 Mutations must be contained within both primers. 
 The mutation should be in the middle of the primer sequence. 
 Primers should have melting temperature (defined as the temperature at which the 
primer dissociates from the template DNA 18) of at least 78 °C, in order to prevent 
mismatches. 
 
There are a number of primer design programmes currently available (many of which have 
been reviewed elsewhere 12,19), capable of optimising primer characteristics such as melting 
temperature and the prevention of mispriming. An example of such software is Primer-
BLAST, available from the National Center for Biotechnology Information (NCBI) 20, this 
software assists in the design of target specific primers. In addition to optimised primer 
design, the resulting nucleotide sequences are searched against BLAST (Basic Local 
Alignment Search Tool) which is coupled to a global alignment algorithm, in order to find any 
regions of similarity over the entire primer range, thereby reducing any cases of mismatching 
21.  
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2.2.1.2 Mutant Strand Synthesis 
Following successful primer design, the double stranded template DNA must be denatured in 
order to separate the DNA strands. The complementary primers containing the mutations (in 
the form of mismatched bases) are then annealed to the DNA. Extension of the primer 
sequence is achieved using a thermostable DNA polymerase, and a mix of deoxynucleotide 
triphosphates (dNTPs) as the monomeric substrates for DNA extension. The DNA polymerase 
continues to extend the DNA in a circular fashion, until it reaches the end of the primer 
sequence (the polymerase is non-strand displacing), and a single stranded copy of the entire 
mutated vector sequence is produced. This process occurs at varying temperatures during 
thermal cycling and is repeated in order to amplify the mutated DNA. Once multiple copies of 
the mutated template DNA have been generated, two complementary single strands anneal, 
resulting in double stranded, mutated plasmid DNA (Figure 3 22).   
 
There are two points to note regarding the newly synthesised mutant plasmids. Firstly, they 
are not completely circular; they contain staggered nicks or strand breaks where the newly 
formed DNA meets the primer (i.e. they are not covalently bound together). This is rectified 
upon transformation of the plasmids into bacteria, where any nicks are sealed by bacterial 
ligases via formation of phosphodiester bonds 23. Secondly, the parental DNA is methylated, 
whereas the newly formed DNA is not. This provides a helpful distinction, facilitating the 
eventual destruction of any non-mutated DNA.  




2.2.1.3 Digestion of Template DNA 
As depicted in Figure 3, following a number of rounds of thermal cycling, some template DNA 
remains which is devoid of the desired mutation(s). This wild type DNA is removed via 
restriction digest using endonucleases. Owing to the fact the parent DNA is frequently 
propagated in Escherichia coli (E. coli), often methylation occurs at the N6 position of an 
adenine residue within the GATC sequence, via a methyltransferase encoded by the dam gene 
24,25. Therefore, utilising dam+ E. coli strains to propagate plasmid DNA for mutagenesis 
results in parental DNA which differs from the resulting mutated DNA (which is not 
Figure 3 Schematic illustrating the generation of mutant DNA strands via thermal cycling. 
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methylated). Therefore, selective digestion can be achieved using restriction endonucleases 
which only target methylated DNA. There are a number of endonucleases which can be 
employed for this purpose, however their precise cleavage site and recognition sequence can 
differ, thus careful selection of the appropriate enzyme must be undertaken 26.  
 
2.2.1.4 Transformation  
The final step in site-directed mutagenesis is the transformation of the newly formed DNA 
into competent cells. These cells are engineered to exhibit a higher degree of porosity in 
order to facilitate plasmid binding to the cell membrane. There are a range of commercially 
available competent cells for use in genetic cloning; commonly prepared by chemical 
treatment (calcium chloride) or via electroporation 27. When selecting competent cells, there 
are a number of considerations to take into account, including: transformation efficiency, 
genetic markers (i.e. antibiotic resistance) and workflow requirements 28,29. Transformation 
typically involves either heat shock of chemically competent cells, or electroporation of 
electrocompetent cells. Transformation efficacy can be evaluated via colony screening using 
antibiotic-containing media. When undertaking genetic cloning, the vector in which the 
mutations are inserted normally carries an antibiotic resistance marker. Hence, any cells that 
have successfully taken up the cloning vector will survive when plated onto antibiotic-
containing agar plates, whereas bacteria without the vector will not 30. Furthermore, in order 
to confirm whether the plasmid contained within the bacteria actually exhibits the desired 
mutation(s), blue/white screening is often employed. This technique can distinguish between 
plasmids containing the desired insert which present as white colonies, and plasmids which 
do not. There may be some failed products (i.e. no insert, unligated insert, modified insert 
etc.), which will result in blue colonies 31.  
 
2.2.2 Post-Translational Modification  
The genetic assembly of bioactive proteins with predefined functionality is achieved during 
transcription and later, translation. However, there are numerous cases throughout nature in 
which the fully translated protein is yet to be considered functional. The post-translational 
modification (PTM) of a protein is a covalent alteration in the protein structure, which occurs 
outside of the ribosome. Largely controlled by enzymes, PTMs may involve the addition or 
removal of a functional groups (i.e. phosphorylation, acetylation, glycosylation), the addition 
of complex molecules, or the formation of inter- or intramolecular bonds. This results in a 
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substantial increase in the diversity of the proteome, thus creating a plethora of proteins far 
exceeding the allowance dictated by gene transcripts. Both reversible and irreversible 
protein PTMs have been extensively reviewed elsewhere 32-34. The ability to tune the 
functionality of a protein provides control over its activity state, cellular location and 
stability. This in turn can both initiate and terminate specific cellular events such as gene 
expression and signalling cascades 35-37. Indeed, PTMs have been implicated in both the cause 
and prevention of a range of diseases including cardiovascular disease, chronic kidney 
disease and a range of neurodegenerative disorders 38,39. 
 
Not surprisingly, the ability to chemically induce post-translational alterations in order to 
synthetically modify proteins has gained considerable attention in recent years. The 
applications of such engineered proteins are vast, including, but not limited to: use as tools in 
synthetic biology, industrial biocatalysis and biological therapeutics 40-42. A principle example 
of the latter is Levemir® (Novo Nordisk), a long-acting insulin, engineered via acylation and 
currently on the market as a biotherapeutic. The addition of a fatty acid to a lysine residue in 
the insulin B chain acts as an anchor point for the binding to human serum albumin in vivo. 
This results in the prolonged release of free insulin, increasing the bioactivity three-fold 43.    
 
2.2.3 Protein Conformational Changes 
Functional conformational changes are commonplace in proteinaceous architectures; they 
can determine both function and activity. Many different techniques have been devised in 
recent years in order to study the nature and effect of such structural transitions, offering 
potential mechanistic insights into protein activity 44,45. There are a number of factors 
involved in regulating the conformation of a protein, some of which include: protein-protein 
interactions, protein-ligand interactions, environmental conditions, transcriptional 
regulation and PTMs 46,47. A change in the conformational state of a protein can be of critical 
importance, the consequences of which are often associated with essential cellular processes 
such as signal transduction, gene regulation and catalysis 48.    
 
2.2.3.1 Adenylate Kinase  
A change in conformation upon substrate binding is a well-documented phenomenon in a 
number of enzymes; a well-studied example of which is exhibited by AK during the catalysis 
of adenine nucleotide interconversion 49-53. The structural dynamics accounting for this 
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process are extensive and complex (a detailed study has been presented by Li et al 54). The 
binding of substrate molecules facilitates opening and closing of the LID and NMP domains, 
resulting in a conformational shift of the protein from open state (PDB ID 4AKE 55), to the 

















The transition between the open and closed states has been reported to occur on the 
microsecond-millisecond timescale and is a common feature of a number of AKs from a range 
of different organisms (including tAK) 58. The difference in spatial arrangement arising from 
the transition from the open to closed form manifests as a change in distance between NMP 
and LID amino acids (Ala55 and Val169), of ~ 17Å upon LID closure in the case of E. coli AK 
59. As an alteration to the induced-fit theory of enzyme-substrate binding (stating that only 
the specific substrate can induce a protein conformational change), the conformational 
selection model (or pre-existing equilibrium model), suggests that an enzyme exists in a 
number of conformational substates and the ligand selectively binds to the active 
conformation. This is the current theory for AK-substrate binding based on a multitude of 
molecular dynamics simulations 57,60. The proposed mechanism of which is shown in Figure 5 
61.  
B A 
Figure 4 Crystallographic ribbon plot showing AK isolated from E. coli, (A) in the open 
form in the absence of substrate and (B) in the closed form. Adapted from 57 Copyright © 
2013 Ping et al. 





The change in proximity of amino acids resulting from the conformational change of a protein 
upon substrate binding has been exploited in a number of studies 62-64. Yuan et al prepared 
enzyme-based hybrid hydrogel structures containing a covalently crosslinked AK mutant. 
The triple mutant was engineered to contain cysteine functionality to serve as attachment 
points for subsequent crosslinking (via thiol-maleimide reaction), with either N-(2-
hydroxypropyl)methacrylamide (HPMA), or poly(ethylene glycol) (PEG) hydrogels. The 
conformational change upon ATP binding resulted in macroscopic motion of the hydrogel 
network (manifesting as a decrease in polymer volume) 59. Similarly, Fujii et al prepared a 
pyrene-conjugated AK mutant in order to create an “in situ chromic system” based on the 
switching of monomer/excimer emission 65. This approach is the basis of the experimental 
work undertaken in this Chapter; in order to remove the luciferase/luciferin coupled system 
and instead, to develop a one component, thermostable biosensor.   
Figure 5 Proposed substrate binding scheme for AK, (a) initially in the open conformation, 
followed by ATP binding to the LID domain (b) resulting in LID closure, AMP binding to the 
NMP domain (c.1), phosphotransfer to form two molecules of ADP (c.2), LID opening resulting 
in release of the first molecule of ADP (d), and return to the open conformation following final 
ADP release via opening of NMP domain. Reproduced from 61. Copyright © the American 
Society for Biochemistry and Molecular Biology. 
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2.3 Materials and Methods 
2.3.1 Materials  
Wildtype tAK (tAKWT), plasmid pMTL 1015 and E. coli expression strain RV308 were all 
obtained from the Technology Development Group, Public Heath England (PHE – Salisbury, 
UK) 66. Luria bertani (LB) broth, mucin from porcine stomach, tetracycline, isopropanol, 
ethanol, sodium dodecyl sulfate (SDS), phosphate buffered saline (PBS) tablets (pH 7.4),  
sodium chloride,  magnesium sulfate, tris-hydrochloride (pH 7.5), sodium phosphate 
dibasic/monobasic, dithiothreitol (DTT), dimethyl sulfoxide (DMSO) were all purchased from 
Sigma-Aldrich.  
 
QIAprep® Spin Miniprep Kit and HiSpeed® Plasmid Purification Midi-prep Kit were 
purchased from Qiagen Ltd.  QuickChange® Lightning Site-Directed Mutagenesis Kit and 
XL10-Gold® Ultracompetent cells were purchased from Agilent Technologies. Super optimal 
broth (SOC), NuPAGE™ 4-12% Bis-Tris Protein Gels (1.0 mm, 12-well), SeeBlue™ Plus2 Pre-
stained Protein Standard, NuPAGE™ MES SDS Running Buffer, SimplyBlue™ SafeStain, 
NuPAGE™ Sample Reducing Agent, One Shot™ TOP10 Chemically Competent E. coli cells and 
N-(1-Pyrene)maleimide were all purchased from Invitrogen™, ThermoFisher.  BugBuster® 
10X Protein Extraction Reagent was purchased from Merck Millipore. ATP Reagent, Diluent C, 
tris-EDTA buffer, ADP and ATP standard solutions were all purchased from BioThema 
(Sweden).  
 
PCR primers were obtained from Sigma Genosys; sequences are shown in Table 1. Bases 
shown in red lower case correspond to the amino acid modified in each case.   
 
Table 1 Oligonucleotide sequences of forward (for) and reverse (rev) PCR primers. 
 


































































2.3.2 Methods  
2.3.2.1 Bacterial Growth Conditions 
Bacterial cultures were grown from frozen stocks via streaking an LB agar plate, incubation 
overnight at 37 °C, addition of a single colony to 10 ml LB broth and further overnight 
incubation with agitation. LB plates used for cloning were supplemented with 0.1% 
tetracycline.  
 
2.3.2.2 Plasmid Isolation, Transformation and Purification 
The plasmid (pMTL 1015) encoding tAK was isolated from an E. coli expression strain 
(RV308) using QIAprep® Spin Miniprep Kit according to the manufacturer’s instructions 67. 
Briefly, an overnight culture was pelleted via centrifugation, resuspended, lysed and 
neutralised in order to release the cellular DNA. The suspension was re-centrifuged and the 
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supernatant passed through a spin column to allow DNA binding to the silica membrane. The 
column was washed to remove any impurities and the DNA was eluted in buffer. Plasmid 
DNA was transformed into Top10 competent cells via heat shock treatment. The DNA was 
added to the competent cells on ice and left for 5 min, the solution was then heated for 30 s at 
42 °C and returned to ice for a further 2 min. SOC was added and the solution was incubated 
with agitation at 37 °C for 30 min. Aliquots were spread onto tetracycline-supplemented LB 
agar plates and incubated overnight at 37 °C. Plasmid DNA was purified using HiSpeed® 
Plasmid Purification Midi-prep Kit according to the manufacturer’s instructions 68. Briefly, a 
single colony from a freshly streaked selective plate was cultured in tetracycline-
supplemented LB broth overnight at 37 °C with agitation. The culture was pelleted via 
centrifugation and resuspended in buffer. The cells were lysed and any RNA digested with 
RNase A.  The solution was neutralised, resulting in the precipitation of any remaining 
detergent (from the lysis step), cellular proteins and genomic DNA. This was removed via 
filtration, the plasmid DNA was bound to a resin-containing column, washed and eluted into 
buffer. The purified DNA was precipitated in isopropanol, filtered, washed with ethanol and 
eluted into buffer.  
 
2.3.2.3 Design and Construction of Oligonucleotide Primers 
Oligonucleotides were designed to introduce the desired amino acid change within the coding 
sequence of the tAK enzyme. Simple design rules were used to generate oligonucleotides with 
mismatched (mutagenic) sequences flanked by 20-24 bases. Pyrimidine bases were used at 
the 3’ end of the oligonucleotide to ensure efficient base-pairing and sequences were checked 
for the formation of primer dimers and/or hairpin structures using primer design software 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/).   
 
2.3.2.4 Mutagenesis and Transformation  
Mutagenesis was carried out using QuickChange® Lightning Site-Directed Mutagenesis Kit 
according to the manufacturer’s instructions 69. Briefly, sample reaction solutions were 
prepared containing buffer, two oligonucleotide primers (containing the desired 
mutation(s)), dNTP mix, varying concentrations of the parental DNA template and 
QuickSolution reagent (to facilitate replication of large plasmids). Control solutions were 
prepared in parallel (in order to assess efficacy of mutagenesis protocol), containing a control 
template (pWhitescript 4.5kb) and control primers. QuickChange Lightning Enzyme (DNA 
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polymerase) was added and the solutions were subject to thermal cycling. Dpn I restriction 
endonuclease was then used to digest any parental DNA and the mutated DNA was 
transformed into XL10-Gold® Ultracompetent cells according to the manufacturer’s 
instructions 70. Control transformations were carried out in parallel using a control plasmid 
(pUC18). Mutant samples were plated on tetracycline-supplemented LB plates and incubated 
overnight at 37 °C. Samples were sequenced to evaluate mutation efficacy.  
 
2.3.2.5 Expression 
Small scale expression was undertaken in order to assess the viability of the newly 
synthesised mutant proteins. Cells containing the mutant plasmid with the desired insert(s) 
were grown overnight at 37 °C in tetracycline-supplemented LB broth. Cultures were pelleted 
via centrifugation and resuspended in BugBuster® Protein Extraction Reagent according to 
the manufacturer’s instructions 71. Briefly, after lysing the cells with BugBuster (detergent), 
the solution was centrifuged, forcing cellular debris into a pellet and retaining any proteins 
contained within the cytoplasm/ periplasm within the supernatant. Dependent on the 
success of the expression, tAKM should be located in the supernatant. However, if there are 
any misfolded proteins or if the expression strain fails to produce the protein correctly, tAKM 
may be located within an inclusion body (insoluble membrane casing) within the pellet. It is 
possible to recover a protein from within an inclusion body but it can be difficult to refold the 
protein into an active conformation. The supernatant was then heated to 80 °C for 20 min, 
centrifuged and recovered. If the tAKM is heat stable it will remain in the supernatant, if not, it 
will precipitate to form a pellet. This process is shown in Figure 6. Samples were run on 
NuPAGE™ Protein Gels at 200 V for 30 min and successful mutations were chosen to take 

































For large scale preparation, 5 ml of overnight culture was added to 800 ml of tetracycline-
supplemented LB broth and incubated overnight at 30 °C with agitation. Samples were 
harvested via centrifugation and resuspended in deionised (DI) H2O (for freezing) or 
equilibration buffer (20 mM Tris, 0.9 mM NaCl, 10 mM MgCl2, pH 8) for purification. 
 
2.3.2.6 Purification 
Protein purification was achieved via ion-exchange chromatography (ÄKTA Purifier, GE 
Healthcare Life Sciences), using HiScreen Capto™ Blue columns. Samples resuspended in 
equilibration buffer were sonicated (50 s on, 40 s off, 10 cycles), centrifuged, heated to 80 °C 
for 30 min and re-centrifuged to release cell contents. Samples were loaded onto the column 
following equilibration and eluted in 10 mM sodium phosphate, 2 M NaCl (pH 12) 72. 
Approximately 10 fractions were collected and 100 µl of neutralisation buffer (0.2 M sodium 
phosphate, pH 6 73) was added to each fraction. Column eluents were run on NuPAGE™ 
Protein Gels in order to determine the fraction containing the modified tAK enzyme. 
NuPAGE™ Sample Reducing Agent was added prior to loading onto the gels in order to reduce 
aggregation.  
 
Figure 6 Protein extraction protocol showing recovery of the desired soluble, thermostable 
protein (blue) from liquid media, as oppose to misfolded or heat-denatured proteins (red). 
Centrifuge 











Soluble, Thermostable Protein 
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2.3.2.7 Characterisation  
Protein concentration was determined via the Bradford Assay 74. Enzyme activity of the tAK 
mutant (tAKM) was determined as previously detailed (Section 1.3.4, Published Article). 
Reducing experiments were undertaken in the same manner with the addition of 300, 200, 
100, 50, 10 mM DTT.  
 
2.3.2.8 Bioconjugation 
Conjugation was carried out according to Invitrogen Molecular Probes 75 with some 
modifications. Briefly, tAKM was dissolved in PBS buffer at a concentration of 50 µM.  In order 
to reduce any disulfide bonds (inter- and intramolecular) within the tAKM solution, 100-fold 
molar excess of DTT (in H2O) was added, this was allowed to react for 10 min at room 
temperature with stirring. The solution was passed through a spin column (10 kDa MWCO, 
10 min) in order to remove the DTT and the reduced enzyme was resuspended in sterile PBS. 
Control experiments were undertaken using the tAKWT in parallel. 100-fold molar excess of N-
(1-Pyrene)maleimide (in DMSO) was added to the resuspended enzymes dropwise and 
reacted for 24 h in the dark with stirring. Solutions were centrifuged and the supernatant 
dialysed for 2 days at 4 °C, firstly against tris-EDTA and then DI H2O. 
Enzyme-conjugate activity was determined as previously described (Section 1.3.4, Published 
Article). Control experiments were undertaken using the mutant enzyme exposed to the 
coupling conditions.  
 
2.3.2.9 Fluorescence Analysis  
Excitation and emission scanning was undertaken (CLARIOstar®, BMG Labtech), in order to 
establish the correct fluorescence parameters. Results are presented in triplicate, 
representing the excitation/emission spectra of the tAK mutant - conjugate (tAKMC), baseline 
corrected against the substrate (ADP).  
 
tAKM and tAKMC were exposed to 5 mM ADP (1:1 v/v tAK: ADP), supplemented with 10 mM 
MgCl2 and the fluorescence output was measured immediately from 360 – 520 nm with an 
excitation wavelength of 340 nm ± 8 nm. The same experiments were undertaken replacing 
ADP with tris-EDTA buffer.   
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2.4 Results and Discussion  
2.4.1 Evaluation of Mutagenesis  
Samples containing the desired mutation(s) were sequenced and compared to the wildtype 
enzyme. Figure 7 shows the sequence alignment demonstrating successful mutagenesis of all 
cysteine substitutions. The double mutant (Sac AK 61 – 148) was chosen to take forward for 
large scale expression, this mutant contains 2 cysteine substitutions at serine 61 and serine 
148 (Scheme 1). The observed success in formation of the double mutant ruled out the 
necessity to induce further mutations into the single mutants, (a concept explored as a 








Figure 7 Amino acid sequence alignment showing cysteine mutations (red) in 7 tAK mutants 
compared to the wildtype (Sac WT) enzyme. 
Scheme 1 - Conversion of serine to cysteine as demonstrated in the double tAK 
mutant. 
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Following expression and purification of tAKM, column fractions were loaded onto SDS-Page 
gels for analysis. Fractions 3, 4 and 5 were found to contain tAKM, exhibited by the band 
appearing at approximately (26 kDa) shown in Figure 8A. Whilst tAK (monomer) has a 
predicted molecular weight of ~23 kDa, the protein fragment runs slightly longer on the gels, 
hence the band at 26 kDa. However, the observed band appears as a doublet, possibly 
indicating the formation of an intramolecular disulfide bond. The bands above 26 kDa suggest 
the presence of intermolecular disulfide bonds resulting in the formation of dimers, trimers 
and tetramers, appearing at 56, 82, 108 kDa respectively. The fractions were reduced (50 mM 
DTT), resulting in removal of both the doublet at 26 kDa and the majority of the larger 




















The sustained presence of some larger aggregates after reduction suggests a higher 
concentration of reducing agent may be required. This was taken into account during 
subsequent activity measurements. The presence of an intramolecular disulfide bond may 
indicate covalent closure of the LID domain which could, in theory, prevent substrate access 
















Figure 8 Gel analysis of the double mutant showing (A) unreduced column fractions, from 
left to right: the loading fraction (L), flow through (FT), wildtype enzyme (WT) and the 
column fractions from fraction 3 onwards. (B) The reduced fractions showing removal of 
doublet at 26 kDa (red circle) and aggregation of longer protein fragments. 
A B 
L     FT   WT     3       4      5      6      7    L     FT   WT     3       4      5      6      7    
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2.4.2 Mutant Activity 
The ability of tAKM to catalyse the formation of ATP from ADP was assessed via the 
luciferase/ luciferin coupled assay, in keeping with previous experiments (Chapter 1). Prior 
to reducing tAKM, the luminescent light output was evaluated relative to tAKWT (in solution) 



















There is a substantial reduction (~66%) in luminescence output as a result of mutagenesis. 
When considering the change in initial rate of product turnover, there is a marked difference 
in the corresponding kinetic parameters as highlighted in Figure 10 and summarised in Table 
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Figure 9 Luminescence output (RLU) plotted as a function of ADP concentration over time. 
This figure represents 40 ng of (A) tAKWT and (B) tAKM.  





Table 2 Summary of calculated kinetic parameters for tAKWT and tAKM, the values presented 
represent the mean of varying concentrations of enzyme (40, 20, 10, 5 ng). 
 
 kcat  (s-1) KM (mM) kcat/KM  (mM-1 s-1) 
 
tAKWT 0.138 ± 0.040 0.017 ± 0.003 8.45 ± 3.04 
tAKM 0.039 ± 0.009 0.015 ± 0.003 2.54 ± 0.15 
 
 
The reduction in both rate of product turnover and catalytic efficiency may arise as a result of 
disulphide formation, as suggested by the gel analysis. The effect of reducing any potential 
disulphide bonds was evaluated in terms of enzyme activity using varying concentrations of 
DTT, shown in Figure 11.  
 
Figure 10 Comparison of initial rate of reaction (RLU s-1) of tAKWT (black) and tAKM (red). 
The figure represents 40 ng of enzyme. Tangents were fitted according to a linear fit 
function between 5 and 15 s. 
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The plateau on the graph may be due to regeneration of the disulfide (in the presence of 
molecular oxygen), or as a result of oxidation of DTT to its corresponding ring system. 
Nonetheless, increasing concentrations of DTT appear to increase the activity of tAKM, 
eventually enhancing the luminescent output > three-fold, resulting in an initial rate of 
reaction comparable to tAKWT. Based on this, tAKM was reduced using excess DTT prior to 
conjugation in order to promote the retention of activity.  
 
2.4.3 Bioconjugation  
Thiol-mediated conjugation is expected to proceed via Michael addition from the cysteine 
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Figure 11 Effect of DTT on tAKM activity expressed as initial rate of reaction (RLU s-1), 
compared to the activity of tAKWT (red box) at the same concentration (40 ng), utilising 0.1 
mM ADP. 
































The monomer emission band (upon excitation at 340 nm) arising from an isolated pyrene (in 
the absence of substrate), appears at ~ 375 – 410 nm. The peaks associated with these 
wavelengths can be attributed to the π ⟶ π * transitions. Additionally, when two pyrene 
molecules come into close proximity, a broad peak appears at ~ 480 nm, corresponding to 
Scheme 2 Nucleophilic addition of N-(1-pyrene)maleimide to cysteine residues on tAKM, 
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the excimer (dimer) emission. This occurs via interaction of a ground state pyrene ring with 
an excited state pyrene ring. In order to confirm the most effective excitation wavelength for 
tAKM conjugated to pyrene (tAKMC), excitation/ emission scanning was performed as shown 

































Figure 12 Fluorescence emission intensity of tAKMC, plotted as relative fluorescence units 
(RFU), as a function of excitation wavelength, aimed at determining the optimum excitation 
wavelength for monomer emission from pyrene rings. 
Figure 13 Fluorescence emission intensity of tAKMC with an extended excitation spectrum, 
aimed at determining the optimum wavelength for excimer emission. 
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Wavelength scanning confirmed the appropriate excitation wavelength as 340 nm with a slit 
width of ± 8 nm, for both monomer (Figure 12) and excimer (Figure 13) fluorescence 
emission. Measuring the fluorescence intensity of tAKMC in the absence of substrate exhibited 
a small peak in the excimer region (~ 480 nm), in addition to the peaks at lower wavelengths 
(associated with the monomer emission). This may be as a result of insufficient reduction of 
disulfide bonds, facilitating an increase in the spatial proximity of intramolecular pyrene 
rings. However, the change in spectra should still be apparent upon substrate binding. This 






















As expected, the monomer emission occurs both in the presence and absence of substrate, 
while the intensity is reduced in the former. There appears to be a small peak in the range of 
the expected excimer emission (481 nm) in the absence of substrate. However, upon addition 
of ADP, the fluorescence intensity of both the monomer and the excimer signal decreases. 
This is in contrast to other studies whereby the intensity of the monomer emission is 






Figure 14 Fluorescence intensity of tAKMC in the absence of substrate (black) and in the 
presence of 5 mM ADP (red). Excitation wavelength = 340 ± 8 nm. 




























 + 5 mM ADP
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are a number of possible explanations for this. Firstly, the nature of the LID domain in tAK 
may influence any potential interactions between the fluorophores. Whilst previous studies 
have focused on AK isolated from E. coli (AKe) (which has a relatively long LID domain), tAK 
isolated from S. acidocaldarius exists in a conformation with a shorter LID 77. This, coupled to 
the chosen mutation sites, may affect the spatial proximity of the pyrene ligands and possibly 
the local secondary structure of the protein itself. Further analysis using molecular modelling 
(YASARA View 78,79), permitted visualisation of the conformational change in tAK relative to 
other AKs. It has been reported that measurable fluorescence intensity as a result of excimer 
formation occurs when pyrene rings are ≤10 Å in separation 80. Figures 15 and 16 show the 
difference in spatial arrangement of the previously reported mutation sites in AKe, in the 


























Figure 15 Crystallographic ribbon plot generated in YASARA View using PDB ID 4AKE 
showing the 29.50 Å distance (Cα – Cα) between alanine 55 and valine 169 (pink) in AKe, both 






























The ~ 17 Å change in proximity of alanine 55 and valine 169 upon closure of the LID domain 
corresponds to a distance which may facilitate stacking interactions upon pyrene conjugation 
(post amino acid substitution, ALA/ VAL ⟶ CYS) 80. The distance reported here represents 
the distance from the α carbons of the native amino acids, rather than the conjugated pyrene 
rings in the AK mutant, however the reported value for the proximal distance between the 
pyrene rings upon conjugation to the double-cysteine AKe is 3.7 Å 76. This is within the range 
of the predicted distance for observable excimer emission. 
 
In contrast, when modelling the change in distance of the mutation sites in tAK upon 
substrate binding and subsequent LID closure, the resulting spatial arrangement may not be 







Figure 16 Crystallographic ribbon plot generated in YASARA View using PDB ID 1AKE 
showing the 12.43 Å distance (Cα – Cα) between alanine 55 and valine 169 (pink) in AKe 
when bound to Ap5A ( catalytic transition state analogue), representing the closed 
conformation. 






































Figure 17 Crystallographic ribbon plot generated in YASARA View using PDB ID 1NKS 
showing the 32.49 Å distance (Cα – Cα) between serine 61 and serine 148 (pink) in tAK, in 




Figure 18 Crystallographic ribbon plot generated in YASARA View using PDB ID 1NKS 
showing the 24.97 Å distance (Cα – Cα) between serine 61 and serine 148 (pink) in tAK, 
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Upon substrate binding, the conformational change in tAK results in a ~7.5 Å change in 
distance between the mutation sites. Not only is this much smaller than previously observed 
in AKe, the final separation of ~25 Å is likely too great a distance to facilitate effective π – π 
stacking interactions between conjugated pyrene molecules. A curious observation is the 
weak excimer signal observed in the fluorescence spectra in the absence of substrate 
(indicating tAKMC in the open form). As previously stated, this may arise from insufficient 
intramolecular (or buried) disulfide reduction, which may hold the protein in a different 
conformation to the substrate-bound tAKMC. However, this could equally be attributed to the 
flexibility of the α-helical scaffold to which the pyrene rings are attached. This flexibility may 
be lost upon substrate binding as a result of the conformational change, impairing any 
stacking interactions and eliminating the excimer signal. It may be argued that the excimer 
signal appears as a result of intermolecular pyrene interactions, rather than intramolecular 
stacking. However, previous studies using similar systems have proven this unlikely as only a 
minimal change in signal intensity was observed upon significant sample dilution 81.  
 
Secondly, the absence of excimer signal may result from the specific spatial arrangement of 
the two pyrene molecules with respect to one another. It may be that the electron-rich 
pyrene rings are not in the correct orientation to facilitate excimer emission (regardless of 
whether spatial proximity is indeed the deciding factor). In order to facilitate effective π – π 
stacking interactions, the pyrene rings must be orientated face on. This configuration is 
enhanced by a number of non-covalent interactions from the surrounding microenvironment, 
for example C–H⋅⋅⋅⋅π interactions between neighbouring amino acid residues and the pyrene 
rings. The mutations in the amino acid sequence and any subsequent changes in protein 
conformation may have reduced the capacity for stabilising interactions to take place, thus 
inhibiting the formation of the favourable ring configuration (as demonstrated in previous 
studies 76).  
 
2.4.3.1 Bioconjugate Activity 
In order to investigate the nature of substrate binding and enzyme activity upon pyrene 
conjugation (relative to tAKWT and tAKM), activity assays using the luciferase/ luciferin 
system were performed on tAKMC. Conjugation appeared to result in almost complete loss of 
enzymatic activity as shown in Figure 19.  
 
 




The effect of conjugation on tAKM manifests as a large decrease in the initial rate of substrate 
turnover. Compared to the reduced tAKM (Figure 11), there is ~1000-fold reduction in the 
initial rate of reaction. However, this may indeed arise as a result of conjugation (affecting the 
thermodynamic properties of the protein itself), or as a result of the conjugation conditions 
alone (i.e. in the presence of solvent). Figure 20 shows the effect of the experimental 
conditions on the reduced tAKM without the addition of the pyrene ligands. Although the 
enzymatic activity is increased ~10-fold (relative to tAKMC), the exposure of tAKM to the 
conditions required to facilitate conjugation results in ~100-fold reduction in rate compared 
to the unconjugated tAKM. The corresponding change in kinetic parameters are summarised 






































n      = 1.70
Figure 19 Comparison of initial rate of reaction (RLU s-1) of tAKMC as a function of substrate 
concentration. Tangents were fitted according to a linear fit function between 5 and 15 s. Kinetic 
parameters are labelled on the graph for 40 ng tAKMC. 




Table 3 Summary of calculated kinetic parameters for tAKMC and tAKM*. The values represent 
the mean of varying concentrations of enzymes (40, 20, 10, 5 ng), alongside the standard 
deviation. 
 kcat  (s-1) KM (mM) kcat/KM  (mM-1 s-1) 
 
tAKMC 3.816 x 10-4  ±  2.421 x 10-4 0.047  ±  0.010 9.10 x 10-3  ±  7.30 x 10-3 
tAKM* 1.679 x 10-3  ±  3.154 x 10-4 0.047  ±  0.009 3.73 x 10-2  ±  1.06 x 10-2 
 
The apparent increase in KM of tAKMC and tAKM* likely indicates reduced substrate affinity. 
Although KM cannot necessarily be considered a direct affinity constant (based on its 
derivation, Chapter 1, Section 1.1.3.2), the fact that VMAX has been reduced so substantially 
indicates very slow turnover of product and therefore a small k2 rate constant. If this constant 
is smaller than k-1, the ratio of k1: k-1 represents the equilibrium constant for the formation of 
the [ES] complex and as such, provides an indication of the enzyme’s affinity for its substrate. 
Figure 20 Comparison of initial rate of reaction (RLU s-1) of tAKM, exposed to the conjugation 
conditions (tAKM*) as a function of substrate concentration. Tangents were fitted according to 
a linear fit function between 5 and 15 s. Kinetic parameters are labelled on the graph for 40 ng 
tAKM*. 
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The increase in KM in this case correlates to a reduced affinity of tAK towards ADP, resulting 
in weak substrate binding. This may have arisen as a result of changes to the secondary 
structure of the enzyme upon conjugation, or through partial enzyme inactivation as a result 
of the coupling conditions (i.e. the presence of DMSO).  
 
2.5 Conclusions and Future Work 
The research presented in this Chapter demonstrates how seemingly small structural 
changes to a protein can have large effects on the resulting physical and catalytic properties. 
The challenges associated with the genetic manipulation of a biological target (such as 
successful expression in a host strain, effective purification and retention of activity) can be 
extensive, yet they serve to highlight the evolutionarily perfected nature of bioactive 
proteins. The introduction of point mutations in tAK, resulting in the substitution of lysine for 
cysteine, was successful despite the formation of disulfide bridges. Upon reduction, the 
mutated enzyme was able to catalyse the formation of ATP at a similar rate to the wildtype 
enzyme. However, coupling of the mutant tAK to pyrene reporter probes reduced the activity 
of the enzyme substantially, likely as a result of both fluorophore attachment (hindering 
substrate access and/or inducing a change in the protein secondary structure), and the 
conditions used for conjugation. Additionally, the expected fluorescence signal from the 
interaction of the pyrene reporter ligands was absent upon substrate binding. Fluorescence 
signals were observed for the individual pyrene rings (monomer emission) in both the 
absence and presence of substrate. This may indicate insufficient conjugation (i.e. the 
attachment of a single ligand to each individual protein), or the generation of incorrectly 
orientated/ spatially arranged fluorophores.  
 
The future development of this work will need to establish two critical parameters, firstly the 
potential alternative amino acids for successful mutagenesis (those not involved in substrate 
binding, exhibiting similar chemical and physical properties to cysteine and located in 
regions which come into close proximity (~10 Å) upon substrate binding). Secondly, the 
choice of fluorophore may need to be further investigated. The nature of the spacer arm 
(separating the protein and the delocalised ring system) can influence the stability and 
orientation of the pyrene molecules. The introduction of an amide bond in the linker arm 
between fluorophore and protein has been shown to facilitate stabilising interactions within 
the protein microenvironment. This has successfully resulted in face-on orientation of pyrene 
rings and subsequent fluorescence output, as a result of π – π  stacking interactions 76. Finally 
the conjugation conditions should be optimised. For example, the choice of solvent  (in order 
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to retain enzyme activity), the choice of reducing agent and/ or chemical denaturant (in order 
to reduce buried disulfide bonds) and the choice of specific reduction and conjugation 
conditions (as the presence of molecular oxygen can initiate disulfide reformation and 
quenching of pyrene fluorescence 80). In addition to changing some of the fundamental 
parameters required for mutagenesis and conjugation, certain techniques may be employed 
in order to fully quantify and assess both experimental procedures. For example, mass 
spectrometry for the determination of single or multiple ligand functionalisation, circular 
dichroism for the evaluation of conjugation effects on protein structure, and column 
chromatography for the separation of unmodified and partially modified proteins from the 
doubly labelled mutant.  
 
As an alternative to optical excitation of fluorescent reporter probes for the detection of 
proteinaceous activity, there are a number of other luminescent-based signalling approaches 
also capable of exploiting changes in the spatial arrangement of biomolecules. 
Bioluminescence-resonance energy transfer (BRET) relies on the non-radiative transfer of 
energy from a bioluminescent donor to a fluorescent acceptor. This process provides certain 
advantages over standard fluorescence measurements (and fluorescence-resonance energy 
transfer (FRET) based measurements), notably a larger Förster distance, allowing signal 
generation over longer distances (5-10 nm) 82.  As a common bioluminescent energy donor, 
luciferase has been utilised alongside green/ yellow fluorescent proteins to form BRET pairs 
for a multitude of biosensing applications 83-85. Upon interaction of luciferase with 
coelenterazine (the substrate in this case), a characteristic fluorescence emission is observed 
which changes according to the spatial proximity of the donor/acceptor pair.  By construction 
of BRET pairs fused to bioactive proteins, it is possible to monitor physical effects of 
substrate binding, for example any conformational changes within a protein. This could be 
implemented with tAK via genetic modification to form a BRET fusion protein as shown in 
Figure 21. As a development of the current clinical biosensor (WASHtAK), a BRET based 
system could provide valuable insight into hospital associated sterilisation procedures, based 
































































Figure 21 Schematic showing potential BRET system using Renilla luciferase (RLuc), green 
fluorescent protein2 (GFP2) and tAK.  The binding of ADP causes a conformational change in 
tAK, decreasing the spatial proximity of the donor/acceptor pair, resulting in a measureable 
change in emission intensities upon energy transfer. 
tAK 
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“If I had thought about it, I wouldn't have done the experiment. The literature was full of 
examples that said you can't do this.” 
 












Part B: Chapter 3 
95 
 
Chapter 3: Recent Advances in Therapeutic Delivery Systems of 
Bacteriophage and Bacteriophage-Encoded Endolysins 
3.1 Introduction 
The purpose of this Chapter is to provide the theoretical basis of the research undertaken in 
the succeeding Chapters. This includes the clinical problem, potential biotherapeutic 
solutions and the current state of research in the context of bacterial infection control.   
 
3.1.1 Antibiotic Resistance 
The discovery and subsequent development of antibiotics has revolutionised modern 
medicine following the clinical introduction of penicillin almost 80 years ago 1. Since then, 
over 20 classes of novel antibiotics have been brought to market, each with a unique 
mechanism of action (MOA), targeting a range of pathogenic bacteria. Despite the initial 
success of antibiotic therapy, bacterial evolution has been equally assiduous in the 
installation of biological countermeasures, aimed at resisting cellular destruction as a result 
of antibiotic exposure. There are a number of different mechanisms of resistance (MOR) 
exhibited by bacteria, resulting in partial or full protection from antibiotics. Aside from 
intrinsic resistance, bacteria can acquire resistance via horizontal gene transfer (HGT)a, 
mutations in chromosomal genes (favoured by hypermutator bacterial strains), and as a 
consequence of selective pressures resulting from the presence of antimicrobial compounds 
or other contaminants 3. The physical manifestation of these resistance mechanisms can be 
classified into three main strategies: reducing the intracellular concentration of drug (via 
uptake inhibition or antibiotic efflux), modification of the antibiotic target (via pre- or post-
translational modification), and inactivation of the antibiotic compound (via enzymatic 
modification), as shown in Figure 1 4,5. A summary of some of the key classes of antibiotics 
and their respective MOA/ MOR is presented in Table 11,b.   
                                                             
a HGT refers to the transmission of genetic information between genomes from processes other than 
parent to offspring. HGT can occur through transduction, transformation and conjugation 2.  
b Gram classification refers to the Gram staining process used to differentiate the two main classes of 
bacteria based on the differences in their cell wall constituents (peptidoglycan content). Gram-positive 
bacteria have thicker cell walls compared to Gram-negative bacteria, and thus retain the colour of the 
stain (crystal violet) 6. 
 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The threat posed by the spread of drug resistant pathogens is particularly ominous owing to 
the fact that the antibiotic pipeline has effectively run dry. There have been only two new 
classes of antibiotics discovered in the last 20 years, yet it is estimated that at least 700,000 
people die globally each year as a result of resistant infections 16. The factors driving the 
continued evolution of bacterial resistance have been associated with their overuse in both 
the medical and the agricultural sectors.  
 
In the medical sense, antibiotics form the clinical basis of modern infection control, both in 
the hospital and in the community. However, their excessive and often inappropriate use has 
contributed to the selection of resistant bacterial variants. In many cases this is as a result of 
exposure to sub-lethal concentrations of antibiotic, (i.e. any concentration which is lower 
than the minimum inhibitory concentration (MIC) required to effectively inhibit bacterial 
growth). The generation of antibiotic concentration gradients within the body exerts a 
multitude of effects upon the bacterial population (both pathogenic and commensal), 
including the selection of resistance (de novo and pre-existing), the initiation of genotypic and 
Figure 1 Summary of some of the common classes of antibiotics and their MOA (top), 
alongside the common bacterial strategies employed in order to resist antibiotics (bottom). 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology 5. 
Copyright © 2017. 
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phenotypic alterations and changes in gene expression 17. There are a number of causes of 
such exposure, including inefficient dosing strategies, poor drug pharmacokinetics and issues 
surrounding patient compliance 5. With over 70 billion clinical doses administered worldwide 
in 2010 18, it is unsurprising that the responsible distribution and consumption of antibiotics 
is a continuous cause for concern and as such, a highly debated topic. The appropriate 
prescribing of any drug is the responsibility of the qualified person (doctor, pharmacist, 
clinician etc.), while the appropriate consumption of the drug is the responsibility of the 
patient. However, this strategy is only effective if both parties are acting upon the correct 
advice. In developed countries, antibiotics are only available with a prescription, which aims 
to standardise and limit antibiotic distribution 19. However, the advice given to patients upon 
prescription of antibiotic therapy has recently come under scrutiny. The current guidelines 
regarding the necessary duration of a course of antibiotics (as advocated by the World Health 
Organisation (WHO) and various governments across the world, including the UK 20), insists 
that a patient must finish the full course of antibiotics as prescribed by their doctor. This is 
(and has been for many years) one of the most widely accepted, fundamental pieces of 
medical advice distributed to the general population. However, a paper published recently 
(July 2017) in the British Medical Journal by a number of prominent health and infectious 
disease specialists, suggests that the current guidelines are advocated in the absence of any 
clinical evidence 21. The authors postulate that in direct contrast to the intended outcome 
(preventing the spread of resistance), the current notion of completing a full course of 
antibiotics is in fact resulting in gross over usage. With excessive use of antibiotics driving the 
evolution and spread of resistance, they suggest instead, that a patient should ‘stop when 
they feel better’, thus reducing prolonged, unnecessary administration. A detailed discussion 
regarding the ongoing debate as to the most effecting dosing strategies is outside the scope of 
this thesis, expert analysis is published elsewhere 22-25. However, the prospect of a tangible, 
clinical division in the recommended advice given to patients, and the inevitable confusion 
this will cause, is yet another ambiguous element in multitude of deciding factors governing 
the spread of antibiotic resistance.  
 
Aside from clinical use, the distribution of antibiotics within the agricultural sector accounts 
for an extortionate percentage of the global consumption. Annually, over 17 million 
kilograms of antibiotics are consumed in the US alone, 80% of which are used in the rearing 
of food animals 26. Furthermore, the administration of antibiotics to livestock is often 
deliberately maintained at sub MIC levels (for example as feed additives aimed at increasing 
growth rates), which has a multitude of negative connotations as previously mentioned. The 
ability of bacterial zoonoses to effectively transmit antibiotic resistance genes to human 
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pathogens is poorly understood (largely owing to a lack of robust surveillance and 
epidemiological data). Nevertheless, the antibiotic reservoir created by the excessive, over-
the-counter use of antibiotics in animal production is very much a threat to human health, as 
evidenced by the initial emergence of colistin resistance from a Chinese pig farm (which has 
now been documented in both clinical and agricultural samples 27,28). As a consequence of 
their overuse, many antibiotics are no longer therapeutically effective (or indeed 
prophylactically effective) in controlling infection in livestock, thus last-resort antibiotics 
(used to treat resistant infections in humans), are used in the agricultural sector. The 
implications surrounding the use of medically important antimicrobials in the production of 
food animals has driven a call from the US Food & Drug Administration (FDA), to limit such 
use to therapeutic purposes only, under the supervision of licenced veterinarians 29. 
Controlling the use of antibiotics outside of the clinic will be an important factor in retaining 
medical efficacy of the current treatment of bacterial infection.  
 
Whilst the administration (including both appropriate and inappropriate use) and the 
dissemination of modern antibiotics has indeed fuelled the ‘antibiotic crisis’ as we know it, 
the acquisition of genetic elements inferring resistance to antibiotics (and the subsequent 
genetic mobility exhibited by bacteria), is not a new phenomenon. Studies have shown that 
the presence of antibiotic resistance genes predates modern, clinical use of antibiotics. 
Analysis of permafrost sediments dating back 30,000 years has identified ancient microbial 
DNA encoding resistance to β-lactam, tetracycline and glycopeptide antibiotics 30. 
Furthermore, bacteria discovered in an isolated cave in New Mexico, devoid of any exposure 
to human activity for over 4 million years, have demonstrated resistance towards 14 
commercially available antibiotics (the genetic and phenotypic presentation of resistance in 
keeping with modern variants) 31. This research suggests that despite the modern selective 
pressure exhibited by the misuse of clinical antibiotics (whether this be overuse or under 
dosage), the future development of new antimicrobial drug compounds may in fact result in 
the inevitable selection of pre-existing resistance determinants, thereby limiting the effective 
lifetime of any new drug candidates. Based on the current trend, the average antibiotic 
encounters resistance within 2 years of marketing, and in some cases resistance is seen prior 
to clinical approval, for example in the case of tigecycline (likely as a result of structural 
similarities to tetracycline, of which tigecycline is a semi-synthetic analogue) 32,33. Both the 
development of novel antibiotics/antimicrobials and the implementation of more effective 
treatment strategies must be globally prioritised in order to prevent a return to the pre-
antibiotic era. The implications of a fast-approaching antibiotic void are vast, both in terms of 
treatment and prevention of infection. Certain surgical procedures would become unsafe and 
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otherwise easy-to-treat infections would prove fatal. Continuing on the current trajectory, it 
is estimated that by 2050 drug resistant infections will account for 10 million deaths 
worldwide (exceeding that of cancer), with a cumulative, global cost of antibiotic resistance 
exceeding $100 trillion (US) 16.  
 
There are a number of factors affecting the clinical development of new drug candidates. The 
economic and regulatory issues governing the initial discovery, successful development and 
marketing of a new antibiotic are undoubtedly hindering investment from large 
pharmaceutical corporations. It has been estimated that the cost of bringing a new drug to 
market can reach $2.5 billion (US), and in the case of antibiotics; phase 3 development alone 
can reach $30 – 150 million depending on the nature of the infection. With this in mind, a 
standardised, numerical prediction of the net value of a new drug over a given time period, 
known as the net present value (NPV), must be evaluated against the risk of failure, in order 
to make any potential investment economically viable. Recent analysis has estimated the NPV 
of an antibiotic to be a negative value (up to -$50 million), predicting an overall financial loss 
upon market entry 26. Antibiotics have a relatively low economic return compared to other 
more lucrative therapeutic areas, largely owing to their smaller contribution to the overall 
market value, thus the fine balance between the financial risk and the expected reward is an 
overwhelmingly unattractive venture for drug development companies.  
 
Despite the stagnation in antimicrobial drug development in recent years, the emergence of 
multidrug resistant (MDR) bacterial pathogens (including those now resistant to last-resort 
antibiotics such as colistin, previously considered exempt from HGT 28), is driving an urgent 
incentive for the establishment of global initiatives aimed at reviving antibiotic development. 
For example, the Innovative Medicines Institute (Europe) started the New Drugs for Bad Bugs 
campaign in 2013 34, the UK initiated a Review on Antimicrobial Resistance in 2014 16, the 
National Action Plan for Combating Antibiotic-Resistant Bacteria was released in the US in 
2015 35 and the WHO instigated the Global Action Plan on Antimicrobial Resistance 36. 
Furthermore, the WHO has recently released a global priority list of antibiotic resistant 
bacteria, identifying the most important resistant bacteria for which urgent (new) treatment 
is sought. Of the two highest priority levels, nine bacterial species are classed as critical, and a 
further six are classified as high priority 37. Alongside current interest in the discovery and 
development of new antibiotics, recent efforts are also aimed at the development of novel, 
alternative treatment options to be included in the ‘antimicrobial arsenal’ for use as single or 
adjunctive therapies alongside antibiotics.   
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3.1.2  Alternative Treatment of Infection 
3.1.2.1 Alternative Drug Based Strategies  
Alternative drug-based strategies aimed at controlling (and in some cases reversing) the 
presentation of antibiotic resistance in specific bacterial species and communities largely 
involve combination therapies; the administration of conventional antibiotics alongside 
additional small molecules, targeting certain features of the bacterial virulence machinery 38. 
This may include efflux pump inhibitors (EPIs); small molecules which prevent cellular 
antibiotic expulsion associated with MDR. At least two broad-spectrum EPIs have been 
identified and extensively characterised (peptidomimetics and pyridopyrimidines), however 
there are no clinical EPIs currently approved for therapeutic use, owing to their high toxicity 
and a lack of understanding regarding their exact mechanism of action 39-41.  
 
An alternative strategy involves the disruption of bacterial communication processes 
(quorum sensing). The ability of bacteria to communicate with one another has been 
implicated in both the onset of bacterial virulence and in the formation of biofilms (surface-
bound communities of microbial cells protected and held in place by an exopolysaccharide 
(EPS) matrix). Disruption or quenching of these processes can be initiated via inhibition of 
the enzymes responsible for the synthesis of quorum sensing molecules. The antibacterial 
Triclosan works in this manner by inhibiting a key enzyme involved in the biosynthesis of 
acyl homoserine lactone (a primary quorum sensing mediator) 42. In Staphylococcus aureus 
(S. aureus), the accessory gene regulator (agr) quorum sensing system regulates a number of 
key staphylococcal virulence factors (including enterotoxins, adhesins and exfoliative toxins) 
and as such, is considered an attractive target for the mediation of staphylococcal virulence 
43. The development of Savarin (a small molecule inhibitor, currently in preclinical 
development) successfully inhibited agr-dependent gene expression involved in 
dermonecrosis 44. A key advantage in targeting bacterial communication processes is the 
limited effect on the development of resistance. Rather than affecting bacterial survival 
directly, quorum sensing inhibitors (QSIs), predominantly target virulence factors whilst 
acting synergistically with antibiotics.  This is especially advantageous in the treatment of 
biofilms (which are notoriously difficult to penetrate using conventional antibiotics); QSIs 
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The development of resistance via the production of antibiotic inactivating enzymes, such as 
β-lactamases (which hydrolyse the β-lactam ring, destroying any antibiotic activity) and 
aminoglycoside modifying enzymes (which transfer functional groups to susceptible 
hydroxyl and amine moieties, again removing antibiotic activity), has also been the subject of 
significant investment into combating antibiotic resistance. One of the first examples of a 
clinically approved β-lactamase inhibitor is Clavulanic Acid. Exhibiting structural similarity to 
a traditional β-lactam antibiotic, Clavulanic Acid is a semisynthetic, suicide inhibitor 
(demonstrating competitive, irreversible binding), isolated from Streptomyces. Clinically 
administered alongside amoxicillin (co-amoxiclav), it inhibits enzymatic hydrolysis of the 
antibiotic, thus restoring antimicrobial efficacy. However, bacteria have subsequently 
evolved to produce previously unknown or rare β-lactamase enzymes which are largely 
unaffected by common β-lactamase inhibitors. Therefore the development of new and novel 
enzymatic suicide inhibitors is an ongoing strategy for many of the large pharmaceutical 
companies 46.      
 
Attenuation of bacterial virulence and/or restoring the potency of existing antibiotics are two 
promising strategies aimed at increasing both the lifespan of current (and future) 
therapeutics, and reducing the development of antimicrobial resistance.  
 
3.1.2.2 Bacteriophage 
Alongside the development of additional drug based therapeutics, the use of biological 
antimicrobials has gained significant attention in recent years owing to the rise in global 
MDR. The use of biological entities to treat bacterial infection may encompass the 
development of antimicrobial viruses/ vaccines, enzymes, peptides or the administration of 
specific genetic material (such as genes aimed at reversing resistance). Of particular 
relevance to this thesis is the use of bacteriophage (phage) and phage-encoded endolysins.  
Phage (from the Greek phagein, meaning ‘to eat’), are ubiquitous, predatory viruses of 
bacteria, outnumbering bacterial cells ten-fold. With an estimated environmental abundance 
of 1031, phage provide a form of biological control, consistently regulating the global bacterial 
population 47.  
 
‘Officially’ discovered in 1917 by Felix d’Herelle (the potential existence of antimicrobial 
viruses had been discovered independently by English bacteriologist Frederick William 
Twort in 1915 but was not pursued), phage were extensively studied in the former Soviet 
Union and Eastern Europe following their initial discovery 48.  One of the most prominent 
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institutions concerned with the therapeutic development of phage during this time (and is 
still very much in operation today), is the Eliava Institute in Tbilisi, Georgia. Established in 
1923 by Giorgi Eliava (who was later executed by Stalin’s secret police as a ‘People’s Enemy’), 
the Eliava Institute conducted a wealth of experiments into the therapeutic potential of phage 
treatment. Most notably, the prophylactic efficacy of phage to treat dysentery in children was 
evaluated in an extensive study in 1963/4 with over 30,000 test subjects included in the 
study 49. Despite some promising initial findings from early experiments into phage therapy 
from the Eliava Institute and the Hirsfeld Institute in Wroclaw, Poland 50, parallel 
development of this potential new technology was absent in the Western world owing to the 
superior development of antibiotics. However, in light of the global dissemination of 
antibiotic resistance, coupled to a greater understanding of phage biology, there has been a 
scientific revival in phage-associated infection control. Advanced studies into phage therapy 
(to the point of human administration) were achieved the West in 2000 with the first phase I 
clinical trial published in the USA in 2009 48,51.   
 
Classification of phage (concerning the wide variation in viral morphology), is governed by 
the International Committee for Taxonomy of Viruses 52, a summary of the different families 
and their characteristics is presented elsewhere 53. For the purpose of this thesis the most 
relevant is the Caudovirales order (which it is estimated that over 96% of phage belong), 
consisting of three distinct families: Myoviridae, Siphoviridae and Podoviridae 54. The key 
features of this family of phage are double stranded, linear DNA, tailed particles (both 
contractile and non-contractile) and adhesion structures (baseplate and tail fibres/ spikes), 













Figure 2 Representative structure of a tailed bacteriophage belonging to the Caudovirales 
order, consisting of (A) icosahedral head containing double stranded DNA, (B) sheathed tail 
comprising (i) multiple tail fibres and (ii) base plate. Adapted from 55. Copyright © 2016 
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There a number of key requirements and considerations associated with the use of phage as a 
biotherapeutic treatment option, including: 
 
 Phage preparations should be fully characterised, including genome sequence and 
structure. 
 The phage should be lytic (virulent) and non-transducing (discussed below). 
 Phage-bacteria interactions should be understood, including the bacterial surface 
receptors required for phage adsorption. 
 Animal models should be employed in order to confirm any in vitro efficacy.  
 Phage preparations should be pure (i.e. have undergone lysate purification), and the 
preparation should conform to all safety and regulatory requirements 56.  
 
Phage infect and replicate in the presence of bacteria in a number of different ways 
(depending on the nature of the phage), either they replicate via the standard viral infection 
cycle (lytic, resulting in bacterial lysis – as described in Section 3.2.4), or they can initiate a 
lysogenic, pseudo-lysogenic or chronic infection. Perhaps one of the most important 
considerations when prospecting phage for use as a therapeutic is the potential for 
transduction. Transduction originates during the lytic cycle, whereby certain phage 
demonstrate the ability to acquire fragments of bacterial DNA. During cell lysis the bacterial 
chromosome is cleaved into small segments which the newly assembling phage virions can 
mistakenly incorporate as opposed to, or in addition to phage DNA (owing to the low fidelity 
in bacteriophage DNA packaging) 57. The resultant transducing phage are then able to infect 
further host strains and inject their genetic material (now containing bacterial DNA), which is 
incorporated into the host chromosome via recombination, yet is defective for replication of 
phage progeny (Figure 3 58). Whilst this mechanism relates to the lytic infection cycle, this 
phenomenon is relatively uncommon in lytic phage owing to the extensive degradation of the 
host genome during infection with virulent phage 59. 
 





However, some phage (termed temperate) do not initiate the lytic infection cycle in the first 
instance, instead they inject their DNA into the host, which becomes incorporated into the 
bacterial chromosome as prophage, where it lies dormant in a latent state. During this time, 
the infected bacterium is resistant to further infection and the phage genome is transmitted 
through multiple bacterial generations at the point of cell division. This type of infection is 
referred to as lysogenic. It is possible for the viral prophage to become activated as a 
response to bacterial stress (such as DNA damage), in which case the lytic infection cycle is 
initiated. In this case, the prophage is excised from the bacterial chromosome and new phage 
virions are assembled according to the expression of lytic genes. Transduction can occur as a 
result of improper excision, resulting in the acquisition of neighbouring bacterial genes. 
Owing to the specific incision sites for the incorporation of prophage into the bacterial 
chromosome, temperate phage are only able to transduce specific host genes, this is referred 
to as specialised transduction, in contrast to generalised transduction (as previously 
described). The phage-assisted horizontal gene transfer of bacterial genes from one 
bacterium (donor) to another (transduced) can increase the virulence of the recipient, as a 
Figure 3 Schematic detailing the steps involved in transduction during the lytic 
phage infection cycle. Upon cell lysis phage acquire fragmented bacterial DNA (a+/ 
b+) from the donor bacterium. These donor genes may then be inserted into a 
recipient bacterium during phage infection, where they are incorporated into the 
bacterial genome via recombination, resulting in the formation of a transduced 
bacterium containing foreign bacterial DNA. 
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result of the expression of gene products encoded by prophage during lysogeny. This has 
been demonstrated via the lysogenic conversion of multiple phage-encoding virulence factors 
including; diphtheria toxin, botulinum toxin, cholera toxin, certain staphylococcal virulence 
factors (such as enterotoxin A) and many more 60,61. In light of the potential for phage to 
increase the fitness and survival of the bacterial host, it is therefore essential that temperate, 
transducing phage are eliminated from any potential therapeutic applications. Successful 
development of clinically relevant phage preparations has been demonstrated in a number of 
pre-clinical and clinical trials (discussed in Section 3.2.4).  
 
3.1.2.3 Bacteriophage Endolysins 
Whilst it is possible to source non-transducing, virulent phage, conforming to all safety and 
regulatory requirements for therapeutic application, perhaps a more convenient approach to 
antimicrobial therapy is the use of phage-encoded enzymes. This term may encompass 
depolymerases (involved in EPS breakdown) and lysins; ectolysins (responsible for 
peptidoglycan cleavage on the cell surface, assisting in phage DNA injection) and endolysins 
(responsible for intracellular peptidoglycan cleavage, facilitating the release of phage 
progeny) 62, the latter being the most relevant to this thesis. Devoid of any transducible 
genetic information, endolysins encoded by the phage genome are expressed during the late 
stages of the lytic infection cycle and are required for successful cell lysis. Despite the fact 
that phage endolysins are endogenous in their native form, they are also capable of achieving 
efficient bacterial lysis when applied extracellularly. Exhibiting the same specificity towards a 
bacterial host strain as the parent phage from which they are derived, endolysins are capable 
of causing rapid bacterial cell lysis and have thus far failed to initiate any form of bacterial 
resistance 63.  
 
Endolysins are broadly categorised according to their structure as globular (consisting of a 
single catalytic domain), or modular (consisting of two or three domains including a catalytic 
domain and a cell wall binding domain, with or without an additional protein domain). As 
evolutionary advanced hydrolase enzymes, the specific activity of endolysins towards the 
peptidoglycan bacterial cell wall can be attributed to either; cleavage of the glycosidic 
linkages (glycosidases and transglycosidases), or cleavage of the peptide cross-bridges 
(amidases and endopeptidases) 64, the specific target sites are shown in Figure 4 65,66.  A 
review detailing a number of different phage-encoded endolysins and their mechanism of 
action is published elsewhere 67. 
 
 
























3.1.3 Therapeutic Delivery Systems 
Both whole phage and phage-encoded endolysins have demonstrated significant potential in 
the clinical treatment of infection 62. However, certain applications require an effective 
delivery system in order to protect and control the release of the therapeutic cargo. In 
addition to the specifications required for any bioactive compound/therapeutic agent, such 
as favourable ADMET parameters (Adsorption, Distribution, Metabolism, Excretion and 
Toxicity), all of which must be critically evaluated and optimised at the preclinical stage, the 
delivery vector must also conform to all current safety and regulatory requirements 68,69. 
Some of the crucial factors governing the clinical success of a drug delivery system include 
biocompatibility, mechanical stability, degradation pathways and manufacturing cost 70.    
 
The nature of the delivery system can have a significant effect on the properties of the 
therapeutic agent; this is especially relevant in the case of biological therapeutics. The 
delivery system may enhance or reduce clinical efficacy of the biological cargo, with respect 
Figure 4 Schematic illustrating the peptidoglycan cell wall consisting of alternating sugar 
units: N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc), crosslinked via 
peptide cross-bridges. The schematic highlights the various target sites of phage-encoded 
endolysins/ virion-associated peptidoglycan hydrolases (VAPGH). Reproduced from 66. 
Copyright © 2015 Taylor & Francis Group, LLC.  
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to crucial considerations such as biodistribution, pharmacokinetics or pharmacodynamics. 
For example, certain polymeric formulations can increase the exposure of therapeutic 
proteins, reducing the frequency of administration, thus potentially increasing patient 
compliance. On the other hand, fusion proteins (consisting of an antibody fused to a 
therapeutic protein), aimed at increasing the serum persistence of the therapeutic agent, 
have shown potential immunogenic properties 71. A comprehensive review of past, present 
and future delivery technologies for a range of drug and therapeutic agents has been 
conducted by Tibbitt et al 72. The following Section details specific strategies employed for the 
therapeutic delivery of phage and phage-encoded endolysins. This review aims to provide the 
theoretical reasoning and key considerations involved in the thermally triggered release of 
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Antibiotics have been the cornerstone of clinical management of bacterial infection since 
their discovery in the early 20thcentury. However, their widespread and often indiscriminate 
use has now led to reports of multidrug resistance becoming globally commonplace. 
Bacteriophage therapy has undergone a recent revival in battle against pathogenic bacteria, 
as the self-replicating and co-evolutionary features of these predatory virions offer several 
advantages over conventional therapeutic agents. In particular, the use of targeted 
bacteriophage therapy from specialised delivery platforms has shown particular promise 
owing to the control of delivery location, administration conditions, and dosage of the 
therapeutic cargo. This review presents an overview of the recent formulations and 
applications of such delivery vehicles as an innovative and elegant tool for bacterial control.  
 
Key Words:  Bacteriophage, Endolysin, Encapsulation, Immobilisation, Stimuli-Responsive, 




Following the discovery of penicillin in 1928 by Alexander Fleming and the subsequent 
development of modern antibiotics, the World has enjoyed a period of relative safety from 
the threat of bacterial infection. However, Fleming himself was discerningly cautious about 
the potential of modern antibiotics to keep this threat at bay, going on to describe the 
possibility of developed resistance in his 1945 Nobel lecture detailing the dangers of 
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“underdosage” 73. This predicted evolution of multidrug resistant bacteria, and the 
subsequent decline in the production of novel antibiotics has driven a resurge of interest in 
the once forgotten viral therapies of the Eastern Bloc countries. Bacteriophage (phage) have 
been developed for therapeutic use since their discovery in the early 20th century, dominating 
antimicrobial treatment in the East where the antibiotic panacea failed to translate as 
effectively 74,75. As ubiquitous predators of bacteria, phage exist in the biosphere alongside 
their host, continuously engaged in a biological game of cat and mouse, resulting in an 
estimated 50% reduction in the global bacterial population every 48 hours, arising from 
phage predation alone 76. Phage propagate in bacteria through lytic development or lysogenic 
replication  (Figure 5) 77. For use as therapeutic agents, lytic phage (incapable of lysogenic 
infection and more potent than temperate phage) are identified by phenotypic and structural 
characterisation as well as genetic sequencing, in order to avoid any possible genetic transfer 
events, such as transduction.  
 
Figure 5 Standard viral replication cycles of bacteriophage. The closure of the newly 
formed circular DNA and corresponding cohesive site is denoted ‘cos’.  Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Genetics 77. Copyright ©2013. 
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As host specific infectious agents, phage have been investigated as a form of bacterial 
biocontrol, with a range of applications in the medical, agricultural and biotechnology 
industries 78-81. Owing to their high natural abundance, phage are relatively easily sourced 
and have been successfully isolated from all ecological environments in which bacteria are 
also present 82. When used in combination as a phage cocktail, they are able to infect and 
destroy a multitude of bacterial species including both Gram-positive and Gram-negative 
strains.  These self-replicating virions are also active against antibiotic resistant isolates such 
as Pseudomonas aeruginosa (P. aeruginosa), a multidrug resistant pathogen associated with a 
range of infectious diseases 83. There have been a number of phage based products approved 
by the FDA within the agricultural sector including; ListSheildTM for use on ready to eat meat, 
seafood and food contact surfaces, SalmoFresh for poultry, fish and fruit and vegetables, 
EcoShield for red meat and LISTEXTM for meat, fish and cheese 84. However, there are 
currently no licenced bacteriophage or bacteriophage derived products approved for human 
therapeutic use in the EU or the USA.  
 
The need for regulated clinical trials and compliance with current manufacturing guidelines 
is a major complication in the implementation of sustainable phage therapy. The reliability of 
early studies from previously inaccessible countries (such as those within the former Soviet 
Union), have since been called into question based on factors such as lack of blinding and co-
administration with antibiotics during early experimental therapy  85. However in response to 
the ever-pressing requirement to develop new and more effective antimicrobials, the 
development of phage based products has recently seen some promising pre-clinical results, 
with a number of clinical trials underway. PhagoBurn (Trial Number NCT02116010 86), 
funded by the European Union is currently undergoing phase I/II trials utilising a phage 
cocktail to treat burn wound infections with results expected in March/April 2017. AmpliPhi 
Biosciences have a phage product AB-SA01 (Trial Number NCT02757755 87), active against 
Staphylococcus aureus (S.aureus) entering into phase II trials for the treatment of both 
chronic rhinosinusitis and bacterial skin infection. Previous clinical trials adhering to modern 
protocols have also seen success in the treatment of a range of infections, including venous 
leg ulcers, otitis and reduction of bacterial load in the nasal carriage 51,88,89. In addition to 
regulatory and clinical requirements, the pharmacokinetics (PK) and pharmacodynamics 
(PD) of phage therapy must be considered. The administration of an antimicrobial at the site 
of infection must be both timely and in sufficient concentration to elicit a response, thus 
avoiding effects such as sub-lethal dose administration (with associated resistance 
development), immune response/ clearance, and diffusion limitations 90. The physiological 
stability of such biological entities must be maintained during treatment, including the 
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prevention of neutralization (by antibodies or other such compounds), and protein 
degradation via localised environmental conditions 91. The trials described above all focus on 
topical application of phage. One of the outstanding questions regarding their suitability for 
treatment of a wider range of infections is their suitability for systemic delivery. To be able to 
apply the phage distant to the site of infection necessitates a greater understanding of the 
clearance of phage from the body and strategies to maintain an effective concentration long 
enough for phage attachment to the pathogen and subsequent infection and amplification. 
Both the innate and adaptive immune system have a role in reducing the level of circulating 
phage. This has been discussed in detail recently and is outside of the scope of the current 
review 78. This is likely to be a key determinant of therapeutic efficacy, but a number of the 
encapsulation and delivery methods described below also help to reduce immune clearance 
as well as enhancing other aspects of PK/PD. Therefore, the development of suitable delivery 
vehicles has received considerable attention recently in order to improve and maintain the 
pharmacological properties of therapeutic phage products in vivo.  
 
A range of techniques have been employed in recent years utilizing various technologies 
(encapsulation, immobilization, conjugation etc.) to successfully exploit bacteriophage for a 
number of applications including; sensing and detection of infection, bacterial capture and 
phage-assisted delivery of therapeutic cargo 92-97. The bacterial acquisition of specific genes 
via phage guided delivery, using CRISPR-Cas technology, for sensitization of previously drug 
resistant bacterial isolates 98,99, and the delivery of genes expressing novel antibacterial 
agents (SASPject; 100) has demonstrated the versatility and extent to which phage have the 
potential to be utilized in modern medicine. This review will focus on the current 
advancements in delivery systems capable of housing phage for the specific therapeutic 
purpose of treating bacterial infection, with particular emphasis placed on the stabilisation 




The successful administration of a therapeutic agent to a target site often depends on a 
suitable delivery vehicle to ensure it reaches the infection site. An example of this is 
pulmonary delivery; an area in which phage have received considerable attention in recent 
years, owing to the increase in multidrug resistance amongst bacterial isolates, including 
those associated with pneumonia and tuberculosis. Klebsiella pneumoniae (K. pneumoniae) is 
a major cause of nosocomial pneumonia, especially amongst immunocompromised patients 
with reported mortality rates as high as 60% 101. Whilst previously considered an 
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extracellular pathogen, this Gram-negative bacterium has shown the ability to become 
internalised in vivo by certain cell types including lung epithelial cells 102. Therefore, effective 
treatment requires intracellular access, a concept referred to as the ‘Trojan horse’ approach, 
relying on a suitable vector to transport phage across the eukaryotic cell membrane, 
delivering the antimicrobial cargo directly into the infected cell. The ability of bacteria to 
colonise intracellularly, serving as a reservoir of infection and the inability of phage to enter 
myeloid cells, has previously rendered phage therapy ineffective for certain conditions. 
However the use of lipid-based carriers as a means of transportation across the cell 
membrane may offer the possibility of phage as a viable treatment option. Liposomal 
entrapment of the fully characterised lytic phage KPO1K2 appears to provide enhanced 
intracellular uptake into phagocytic cells in order to target engulfed K. pneumoniae present 
within macrophages. In the case of encapsulated phage, ~95% of the intracellular bacteria 
was eradicated within 24 hours compared to no significant difference in intracellular 

















Liposomal entrapment has also been utilized for the potential intracellular treatment of 
tuberculosis via successful encapsulation of the mycobacteriophage TM4 or the reporter 
bacteriophage λeyfp into giant unilamellar vesicles (GUVs), by a variety of preparation 
techniques. Enhanced uptake into eukaryotic cells (THP-1 macrophages) was seen with 
encapsulated phage compared to free phage, and no sign of mechanical damage to the 
liposome was observed as a result of phage encapsulation 104.  
A B C 
Figure 6 Confocal micrograph showing intracellular bacterial content using Live/Dead 
fluorescent staining A) Untreated macrophages, showing intracellular bacteria in yellow B) 
Infected macrophages treated with free phage, but with intracellular bacteria still evident C) 
Liposome treated macrophages with apparent intra cellular eradication of bacteria. Figure 
adapted from 103. 
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Encapsulation of phage for the purpose of treating pulmonary-associated infection has shown 
additional benefits in terms of neutralisation protection. Cationic liposomal entrapment 
appears to offer a protective barrier from which phage are able to evade anti-phage 
antibodies. Antibodies produced by the mammalian immune system in response to phage 
therapy have shown the potential to render phage inactive, a problem which appears to be 
dependent both on the type of phage used and the delivery route chosen 105. Liposome 
encapsulated phage (active against K. pneumoniae) incubated alongside bacteriophage 
antibodies from mouse serum, experienced complete protection from any degradative effects, 
whereas unencapsulated phage appeared to undergo complete neutralisation, with no active 
phage particles remaining after 3 hours incubation in-vitro 103.  
 
Moreover, previous studies have shown that the efficacy of phage therapy in animal models is 
effective only after almost immediate administration post infection, whereas liposome 
entrapped phage appear to retain antibacterial activity against pulmonary associated 
infection even when treatment is delayed for up to 3 days post infection 106. Furthermore, 
liposomal encapsulation of phage has demonstrated a greater degree of bio-distribution and 
bio-retention compared to free phage. This has been shown in in vivo experiments via the 
inoculation of mice with both free phage and phage encapsulated within phospholipid 
vesicles. Encapsulated phage were present at higher peak levels and concentrations were 
maintained longer, declining after 12 hours for encapsulated phage compared to 6 hours for 
free phage. Phage remained detectable for up to 4 days in blood, 6 days in the liver, lungs and 
kidney, and up to 14 days in the spleen following a single intraperitoneal injection, compared 
to undetectable levels after 48 hours in all four organs when using free phage (aqueous 
suspension) 107. The maintenance of maximal concentration and length of persistence of 
phage in the circulation observed in this study, suggests that systemic treatment may be 
possible using such approaches.  
 
Nanoemulsions consisting of phage within the aqueous core of a lipid suspension (water-in-
oil-in-water), have gained attention, owing to the enhanced functional and structural stability 
of the entropically confined phage encased within such micelles. A positive correlation has 
been seen between the fatty acid chain length of the lipid micelle and the emulsion stability, 
manifested as an overall long term stability of up to 3 months at room temperature 108. 
Alongside an increase in shelf life, the use of nanoemulsions has previously shown higher 
infectivity rates of bacteriophage when compared to aqueous phage suspensions, possibly as 
a result of the elimination of electrostatic repulsions between the negatively charged phage 
and bacteria 109,110.  
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Encapsulation of phage and the resulting protective effect has been exploited in the targeted 
delivery of bacteriophage K (active against S. aureus) to the intestine via oral delivery. 
Ensuring the successful delivery of phage (or any biological therapeutic) through the 
gastrointestinal (GI) tract relies on a protective strategy to prevent  inactivation by stomach 
acid, an issue previously encountered with other encapsulation formulations, with 
detrimental effects observed as a function of microsphere size (<100 µm) and possible acid 
diffusion into the microspheres 111. The utilisation of a microsphere delivery system 
consisting of alginate microspheres co-encapsulating calcium carbonate and phage K has 
shown to provide a more robust protective effect against simulated GI fluid than alginate 
microspheres alone. Moreover, the addition of protective additives such as maltodextrin (up 
to 20% w/v) to the microcapsules has shown to increase the viability of phage K after drying, 
thus allowing for dry form encapsulated phage preparation 112. This was further investigated 
using alginate-whey protein microspheres with maltose as a protective agent against 
dehydration effects. The encapsulated phage K exhibited enhanced stability after drying, 
likely as a result of the high glass transition temperature of the disaccharide: preventing 
denaturation by alteration of the protein dynamics through physical confinement. In addition 
to any benefits offered by dry formulations in this instance (ease of storage, transport and 
administration), dry powders containing phage exhibited storage stability at both 4 °C and  
23 °C with over 80% of the encapsulated phage retaining viability at the higher temperature 
after two weeks 113. Similarly, Escherichia coli (E. coli) O157:H7 bacteriophage have been 
successfully encapsulated in chitosan-alginate microspheres, demonstrating stability and 
sustained release under simulated gastric conditions at pH 2 and 2.5. This has potential 




The surface anchoring of biological entities with retention of their original function can be 
problematic owing to conformational changes in tertiary protein structure (denaturation) 
and changes in water content caused by the binding of proteins and protein ensembles to 
what are often rigid supports. However, the therapeutic use of phage may require 
immobilisation on abiotic surfaces (such as medical devices including stents, tracheal tubes, 
catheters etc.) since such devices are particularly prone to bacterial biofilm formation: the 
ability of bacteria to colonise surfaces, forming dense and often impenetrable biofilms. A 
recent method targeted at successful phage immobilisation, has utilized plasma-associated 
activation of polytetrafluoroethylene (PTFE) and ultra-high molecular weight polyethylene 
(PE). Low temperature plasma treatment of such polymers created reactive acid groups 
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which were used as anchor points for phage attachment. Such immobilised phage retained 
activity against both E. coli and S. aureus despite confinement at the surface. Figure 7 shows 
the steps involved in amide formation and subsequent phage attachment. Furthermore, the 
surface-bound phage retained bactericidal activity for several months under specific 
conditions (high humidity/ aqueous environment) 115. This technology demonstrates the 
potential of phage-coated surfaces as potent antimicrobial interfaces capable of targeting 
important human pathogens, with the potential to prevent biofilm formation.  
 
 
Figure 7 Steps involved in phage anchoring for the prevention of bacterial adhesion and 
biofilm formation. A) Plasma mediated formation of surface acid groups B) Phage 
attachment via amide bond formation C) Phage capture of bacterial cells D) Bacterial 
lysis post phage infection. Reprinted with permission from 115. Copyright © 2013 
American Chemical Society. 
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There are additional examples in the literature of successful phage binding to surfaces for 
purposes other than therapeutic treatment such as biosensors, bacterial capture platforms 
and antimicrobial coatings for food packaging 116-118. Optimizing the parameters for 
successful phage immobilisation in terms of surface density, orientation, infectivity and 
stability is paramount in the development of any phage-based surface platform. Once 
established, this technology has the potential to be utilized for a range of applications, 




Inactivation of phage as a result of environmental factors such as temperature, pH and UV is a 
major hurdle in the development of phage therapy, affecting both delivery route and stability. 
Phage-polymer ensembles have been shown to offer beneficial effects in terms of protein 
stability with respect to external conditions, offering the possibility of efficient storage and 
therapeutic use of phage for the treatment of infection. An example of this is the use of the 
naturally occurring polymer, poly-γ-glutamic acid (γ-PGA). Whilst the mechanism behind the 
protective effect is not yet fully understood, even in very low concentration ~1%, this 
biodegradable polymer has shown to effectively protect two different E. coli phage, MS2 and 
T2 (from the Leviviridae and Myoviridae families respectively), against temperatures of up to 
60 °C, possibly as a result of physical protection of the viral particles. Protection against UV 
exposure was also seen with γ-PGA formulated phage, again possibly as a result of physical 
protection or refraction of the radiation. In the case of the T2 phage, a significant increase in 
survival rate was seen at a range of pH values via polymer stabilisation 119. This is likely due 
to the pH sensitive nature of the polymer itself, which undergoes a conformational change at 
low pH where it exists in an alpha-helical conformation, potentially encasing the phage and 
protecting it from the acidic environment. γ-PGA exists in a linear random-coil conformation 
at neutral pH, hence the protective effects at higher pH are still poorly understood. However, 
further research may provide enhanced techniques for the protection of phage, with 
implications for both delivery and storage conditions.  
 
Naturally occurring polymers such as proteins have shown potential to stabilise vaccine 
formulations, a concept which would have significant implications for the transportation and 
successful administration of human vaccines, especially in the developing world. Long term 
stability in elevated temperatures would drastically improve the often unreliable and 
expensive ‘cold chain’ transportation network required to distribute global immunisation 
treatment 120. Building on this concept, recent efforts have taken the same approach using silk 
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proteins to stabilise phage against high temperatures, showing greater efficacy in protective 
effects when compared to a non-silk protein (bovine serum albumin). Results obtained 
showed 100% loss of viable phage in the absence of protein after one day incubation at 37°C, 
whereas the addition of various silk proteins (honeybee, hornet and silkworm), resulted in a 
maximum loss of 6% viable phage (Figure 8A). Indeed, the use of honeybee silk significantly 
enhanced phage survival even at 50 °C for up to 8 weeks (Figure 8B) 121. A suggested reason 
for this is the increase in favourable protein-protein interactions, in preference of water-
protein interactions within the hydration shell surrounding the phage.  
A 
B 
Figure 8 Loss of viral infectivity as a function of protein addition. A) After incubation at 37 °C 
with and without different proteins B) After incubation at various temperatures alongside 
honeybee silk. Inset highlights the correlation between viral viability and incubation 
temperature. Adapted with permission from 121. Copyright © 2014 American Chemical 
Society. 
 





Nebulization of drug formulations is a common methodology for the delivery of 
pharmaceutics and biopharmaceutics for inhalation directly to the lung. Patients suffering 
from cystic fibrosis (CF) are of particular concern, owing to their high susceptibility to 
infection. The administration of aerosolized phage via nebulization has previously been 
employed in a mouse model to evaluate the efficacy of phage therapy against a group of 
opportunistic pathogens: Burkholderia cepacia complex (BCC) organisms, capable of infecting 
immunocompromised patients. The results obtained showed a significant reduction in 
bacterial load within the lungs of immunocompromised and BCC infected mice (in some cases 
comparable to conventional antibiotics), using a range of different phage with varying 
multiplicities of infection (MOI) 122. Further investigations into the use of nebulization as a 
delivery system for phage treatment has focused on P. aeruginosa, another common pathogen 
associated with CF, capable of causing respiratory failure in up to 95% of patients 123. In this 
case, it was determined that the amount of phage delivered to the infection site which, for an 
infection such as this, concerns the lower respiratory tract, the choice of nebulizer also plays 
a significant part. It was concluded that a jet nebulizer is most effective, as 12% of the phage 
contained within particles and placed within the nebulizer, were small enough (< 4.7 µm) to 
be inhaled into the lower lung whilst retaining viability 124.  
 
Another important consideration in the development of any therapeutic system is the 
potential for scale-up operations. In order to establish a viable delivery system, one must take 
into consideration a number of different factors including cost, feasibility of application, 
convenience and downstream processing steps. Whilst nebulization has shown promising 
results in terms of successful delivery, there are some concerns surrounding the expense and 
the complexity in the procedures associated with their use outside of the clinic (i.e. in a 
patient’s home). As a potential alternative, recent efforts have focused on dry powder 
inhalers (DPIs), as a means of delivering phage in order to combat respiratory infection. 
Compared to nebulizers, DPIs are small, cheap, easy to operate and have been shown to 
successfully deliver a wide range of pharmaceuticals 125. Aerosolized powders containing 
bacteriophages KS4-M and ɸKZ, targeting both BCC and P. aeruginosa respectively, 
demonstrated successful stabilisation of the lyophilized phage alongside retention of viability 
utilising a 60: 40 w/w matrix of lactose/lactoferrin 126.  
 
In addition to freeze dried formulations for use in DPIs, spray drying has been investigated 
for pulmonary delivery of phage as it is a less energy intensive process and requires fewer 
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downstream processing steps. Using atomization as a potentially scalable process, two 
morphologically different phage, Pseudomonas phage LUZ19 and Staphylococcus phage 
Romulus, were successfully formulated into respirable powders in the presence of various 
excipients in order to protect the phage. Of those investigated, trehalose was found to be 
most effective in terms of protective effects, demonstrating increased stability at low 
temperature (4 °C). However, further investigation into thermal stability showed a 
pronounced effect on phage viability at higher temperature (25 °C) and high humidity. This is 
likely as a result of crystallization of the trehalose-phage amorphous matrix, thus highlighting 
the importance of suitable storage conditions of powder formulations containing phage 
particles 127.  In addition, the formation of phage-containing particles with the correct size 
parameters suitable for pulmonary delivery (between 1 and 5 µm) was found to be 
dependent on the type of phage, as previously postulated. Romulus-containing powders 
exhibited a higher percentage of suitably sized particles, when compared to podovirus 
LUZ19-containing particles. In contrast, the reduction in phage titre post spray drying (even 
in the presence of stabilising agents) was higher for Romulus phage (>2.5 log reduction), 
compared to LUZ19 (<1 log reduction), possibility as a consequence of shear stress on the 
long tail structure of the myovirus Romulus 128. Therefore, the utilisation of dry powder 
phage therapy for treatment of pulmonary infection must rely on a compromise between 
particle size and phage survival, a fine balance which is evidently phage specific and very 




Alongside the stability and release-location of bacteriophage, the release-kinetics from the 
delivery matrix must also be considered. Stimuli-responsive systems should remain 
kinetically silent, unless a ‘burst release’ of the therapeutic agent is initiated in response to an 
external stimulus (e.g. temperature, pH, light, ultrasound or biomarker signals). Thereupon, 
adequate dosage of the antimicrobial is rapidly delivered to the correct physiological location 
in response to a successful bacterial infection. By avoiding systematic dosage of the often 
delicate biological cargo, triggered phage release systems can in principle avoid reduction in 
viable phage count commonly associated with exposure to biological fluids/ temperature 
fluctuations 129. Moreover, triggered release systems can help ensure bacterial pathogens are 
not exposed to sub lethal doses of phage, making the phage more effective and slowing 
evolution of bacterial resistance.  
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Triggered-release phage systems are being developed with the potential for treatment of 
wound infection. Such systems are designed as modifications of existing wound dressing 
materials such as non-woven polymers, in order to incorporate stimuli-responsive phage 
delivery systems. One such system employs the thermally responsive polymer poly(N-
isopropylacrylaminde) (PNIPAM), which undergoes a reversible, temperature-dependent 
phase transition at the lower critical solution temperature (LCST), manifesting as an 
unambiguous change in polymer volume. Control of the LCST was established via formulation 
with allylamine (ALA), allowing the system to undergo a transitional collapse at 34 °C. 
Impregnation of PNIPAM-co-ALA nanospheres with S. aureus phage K, and subsequent 
grafting to a non-woven polypropylene ‘dressing’ was achieved via amine coupling to plasma 
deposited maleic anhydride. Utilising the proximity of the polymer’s morphological change to 
healthy skin temperature (32 °C), thermally-triggered release of phage K from the 
nanospheres was engineered to occur in response to infected skin, which often displays an 
increase in skin temperature as large as 3.6 °C. Incubation of phage-loaded nanospheres with 
S. aureus ST228 showed release of the phage cargo and subsequent cell lysis at 37 °C, whilst 
the bacterial lawn remained confluent at temperatures associated with healthy skin 130.  
 
In addition to secondary physical stimuli, primary biomarker signals have been utilised to 
trigger the release of phage K for the treatment of infected skin wounds. Hyaluronidase 
(HAase) is an important virulence factor known to be secreted by pathogens associated with 
skin infection, including S. aureus. Degradation of hyaluronic acid (HA) in the skin by HAase is 
thought to aid bacterial invasion of tissue via cleavage of the β-1,4 position in HA, hence 
allowing the enzyme to act as a spreading factor within the process of bacterial pathogenesis 
131. A HA/HAase system has been developed comprising of a dual-layered hydrogel matrix 
which allowed HAase to trigger release of phage K for treatment of pathogenic skin infection 
132. Photo-cross-linked HA methacrylate (HAMA) hydrogels were used to cap and seal a lower 
reservoir layer of phage K containing agarose hydrogel. Clear visual signs of enzymatic 
degradation and subsequent phage release (ca. 105 PFU/ml) were observed when incubated 
with the supernatant of a wide range of S. aureus isolates. Both aforementioned examples of 
the incorporation a bacteriophage delivery system to a dressing platform exemplify the 
potential for future phage therapy, where phage virions are incorporated into a compatible 
carrier matrix.  
 
Examples of photo-responsive systems utilizing bacteriophage, either within a 3 dimensional  
supramolecular hydrogel for cell culture and release 133, or in the derivation of a virus-like 
particle (VLP) for the photocaged delivery system of the anticancer drug doxorubicin 134, 
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demonstrate the wide-reaching applications of stimuli-responsive phage technologies. In 
particular, release systems based on VLPs have made a promising start within biomedical 
research for both diagnostic and therapeutic roles 135. As the recombinantly expressed and 
non-infectious structural analogues of virus particles, VLPs still possess native viral 
recognition elements. When appropriately functionalised, the clinical tunability of such 
particles allows them to act as candidates for a multitude of medical purposes, including drug 




In addition to using whole phage as a potential alternative to conventional antibiotics, there 
has been recent interest in using phage derived products, specifically endolysins as 
therapeutics. Encoded by the phage genome, these small molecules are transcribed and 
synthesised within the bacterial host’s cytoplasm following phage infection. They are then 
translocated through the cytoplasmic membrane during the late stage of the infection cycle 
and are responsible for breaking down the bacterial cell wall, thus facilitating the release of 
the newly formed phage virions from the infected cell 136-138. The primary benefit of using 
endolysins as opposed to whole phage lies with the elimination of genetic material from the 
therapeutic, thus eliminating the possibility of any genetic transfer events previously 
demonstrated with certain temperate phage 139. Whilst bacteriophage undergoing 
consideration for medicinal use are incapable of such transduction, removal of phage genes 
entirely may help to subdue any concerns surrounding the opening of ‘Pandora’s Box’ in 
terms of encouraging any phage assisted genetic mobilization. This may also help to speed 
regulatory acceptance of these new therapeutics. Furthermore, there are currently no 
identified resistance mechanisms towards phage lysins, indicative of the highly conserved, 
essential bacterial cell wall target sites of the phage-encoded enzymes 140. Unlike many 
antibiotics, lysins are specific in their target bacterial strain and have shown the ability to 
eliminate staphylococcal biofilms including persister cells (dormant, drug tolerant variants) 
141-143. The primary disadvantage of using lysins compared with whole phage is that they are 
not amplified in the host cell, thus larger doses are required for antimicrobial effect.   
 
A number of different endolysins have been isolated, characterised, and produced 
recombinantly, demonstrating lytic activity against a range of bacterial species (including 
Acinetobacter baumanni, Bacillus anthracis and Streptococcus pyogenes 144-147). Owing to the 
specific advantages over whole phage therapy, there is currently an endolysin based medical 
device registered for human use. Staphefekt™, marketed by Micreos consists of an endolysin 
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active against S. aureus which can be used on intact skin for the treatment of conditions such 
as eczema, acne, rosacea and skin irritation. Whilst it is not licenced for use in open wounds 
or within the medical setting at present, future clinical trials are expected to explore the 
possibility of developing Staphefekt™ into a clinical treatment 148.  Similarly ContraFect 
Corporation have developed an endolysin, CF-301, in collaboration with The Rockefeller 
University for the treatment of S. aureus associated bloodstream infections. As the first lysin 
to enter clinical trials in the US, the recently completed phase I trial results in healthy 
volunteers have shown promising results with no adverse clinical safety signals observed. CF-
301 has shown potency in combination with approved anti-staphylococcal agents and in the 
eradication of methicillin resistant S .aureus (MRSA) biofilms 149. Additionally CF-301 has 
been granted Fast Track Designation from the FDA in order to expedite its clinical 
assessment, a clear indication of how lysins have the potential to fill unmet medical needs.  
 
Additional protein engineering approaches have also enabled lysins to be developed for 
Gram-negative pathogens which are usually considered to be recalcitrant to endolysin 
treatment 150. Artilysin®s, consisting of an endolysin and an amphipathic or polycationic 
lipopolysaccharide-destabilizing peptide, are able to successfully penetrate the outer 
membrane of Gram-negative bacterial cells. Through disruption of ionic and hydrophobic 
forces within the protective outer membrane, these engineered fusion proteins are then able 
degrade the peptidoglycan cell wall 151. Artilysin®s have shown bactericidal efficacy both in 
vitro and in vivo against P. aeruginosa and Acinetobacter baumanni 152,153. Similarly, 
‘artilysation’ of endolysins effective against Gram-positive bacteria has shown to improve 
enzymatic and antibacterial activity compared to the wild type enzyme, through addition of a 
peptide selected to improve cell wall affinity 154.  
 
However, as a relatively recent development, there are limited examples of successful 
delivery systems capable of carrying such antimicrobial cargo. One such study has 
successfully stabilized a staphylococcal endolysin, LysK (active against both methicillin and 
vancomycin resistant S. aureus), through complexation with polycationic polymers. 
Complexation resulted in increased activity, retention of specificity, and increased stability at 
physiological temperature. An increase in stability was also seen at 22 °C, with poly-L-lysine 
and 10 mM NaCl, manifesting as an increase in the half-inactivation time from 2 days for the 
free enzyme, to 2 months for complexed LysK 155. It is believed that the change in kinetic 
properties of LysK upon complexation is likely a result of charge redistribution in the 
bacterial cell wall, following interaction between the cationic polyelectrolytes and the 
negatively charged surface proteins enclosed within the wall itself.  
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As previously stated, stimuli-responsive materials are of particular interest as they allow for 
the controlled release of therapeutic cargo. The truncated form of LysK, denoted CHAPK, 
consists of the single catalytic domain and has shown to exhibit lytic activity both in vitro and 
in vivo and against staphylococcal biofilms 143,156,157. Exploiting synergistic effects with the 
bacteriocin lysostaphin, temperature responsive polymeric nanoparticles (PNIPAM) have 
demonstrated controlled release of the enzyme cocktail at an elevated temperature 
associated with infection in vitro. Formulated into a prototype wound dressing, nanoparticles 
containing the enzybiotics were anchored onto non-woven polypropylene via plasma 
activation of the surface and demonstrated statistically significant cell lysis at the elevated 
temperature (> 4 log reduction in cell count), compared to the lower temperature associated 
with uninfected skin (< 1 log reduction) 158.  
 
Additional studies have investigated possible transportation methods for the delivery of 
endolysins to specific infections sites. The GI tract is capable of harbouring a range of 
pathogenic bacteria, many of which are difficult to treat (especially with a biopharmaceutical 
agent), owing to the harsh conditions found throughout the alimentary canal. Delivery of the 
endolysin CP25L, active against Clostridium perfringens (C. perfringens), to the GI tract has the 
potential to treat a range of diseases, including necrotic enteritis, gas gangrene and many 
common forms of food poisoning. Employing a dominant resident of the human intestinal 
flora, Lactobacillus johnsonii researchers have engineered this probiotic microbe to express 
CP25L, demonstrating successful production and secretion in vitro with retention of 
enzymatic lytic activity against C. perfringens. This engineered system provides a dual 
approach to targeting bacterial colonisation of the GI tract (initially via use of a probiotic 
microbe with the potential to be used as a competitive exclusion agent for the control of C. 
perfringens in its own right), and secondly through the secretion of an active endolysin with 
the potential for directed delivery to the gut 159,160.  
 
Conclusion and Future Perspective  
 
Current research into bacteriophage as an alternative or complementary treatment option for 
infectious diseases has shown encouraging results with a number of phage cocktails and 
products entering clinical trials. The development of phage therapy in Eastern Europe, in 
particular at the Eliava Institute in Tbilisi, Georgia, has laid the foundation for the potential 
implementation of global phage treatment in the 21st century. Recent research into phage 
delivery systems has shown advantages over the administration of unprotected phage 
including enhanced bioretention, stability and protection from harsh environmental 
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conditions or inactivating agents. Optimisation of such carrier/support systems has the 
potential to enhance phage therapy to treat a range of infections. 
 
However, despite the current success in the development of phage based therapeutics and 
the relatively large number of phage products in the pipeline, one of the major hurdles for 
future phage therapy will be clinical approval. The need to address the antibiotic vacuum is 
currently driving a call for a more economically viable drug approval process, specifically to 
allow phage to enter clinical trials whilst being relieved of the rigid and time consuming 
regulatory framework associated with classical clinical trials 90. In recognition of the unmet 
medical requirement for the development of novel antimicrobials, a recent (2015) 
amendment to the Federal Food, Drug and Cosmetic Act was introduced in the US proposing a 
modified pathway for the approval of antibacterial drugs within a highly defined, limited 
population. Denoted the Promise for Antibiotics and Therapeutics for Health (PATH) Act 161, 
this modification to current legislation may allow for the approval of certain antibacterial 
agents for use within a defined population for treatment of a serious infection, whilst 
circumventing restrictive, conventional clinical trials. This type of adaptive licencing, 
alongside possible implementation of compassionate use guidelines such as the Right to Try 
Act of 2015 162 (allowing unlicensed phase I experimental drugs, biological products or 
devices to be used by patients diagnosed with a terminal illness), are encouraging signs that 
some obstacles facing future phage therapy are being addressed from a regulatory 
standpoint. The current clinical framework for conventional antibiotic approval may indeed 
prove unsuitable for whole phage which, as self-replicating biological entities are unlikely to 
conform to classical drug analysis. Following successful bacterial binding and infection, there 
is likely to be a significant increase in local phage concentration which may result in an 
underestimation of phage efficacy via standard PK/PD analysis. Conversely, phage endolysins 
which show a far greater similarity to chemical antibiotics may conform more successfully to 
current clinical assessment.  
 
The future of bacteriophage therapy using targeted delivery systems looks promising for the 
treatment of serious, chronic and multidrug resistant bacterial infections, owing to the 
capability of controlling the pharmacokinetics/ dynamics of the phage, alongside offering 
protective and stabilising effects. However in order to continue driving the development of 
phage based therapeutics and the possible adaptation of regulatory pathways towards their 
approval, focus must be placed on stringent pre-clinical evaluation, with particular emphasis 
placed on phage concentration (MOI), biodistribution and suitable in vivo modelling. The 
current antibiotic crisis facing modern medicine appears to be shifting the paradigm in 
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favour of non-traditional therapy, affecting both development and approval strategies. Thus 
the next 5-10 years will be an intriguing time for bacteriophage research, offering the 





 Liposomal encapsulation can provide effective protection of phage from degradative 
effects including neutralisation by anti-phage antibodies and systematic clearance in 
vivo. Liposomes provide enhanced cellular uptake of phage in order to target 
intracellular diseases such as pneumonia and tuberculosis. 
 Nanoemulsions can stabilise phage via aqueous encapsulation manifesting as an 
increase in shelf life and higher infectivity rates.   
 Encapsulation within modified alginate microspheres provides a protective strategy 
capable of preventing phage inactivation under simulated gastric conditions. Addition 
of stabilising agents such as maltose and maltodextrin allow for the formulation of 
dry powders containing phage with retention of phage activity and stability.  
 
Immobilisation 
 Anchoring to surfaces via plasma activation has successfully immobilised active 
phage capable of causing bacterial lysis. Retention of activity was achieved for several 
months under the correct conditions.  
 
Polymeric Formulations 
 Complexation with naturally occurring polymers can provide protection against 
temperature, pH and UV, increasing both the versatility and long term stability of 
complexed phage. Increased activity and stability has also been seen with phage 
endolysins through complexation with polycationic polymers.  
 
Aerosol Formulations 
 Aerosol formulations for treatment of pulmonary infection can effectively incorporate 
phage, both in liquid form for use in nebulizers and in dry form for use in inhalers.  
 By careful control of particle size, phage containing aerosols can successfully target 
pulmonary infection. However delivery formulation, storage conditions and the use of 
stabilisers must be considered individually for each phage administered in order to 
retain viability and stability.  
 




 Controlled release of both phage and phage endolysins offers benefits in terms of 
preventing unnecessary administration of an antimicrobial and protection of the 
cargo from environmental conditions until it is required.  
 Successful triggered release systems have been shown to release phage/ phage lysins 
as a response to various stimuli including temperature and bacterial toxin production 
for the treatment of wound infection.  
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Chapter 4: Poly(N-isopropylacrylamide-co-allylamine) (PNIPAM-co-
ALA) Nanospheres for the Thermally Triggered Release of 
Bacteriophage K 
4.1 Introduction 
The research presented in this Chapter is based on the utilisation of bacteriophage for the 
treatment of wound infection. As discussed in Chapter 3, phage have been used in the 
treatment of a wide variety of bacterial infections, demonstrating clinical success in their 
application. This Chapter describes a stimuli-responsive carrier matrix for the controlled 
delivery of bacteriophage K, based upon the physiological change in skin temperature 
associated with wound infection (Figure 1). This research aims to provide a proof of concept, 
prototype wound dressing, housing staphylococcal phage encapsulated within polymeric 
nanoparticles, anchored onto non-woven polypropylene via plasma activation. Conceptually, 
this work is concerned with the prevention of any unnecessary administration of an 
antimicrobial, whilst reducing the need for continuous wound inspection and dressing 
changes. This aims to decrease patient discomfort and reduce clinical intervention.   
 
Figure 1 Schematic representation of the thermally triggered release of bacteriophage 
from PNIPAM-co-ALA nanospheres, arising as a result of the entropically driven 
collapse of the polymeric particles at higher temperature. 
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4.1.1 Cutaneous Wounds  
As the largest organ in the human body, the skin comprises of multiple, histological layers 
which, alongside controlling thermoregulation, maintaining fluid homeostasis and regulating 
metabolic processes, acts as a primary external defence system, preventing entry of 
pathogenic organisms. Should an epithelial breach in the skin occur (for example as a result 
of a cut, graze or burn), the resultant wound must undergo a complex healing process in 
order to regain structural integrity and prevent infection. In 2013, the annual NHS cost of 
wound management was reported as £5.3 billion, representing 4% of the total expenditure 
on public health in the UK, comparable to the cost of managing obesity in the same year 1. The 




























Figure 2 Schematic representing the classical wound healing process following injury. 
 A) Inflammation; commences immediately after injury (alongside haemostasis), a fibrin clot 
forms and the wound environment becomes hypoxic. Neutrophils, platelets and bacteria are 
present within the wound. B) Proliferation; involving re-epithelialisation, angiogenesis and 
granulation. The fibrin clot is replaced with an eschar (scab) and new blood vessels populate 
the area, re-vascularising the wound. C) Maturation; can occur for up to 2 years post injury 
and involves development of the normal epithelium and maturation of the scar tissue. Adapted 
by permission from Macmillan Publishers Ltd: Nature 2. Copyright ©2008. 
Part B: Chapter 4 
145 
 
4.1.1.1 Wound Classification 
Wounds that heal according to the carefully regulated, systematic cascade within a predicted 
timeframe (as detailed in Section 4.1.1) are referred to as acute wounds. This term may 
encompass surgical site wounds or traumatic wounds such as burns. Whilst there may be 
certain factors (such as infection) which temporarily affect the normal healing process, with 
appropriate and timely intervention (which is often minimal), an acute wound is expected to 
heal according to the classical wound healing timeline, resulting in successful tissue 
regeneration 3.  
 
In contrast, a chronic wound is defined as a wound which has failed to heal in a timely and 
orderly manner, in order to re-establish anatomical and functional integrity over a 3 month 
period 4.  Chronic wounds do not conform to the linear progression of classical wound 
healing, rather, they exhibit a prolonged inflammatory phase, becoming trapped in a 
continuous cycle of tissue renewal and breakdown, thereby preventing the continuation of 
the normal wound healing process 5.  There are a number of reasons why a wound may fail to 
heal correctly (both local and systemic factors), however chronic wounds are often 
associated with an underlying condition (such as diabetes or obesity) and are rarely seen in 
individuals who are otherwise healthy. The burden associated with treating chronic wounds 
is rapidly increasing (chronic wounds have been referred to as ‘the silent epidemic’), owing 
to the aging population, increasing healthcare costs and a global increase in the incidence of 
diabetes and obesity 6. In the USA alone, it has been reported that chronic wounds carry an 
annual cost of $25 billion. Furthermore, it has been estimated that 1 -2% of the population in 
developed countries will develop a chronic wound in their lifetime 7.  The Wound Healing 
Society classifies chronic wounds into 4 categories: diabetic ulcers, venous ulcers, pressure 
ulcers and arterial insufficiency ulcers 8. A detailed discussion surrounding the 
pathophysiology of chronic wounds is presented elsewhere 9. 
 
4.1.2 Wound Infection 
Healthy skin is permanently colonised by a number of bacterial species with a reported 103 -
104 microorganisms per cm2 skin (rising to 106 in moist areas) 10. Exhibiting a symbiotic 
relationship with the host and contributing to a healthy skin microflora, microbial 
colonisation at the point of injury can play a significant role in subsequent wound healing. In 
some cases, opportunistic and pathogenic organisms located in close proximity to the wound 
gain entry to the surrounding tissues and initiate an infection, thus impairing successful 
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wound healing. The nature of the infection can vary; it may be localised (requiring minimal 
intervention) or it may spread to surrounding tissues, causing a deep or systemic infection 
(requiring significant clinical intervention). One of the most challenging aspects of wound 
management is the clinical definition and assessment of the wound itself. It is important to 
note that contamination of a wound (either by opportunistic members of the normal skin 
flora, exogenous bacteria introduced from the environment or endogenous bacteria from 
surrounding mucosal membranes), does not necessarily result in infection. However, the 
sustained presence of proliferating microorganisms residing within a wound eventually 
increases the bacterial burden to a critical level (critical colonisation), which is sufficient to 
overcome the host inflammatory response, thus resulting in infection. The extent of the 
infection, relative to the nature of the wound often dictates the healing process; therefore, 
both of these variables must be established in order to initiate effective treatment. To date, 
there is no universally accepted classification system for skin and soft tissue infections 
(SSTIs), likely owing to the vast number of variables associated with clinical presentation 
(such as the anatomical location, rate of progression, degree of necrosis, aetiological agent(s) 
responsible and severity of both the wound and the infection) 11. 
 
4.1.2.1 Acute Wound Infection 
In 2013 the FDA defined the term acute bacterial skin and skin structure infection (ABSSSI) 
and published guidelines on the clinical presentation of such infections. This term 
encompasses cellulitis, major skin abscesses, wound infections (with a minimum lesion 
surface area of 75 cm2) and erysipelas 12. In terms of diagnosis, the most effective techniques 
(and the point at which they are initiated or deemed necessary) for microbiological analysis 
of an infected wound, alongside the most appropriate wound management strategy, are two 
critical factors debated amongst clinicians 13,14. Cultures obtained from surface swabs often 
only identify commensal colonising microbes, failing to represent the specific pathogen(s) 
responsible for infection, and the sensitivity of blood cultures is low. Tissue biopsies, 
radiological imaging and ultrasonography are the most valuable tools in diagnosis of ABSSSIs 
15. However, the clinical identification of the pathogen(s) responsible for an ABSSSI is often 
neglected in favour of commencing antibiotic therapy in cases of suspected (or confirmed yet 
unidentified) wound infection. This largely involves the administration of broad-spectrum 
antibiotics and arguably, often subjective monitoring of the therapeutic impact 16. Recent 
evidence suggests that a 5-7 day course of antimicrobial therapy is sufficient to treat 
uncomplicated SSTIs, however clinically; courses of up to 2 weeks are often prescribed 17. Not 
only does this contribute to drug resistance (as discussed in Chapter 3), it is also associated 
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with enhanced drug toxicity and the development of secondary infections (for example 
infections caused by Clostridium difficile) 18,19.  
 
Globally, the most common pathogen associated with ABSSSIs is S. aureus, including MRSA 15. 
Potential resistance to antibiotic therapy offers an additional challenge in the successful 
treatment of such infections. In fact, inappropriate treatment of MRSA-associated infections is 
a significant factor in the development of recurrent infection, such that the 2013 FDA 
guidelines specify certain considerations for the development of new drugs for complicated 
ABSSSIs 12,20. MRSA infections result in extended hospitalisation, increased mortality and a 
significant increase in associated cost. It has been reported that for surgical site infections 
caused by S. aureus, the average, excess hospital charges associated with MRSA compared to a 
susceptible infection is ~$14,000 per case 21.  
 
4.1.2.2 Chronic Wound Infection 
The complexity of infection is complicated further in the case of chronic or non-healing 
wounds. A recent systematic review and meta-analysis of published literature conducted by 
Malone et al, analysed 185 chronic wounds and identified bacterial biofilms in 78.2% of the 
wounds. Further analysis of current in vitro and animal models resulted in a final conclusion 
stating that bacterial biofilms are ubiquitous in human, non-healing chronic wounds 22.  The 
establishment of bacterial biofilms in chronic wounds causes a number of complications with 
respect to effective treatment. The protective nature of a biofilm enables microbial cells to 
evade the host immune response, alongside providing an environment in which bacteria are 
often more virulent and resistant to antibiotic treatment 23. Indeed, bacteria within a biofilm 
often exhibit increased tolerance to systemic antibiotic treatment, owing to their reduced 
metabolic activity (certain classes of antibiotics: β-lactams, aminoglycosides and quinolones 
are only effective against actively dividing cells) 24.  
 
Furthermore, the aetiology of chronic infections often differs from acute infections. In 
addition to commensal microbes, opportunistic pathogens (especially Gram-negative species 
such as P. aeruginosa), play a greater role in chronic infections and impaired wound healing 
25. The formation of polymicrobial biofilms can lead to enhanced virulence; a study conducted 
by Korgaonkar et al demonstrated the synergistic interaction between P. aeruginosa and S. 
aureus in a polymicrobial biofilm, resulting in the production of extracellular, lytic virulence 
factors 26. The propensity towards infection (and the subsequent formation of biofilms), 
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alongside the rise in MDR (as discussed in Chapter 3) makes effective treatment of chronic 
wounds notoriously difficult to implement and sustain.  
 
4.1.3 Temperature as an Indication of Infection  
Alongside the microbiological characterisation/assessment of a wound, there are other 
physical characteristics associated with the development of infection. As indirect indicators 
of infection, these features may include an increase in wound pH, a change in wound exudate 
or an increase in surface temperature, the latter being the most relevant to this thesis 27. A 
number of different studies have evaluated the change in temperature of a wound (both acute 
and chronic) and how it correlates to wound healing 28,29. An initial, localised increase in 
wound temperature (via inflammation), is often associated with successful healing 30.  
 
However, a prolonged or significant increase in temperature has been correlated with the 
development of infection. A study involving 112 patients over a 6 month period used infrared 
thermography to measure the periwound temperature of leg and foot ulcers, in order to 
evaluate surface temperature as an indicator of infection. Patients presenting with an 
elevated periwound temperature were eight times more likely to be diagnosed with a deep 
infection 31. Furthermore, a clinical pilot study identified a statistically significant relationship 
between skin temperature and wound infection, manifesting as a difference of 3 – 4 °C 
between a chronically infected wound and normal tissue 32.  
 
One of the most challenging aspects of evaluating temperature as a marker for infection is 
eliminating any temperature fluctuations associated with the normal healing process. A study 
aimed at quantifying the temperature gradient of healing wounds, post infection (i.e. 
inflamed but uninfected) reported a temperature change of ±2 °C, whereas the temperature 
of healthy skin is reported to fluctuate by ±1 °C 33,34. Therefore, despite the observed increase 
in skin temperature as a result of an inflammatory response to wound healing, an infection 
appears to increase the temperature further, providing a significant physical change 
associated with infection. A recent study conducted by Chanmugam et al, confirmed this by 
using long-wave infrared thermography to measure the difference in the relative 
temperature maximum of normal healing wounds (control group), wounds with associated 
inflammation and clinically infected wounds. The results indicated a temperature fluctuation 
of ±1.1 - 1.2 °C in normal healing wounds, a temperature gradient of ±1.5 - 2.2 °C in inflamed 
wounds and a maximum temperature differential of infected wounds of +4 - 5 °C (Figure 3) 35.  
 

























The research described henceforth in the succeeding publication aims to utilize a change in 
temperature, in order to deliver a biological antimicrobial agent (as an alternative to 
antibiotics), in a timely and controlled manner. This proof of concept technology may be 
developed further for use in a wound dressing owing to the temperature-associated 
presentation of infection in cutaneous wounds (predominantly chronic wounds).  
 
4.2 Extended Methodology  
4.2.1 Principles of Bacterial Growth  
In order to study and quantify bacterial growth, cells are cultured in liquid medium (which 
provides optimum growth conditions and contains all the necessary nutrients required for 
reproduction). Aliquots are subsequently plated onto solid agar medium in order to quantify 
bacterial cell numbers. During cultivation in liquid media, bacteria exhibit four distinct 
Figure 3 Long-wave infrared thermography showing the change in temperature gradient 
of an open wound on an amputation site (A) at the point of infection, pre-antibiotic 
treatment, exhibiting a relative, wound bed temperature maximum of +5 °C (B) free from 
infection, post-antibiotic treatment, exhibiting a relative, wound bed temperature 
maximum of +0.8 °C. Reprinted from 35 with permission from Wolters Kluwer Health, Inc. 
Copyright © 2017. 
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growth phases, which can be monitored according to the change in cell density over time. The 
first phase in the bacterial growth curve is referred to as the initial lag phase, whereby the 
cells are preparing for reproduction (i.e. via DNA replication and enzyme production). The 
second is the exponential growth phase, during which time the cells begin dividing (via 
binary fission) and cell numbers increase exponentially. Following the exponential phase the 
cells enter a stationary phase, during which the rate of cell growth (division) is equalled by 
the rate of cell death, resulting in a plateau with no net increase in cell numbers. Finally, upon 
depletion of available nutrients and accumulation of waste products, the cells enter the death 
phase where bacterial cell count begins to decline. Cell density may be assessed 
photometrically using optical density (OD) measurements, which correlate the degree of light 
scattering (or turbidity) to cell density. The bacterial growth curve as a function of both cell 



















4.2.1.1 Quantifying Bacterial Cell Count 
A measure of bacterial cell count is the colony forming unit (CFU). This refers to a single 
colony (grown on an agar plate) which has arisen from a singular viable cell, resulting in a 
cluster of cells derived from the same parent, which are genetically identical (forming a 



























Figure 4 Bacterial growth curve showing the change in bacterial cell count over time 
(solid line) and the corresponding change in optical density at 600 nm (dotted line). The 
graph shows (A) the lag phage, (B) the exponential growth phase, (C) the stationary 
phase and (D) the death phase. The OD does not decline during the death phase as dead 
cells will still scatter light and exhibit turbidity in solution.  
Part B: Chapter 4 
151 
 
culture 36. Following incubation, plates with 30 – 300 colonies may be used in order to 
calculate the number of CFU per unit volume (CFU/ ml), providing an estimate of the number 
of cells in the original culture, according to the following equation:  
 
CFU/ ml =  
Number of Colonies
d ×  V
 
 
Where d is the dilution factor (from original culture) and V is the volume of inoculum (ml).  
 
4.2.2 Principles of Bacteriophage Propagation 
Phage propagate within a bacterial host (as described in Chapter 3). In order to obtain pure 
phage lysate, the phage and corresponding bacterial host strain are incubated together to 
facilitate phage infection and replication. There are a number of methods of obtaining phage 
lysate, however the research presented in the succeeding publication utilises the double layer 
method. Following overnight incubation of phage/ host cultures, soft agar is added (which 
facilitates an even distribution of bacteria and phage, providing optimum visualisation of 
phage activity). The solution is then poured onto agar plates and incubated overnight. Buffer 
containing chloroform is then added to the plates displaying confluent lysis (clearance of 
bacteria) in order to kill any resistant isolates. The plates are incubated again in order to 
extract the phage and the solution is removed from the plate. Finally, the lysate is centrifuged 
and filter-sterilised in order to remove any cell debris and stored at 4 °C, for use 
experimentally or for further propagation.  
 
4.2.2.1 Quantifying Phage Titre 
The titre (or concentration) of a phage solution can be quantified via the spot test. Phage 
form plaques (zones of bacterial clearance) when spotted onto a bacterial lawn. The number 
of plaque forming units (PFU) on a bacterial lawn can be quantified, which provides an 
estimate of the number of phage in the starting lysate. The spot test involves the addition of 
100 µl of growing host culture to 3 ml of soft agar, which is then poured onto agar plates and 
left to dry. The phage lysate is then serially diluted 10-fold in buffer and 10 µl aliquots are 

























PFU/ ml =  
Number of Plaques
d ×  V
 
 


























Figure 5 Schematic outlining the spot test method for bacteriophage titration. 
(2) 
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Due to the increased prevalence of resistant bacterial isolates which are no longer susceptible 
to antibiotic treatment, recent emphasis has been placed on finding alternative modes of 
treatment of wound infections. Bacteriophage have long been investigated for their 
antimicrobial properties, yet the utilization of phage therapy for the treatment of wound 
infections relies on a suitable delivery system. Poly(N-isopropylacrylamide) (PNIPAM) is a 
thermally responsive polymer which undergoes a temperature dependent phase transition at 
a critical solution temperature. Bacteriophage K has been successfully formulated with 
PNIPAM nanospheres copolymerized with allylamine (PNIPAM-co-ALA). By utilizing a 
temperature responsive polymer it has been possible to engineer the nanospheres to collapse 
at an elevated temperature associated with a bacterial skin infection. The nanogels were 
reacted with surface deposited maleic anhydride in order to anchor the nanogels to non-
woven fabric. Bacteriophage incorporated PNIPAM-co-ALA nanospheres demonstrated 
successful bacterial lysis of a clinically relevant bacterial isolate - Staphylococcus aureus 
ST228 at 37 °C, whilst bacterial growth was unaffected at 25 °C, thus providing a thermally 
triggered release of bacteriophage. 
 
Keywords: PNIPAM, Bacteriophage, Thermal Release 





The triggered release of a pharmaceutically active substance (small molecule, protein, virus) 
from a particle has been the subject of much interest in recent years as the utilization of such 
a device clinically could be used to provide dosing of a drug or drug candidate both where, 
and when it is needed and at a high local concentration 37,38. Triggered delivery can mean that 
an agent is only released following a pathological change in the patient, preventing 
unnecessary usage of a drug, but also ensuring that it is provided at a sufficiently high dosage 
in-situ to be pharmacologically effective. Systemic antibiotics to combat bacterial infection 
have to be used at relatively high dosages to give a sufficiently high concentration within 
blood / tissue at the infection site in order to prevent further bacterial growth. Indeed, should 
the concentration of an antibiotic be too low at the site of infection, the effect can be to 
increase the rate of evolution of antibiotic resistance and virulence within the infecting 
organism 39. 
 
The delivery of a drug to a target site via a carrier particle or matrix can allow the slow, 
passive diffusion of that drug from the carrier matrix, with the diffusion rate being controlled 
by the matrix viscosity and size of the drug (based on Fick’s laws). Examples of such systems 
for topical application of drugs include skin patches for nicotine administration and 
transdermal pain relief delivery 40,41. Alternatively, a burst response can be engineered, which 
though still ultimately diffusion controlled would deliver the drug at a much higher rate. The 
initiation of the burst response might utilize an external trigger, which in a wound site could 
be a molecule released by the infective bacteria: secretion toxins, enzymes, signalling 
molecules etc. 42-44, changes in the host immune response (e.g. cytokines) or a more general 
host tissue response such as pH or temperature change 45,46. 
 
Poly (N-isopropylacrylamide) (PNIPAM) is a thermally responsive polymer which undergoes 
a fully reversible temperature dependent phase transition at a lower critical solution 
temperature (LCST) which manifests as a change in polymer volume. Following the 
entropically favoured expulsion of water at the LCST, the polymer undergoes a characteristic 
morphological change from a random coil structure to a hydrophobic globule structure 47. 
The LCST of PNIPAM can vary from 32 °C to 36 °C depending on a number of factors including 
polymer concentration, the presence of surfactants and the use of copolymers 48. The fact that 
the LCST is near to body temperature of 37 °C means that PNIPAM has been relatively well 
researched and utilized within the bioengineering industry as a drug delivery platform 49. 
PNIPAM nanospheres copolymerized with allylamine (PNIPAM-co-ALA) made in previous 
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work were measured using Dynamic Light Scattering (DLS) to change from a mean diameter 
of 210 nm at 33 °C to 70 nm at 37 °C 50. This decrease in size was previously utilized to 
release silver ions, the putative aim being to exploit the potentially antimicrobial properties 
of silver in a future wound dressing.  
 
Bacteriophage (phage) are viruses which reproduce via infection of specific bacterial hosts. 
They are capable of attaching themselves to specific receptors located on the surface of a 
bacterial cell, injecting their genetic information (in the form of DNA or RNA) into the cell 
taking advantage of the bacterium’s cellular machinery in order to replicate in vivo, 
ultimately resulting in the rupture and destruction of the bacterium 51. First discovered and 
used clinically in the 1930s in the former Soviet Union, their potential utility as antimicrobial 
agents is being re-examined with the rapid evolution of antibiotic resistance in many 
common infectious bacterial organisms such as Staphylococcus aureus (S. aureus) 52. The 
potential advantages of phage are that they co-exist with their host bacteria, so strains which 
are active against target bacteria can be prospected for and isolated with relative ease. 
Moreover they are fairly host strain specific, and are normally harmless to host eukaryotic 
cells. However the regulatory environment surrounding the clinical application of phage is 
only slowly adjusting to the utilization of a biological agent for infection control, in part 
because some types of phage can deliver host virulence or antibiotic resistance factors via 
lysogenic conversion: an example being the shiga toxin in Escherichia coli and the mecA 
resistance cassette in methicillin resistant S. aureus 53,54. However, by careful selection of 
phage phenotypes and genotypes, lysogenic strains can be avoided and current indications 
are that phage may have an important role in the future armoury of antimicrobial substances. 
 
One important consideration when utilizing phage to destroy pathogenic bacteria is the 
multiplicity of infection (MOI), the ratio of phage to bacteria. The concentration of phage 
must be high enough to ensure rapid infection, multiplication and lysis of the target bacteria 
before non-susceptible bacteria present at the point of infection utilize the space and 
resources provided by death of their co-infecting cells 55. Much of the current effort in phage 
therapy is concerned with topical delivery, for example in chronic otitis media (ear infection) 
and wounds. Delivering phage via a wound dressing requires the phage to be contained 
within a reservoir until required, ideally only when their target bacterial hosts are present 
and at a sufficient density to provide an environment for efficient phage propagation. 
 
In this paper, bacteriophage have been formulated with PNIPAM-co-ALA nanospheres and 
the particles grafted via a plasma deposited film of maleic anhydride to non-woven 
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polypropylene. Allylamine was chosen as the copolymer in order to control the LCST and to 
provide readily available functional groups for the surface anchoring of the nanoparticles. 
The use of plasma deposited maleic anhydride for attachment of particles / proteins / 
molecules to surfaces has been discussed in detail elsewhere 56-58. The infectivity of the phage 
was assessed against a clinically relevant Methicillin Resistant S. aureus (MRSA) strain 
(ST228). The bacteria itself is a multiple-antibiotic resistant, gentamicin resistant SCCmec 
(Staphylococcal chromosomal cassette mec) I strain of MRSA from clonal complex (CC) 5 59, 
one of the most clinically relevant clonal complexes worldwide 60. This clonal lineage is of 
particular interest clinically due to previously documented instances in which the clone has 
exhibited sporadic periods of extremely high transmissibility 61. 
 




N-isopropylacrylamide, allylamine, ethylene-glycol diacrylate, sodium persulphate, sodium 
dodecylsulfate (SDS), poly(ethylene glycol) (PEG), sodium chloride, magnesium sulphate, 
calcium chloride and tris-hydrochloride (pH 7.5) were all purchased from Sigma-Aldrich 
(Poole, Dorset, UK). 
 
Bacteriophage K (phage K) was obtained from D. Alves (University of Bath) from a previously 
sourced collection. Tryptic Soy Broth (TSB) and Tryptic Soy Agar (TSA) were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). Luria-Bertani broth (LB) was purchased from Invitrogen 
Life Technologies Ltd, Paisley, UK and Bacteriological agar was purchased from Thermo 
Scientific, Hampshire, UK. Pseudomonal and Staphylococcal bacterial isolates used in 
experimental work were obtained from a bacterial strain collection belonging to the 
Biophysical Chemistry Research Group housed at the University of Bath and the University 
Hospital of Lausanne respectively.  
 
Bacteria, Bacteriophage and Growth Conditions 
 
For this study S. aureus ST228 and P. aeruginosa PAO1 isolates were used. The isolate of 
ST228 used was isolated from a patient soft tissue infection. The strain was PVL negative and 
is PFGE subtype Db. Bacteria from TSA plates were grown at 37 °C with continual shaking 
(170 rpm) in TSB. TSB-soft-agar containing 0.65% of bacteriological agar and SM buffer (5 M 
NaCl, 1 M MgSO4, 1 M Tris–HCl [pH 7.5], 0.1% gelatine solution) were used for bacteriophage 
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propagation and plaque count assays. Note that media was supplemented with 1 mM CaCl2 
and MgSO4 to improve phage adsorption 62. Bacterial aliquots were stocked at -80 °C in broth 
containing 15% glycerol (v/v). 
 
Bacteriophage Propagation and Purification 
 
Phage K was propagated in the prophage-free isolate S. aureus RN4220 in order to avoid any 
potential contamination with mobilized phage. Briefly, 100 μl of phage lysate and 100 μl of 
host growing culture were mixed and left for 5 min at room temperature. 3 ml of soft-agar 
was added and poured onto TSA plates. The following day, after an overnight incubation at 
37 °C, plates displaying confluent lysis were selected and 3 ml of SM buffer and 2% 
chloroform were added before incubating at 37 °C for 4 h. High titre (or concentration) phage 
solution was removed from the plates, and centrifuged (8,000 x g, 10 min) to remove cell 
debris, then filter sterilized (pore size, 0.22 μm) and stored at 4 °C. By dilution of phage titre 
it was thus possible to observe plaques that would have been formed by an individual phage, 
allowing both phage concentration to be estimated and lytic activity to be quantified.  
 
Phage K lysate purification was performed by adding 1 M NaCl and left at 4 °C overnight. The 
following day the solution was centrifuged (4000 rpm, 1 h) and the supernatant was carefully 
transferred to a new tube. 10% (w/v) PEG (m.w. 8000) was added to the lysate and left at 4 
°C overnight. The solution was then centrifuged (4000 rpm, 30 min) to obtain a PEG-phage 
pellet. The pellet was resuspended gently in 1 ml of SM buffer and vortexed thoroughly. 
 
PNIPAM-co-ALA Nanosphere Preparation  
 
PNIPAM-co-ALA nanospheres were synthesized via precipitation polymerization, (Scheme 1, 
Supplementary Information). To a round bottomed flask containing 57.5 ml deionised water, 
0.96 g N-isopropylacrylamide (10% molar ratio), 65.5 μl allylamine, 20.8 μl ethylene-glycol 
diacrylate (cross-linker, 1% molar ratio) and 0.0185 g SDS were added. The solution was 
freeze-thawed three times and purged with N2. The solution was heated to 70 °C with stirring 
for 10 min, after which 0.03875 g of initiator (sodium persulphate) in 5 ml of deionised water 
was added and the reaction was allowed to proceed for 4 h. The gels were purified by dialysis 









Phage particles in water were deposited on carbon coated copper grids and negatively 
stained with 1% uranyl acetate (pH 4). Visualization was performed using a transmission 
electron microscope (TEM) (JEOL JEM1200EXII ) operated at 120 kV. 
 
Dynamic Light Scattering and Zeta Potential Measurements 
 
Particles were sized and characterized using a Zetasizer Nanoscale light scattering device 
(Malvern Instruments, Malvern, UK), which allowed measurements to be made as 
temperature was varied.  
 
Grafting of PNIPAM-co-ALA Nanospheres to Non-Woven Polypropylene 
 
Non-woven polypropylene (2 x 2 cm squares) were washed in isopropyl alcohol, dried and 
placed in a radio-frequency plasma reactor. Pressure was reduced to 0.001 mb, and maleic 
anhydride vapour introduced in a continual flow. RF radiation was coupled into the reactor 
via an inductive loop to create a plasma. The plasma was pulsed: 1 ms on / 40 ms off for 10 
min. The deposition of anhydride groups was observed using Fourier Transform Infrared 
spectroscopy (FT-IR). Full details of this procedure are described elsewhere 63,64. The plasma 
modified fabrics were then immediately placed in a suspension of the PNIPAM-co-ALA 
nanospheres at room temperature for 60 min. The formation of amides, indicative of the 
coupling of free amines in the PNIPAM-co-ALA nanospheres via nucleophilic attack to the 
plasma deposited maleic anhydride film was ascertained by FT-IR. 
 
Addition of Phage to Fabric Grafted Nanospheres 
 
Bacteriophage K of titre 109 PFU/ml was incorporated into the anchored gel matrix via 
soaking in 500 µl of phage solution for 4 h at 25 °C. The fabric was washed 3 times in 
deionised water to remove unbound phage and allowed to dry.  Control experiments were 
undertaken by replacing the phage solution with SM buffer. 
 
Bacterial Confluent Lysis Preparation and Deposition of PNIPAM-co-ALA Nanospheres 
 
TSA culture plates were spread evenly with 100 μl of bacterial suspension. The plates were 
allowed to dry in aseptic conditions for 1 h. The nanogel-fabric swatches incorporating the 
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phage particles were placed onto the agar plates and incubated for 24 h. The plates were 
incubated upside down in order to prevent any condensation that could interfere with the 
phage release.  Half of the plates were incubated at 37 °C (above the LCST) and half at 25 °C 
(below LCST). Spots (10 µl) of the phage solution were also added to individual plates in 
order to assess successful phage replication and growth inhibition at both temperatures 
without the use of nanospheres or fabric, via the appearance of plaques. Control experiments 
were undertaken using phage K resistant P. aeruginosa PA01. The thermal release of 
bacteriophage from the nanosphere grafted non-woven fabrics was observed as the 
formation of an inhibitory zone on and around the bacterial culture plate. 
 




The DLS measurements of the nanospheres showed an LCST at around 34 °C with the 
diameter of the particles decreasing from 400 nm +/- 50 nm to 170 nm +/- 30 nm, as shown 
in Figure 6. The collapse of the nanoparticles at 34 °C is clinically relevant as it corresponds 
to an elevated temperature associated with a bacterial skin infection. Whilst healthy skin has 
a surface temperature of around 32 °C, infected skin presents an increase in temperature of 







































Figure 6 DLS measurement of PNIPAM-co-ALA nanoparticles prior to 
coupling to non-woven polypropylene and phage addition. 
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Zeta potential analysis showed a sharp increase in potential at the LCST, owed to the increase 
in overall surface area of the collapsed nanospheres (Figure 7).  
 
 Both measurements show the LCST clearly at 34 °C, the effect of which can also be clearly 
seen by eye (Figure 8). 
 
Figure 8 PNIPAM-co-ALA nanospheres in the swollen state (left) and collapsed state (right), the 
visible change is accounted for due to a change in refractive indices between the polymer and the 
solvent upon collapsing. 
Figure 7 Zeta potential measurement of PNIPAM-co-ALA nanoparticles prior to coupling to non-
woven polypropylene and phage addition. 
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Bacteriophage activity was measured in terms of its ability to form zones of clearance 
(plaques) in lawns of S. aureus. A standard phage titre of 109 PFU/ml was determined for 
phage K, when measured on a susceptible strain of S. aureus ST228. Non-infectivity of phage 
K to P. aeruginosa PAO1 (control) was also confirmed. Transmission Electron Microscopy 




Attachment of PNIPAM-co-ALA Nanospheres to Non-Woven Polypropylene 
 
Plasma modification of non-woven polypropylene with maleic anhydride (MA) was 
confirmed by FT-IR (Figure 1, Supplementary Information). The absorption peak at 1780 cm-
1 indicative of the anhydride group is a reliable indicator of successful deposition of MA. The 
attachment of the PNIPAM-co-ALA nanospheres to the MA modified polypropylene was again 
confirmed by FT-IR (Figure 2, Supplementary Information) and also qualitatively implied via 
the subsequent thermal triggered release of phage at temperatures above the LCST. 
 
 
Figure 9 TEM image of phage K. Note the icosahedral head, tail fibre and base plate 
containing host bacterial recognition moieties. 
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Measurement of Thermally Triggered Release of Bacteriophage k from PNIPAM-co-ALA 
Nanospheres 
 
The thermally triggered release of phage K was measured qualitatively via the formation of 
zones of clearing under and around the phage-PNIPAM-co-ALA non-woven polypropylene 















The clearance of the S. aureus ST228 by released phage at 37 °C is clearly visible in Figure 10 
(left), with the attached PNIPAM-co-ALA nanospheres collapsed and by implication, its cargo 
of phage k released. The transparency of the polypropylene swatch containing phage K at 37 
°C is indicative of an absence of bacterial growth under the swatch itself.  At 25 °C (right), 
below the LCST, the bacterial growth is little affected by the placing of the phage-PNIPAM-co-
ALA non-woven polypropylene on the bacterial lawn, indicating  that the  immobilized phage 
are not released due to the retention of the swollen polymer state. The result of the phage 
containing swatch incubated at 25 °C is comparable to that of the control swatch incubated at 
37 °C. Further control measurements were made on lawns of P. aeruginosa PAO1 (Figure 11). 
P. aeruginosa is not infected by phage K, so its inclusion was to ensure that the clear zone 
seen with S. aureus (Figure 10) was due to the release of phage and not by any other 
interfering process.  
Figure 10 Confluent lawns of S. aureus ST228 at 37 °C (left) and 25 °C (right). A clear zone of 
bacteria where the phage modified PNIPAM-co-ALA modified non-woven polypropylene is 
clearly seen at 37 °C. The control in each case is the PNIPAM-co-ALA modified non-woven 
polypropylene without phage added. 





Whilst the optimum conditions for bacterial growth exist at 37 °C, confluent bacterial growth 
was assessed at 25 °C in order to confirm the successful infectivity of phage K under these 
conditions. This was undertaken to ensure the absence of bacterial lysis at 25 °C was not as a 
result of an inability of the phage to replicate. The results of this are included in the 
Supplementary Information for clarity, demonstrating successful bacterial lysis even at a 




In summary this work has demonstrated a new and previously unreported application of a 
thermoresponsive polymer, engineered to provide a biologically significant trigger for the 
administration of bacteriophage. The importance of controlled release when evaluating 
treatment for bacterial infection is of the utmost importance in preventing the spread of 
resistance towards current and new therapies. By exploiting and developing the physical and 
chemical properties of new and existing ‘smart materials’, such as PNIPAM, it has been 
possible to selectively control the release of a new and potentially viable alternative 
treatment for bacterial infection, whilst avoiding the presentation of the continual selective 
pressure so often faced by bacteria due to improper administration of antimicrobials. 
Alongside the development of the carrier matrix for the bacteriophage, we have also 
Figure 11 Control experiments with phage K modified PNIPAM-co-ALA nanospheres 
anchored onto non-woven polypropylene grown on a P. aeruginosa PAO1 lawn. No 
attenuation of bacterial growth was observed. 
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successfully covalently anchored the delivery system onto a simulated dressing platform via 













Supplementary Figure 1 FT-IR of non-woven polypropylene (NW-PP) prior to and following 
plasma deposition of maleic anhydride (NW-PP-MA). The peak at 1780 cm-1 in the NW-PP-













































Supplementary Figure 2 FT-IR of maleic anhydride deposited non-woven polypropylene 
(NW-PP-MA) prior to and following addition of PNIPAM nanospheres (NW-PP-MA-PNIPAM). 
The shift in the C=O peak from 1780 cm-1 in the deposited anhydride to 1662 cm-1 after 














Supplementary Figure 3 10 µl of phage K spotted onto a  lawn of S. aureus ST228 and 
incubated at 37 °C (left) and 25 °C (right) in order to demonstrate successful infection. The 
control in each case was a 10 µl spot of SM buffer only. 
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4.4 Additional Results 
Owing to the specific requirements for publication, it was not possible to include multiple 
images demonstrating similar results within the preceding article. However, for the purpose 
of clarity, additional images are presented below, aimed at providing further evidence of the 
thermally triggered release of bacteriophage, as detailed in the publication.  Figure 12 shows 
the same set of plates shown in Figure 10 but with natural light behind, highlighting the 





Additional experiments were undertaken aimed at increasing the encapsulation efficiency of 
the phage within the nanoparticles. As oppose to relying on diffusion of the phage into the 
surface-anchored particles in their swollen state, the addition of phage to the collapsed 
polymer was investigated. However, the addition of phage to the nanoparticle solution above 





Figure 12 MRSA bacterial lawns showing temperature dependent release of bacteriophage 
K. The absence of bacterial growth under the PNIPAM-co-ALA fabric swatch at 37 °C (left), 
results from the antimicrobial activity of the phage released from the polymer matrix. The 
consistent bacterial growth seen under the swatch at 25 °C (right) indicates retention of the 
phage within the swollen nanoparticles.  




A possible explanation for this is the effect on the entropy of mixing upon addition of phage 
solution. Above the LCST the solvent-polymer interactions are replaced by favourable 
polymer-polymer interactions (Figure 14). Upon addition of aqueous phage, the apolar 
isopropyl units on the polymer chains facilitate ordering of the water molecules, resulting in 
a large negative contribution to the entropy of mixing (ΔSM). The ΔSM contribution is reflected 
in the Gibbs free energy of mixing (ΔGM), resulting in a positive ΔGM and the polymer 













The observed polymer precipitation indicates that encapsulation in aqueous solution should 
be undertaken at the LCST or below it. It has been suggested that PNIPAM exists in a number 
of thermodynamically stable intermediate states during the transitional collapse of the 
polymer at the LCST, which may provide a stable polymeric solution in which to encapsulate 
phage 66.  
Figure 13 Solution of PNIPAM-co-ALA nanoparticles and bacteriophage K, showing 
polymer precipitation at 40 °C. 
Figure 14  The change in hydrophilicity of the PNIPAM polymer above the LCST, resulting 
in the entropically driven expulsion of water from the hydrated polymer and the formation 
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4.5 Conclusions and Future Work 
The research presented in the preceding publication describes an early, proof of concept 
formulation for the controlled release of a biological therapeutic from a thermoresponsive, 
polymeric platform. The study has focused on the potential incorporation of such technology 
into a dressing-based system, owing to the increase in skin temperature as a result of 
infection (the advantages of stimuli-responsive systems are discussed in Chapter 3). There 
are undoubtedly some limitations to the study presented, however as mentioned, this 
research is intended as a preliminary study into the retention of biological activity of 
encapsulated phage within a stimuli-responsive delivery system. Alongside the reported 
application, the technology underpinning this research has the capacity to be utilised for 
other biotherapeutic applications (this may include the utilisation of phage as transport 
vectors for the delivery of genetic material in order to sensitize bacteria to antibiotics, i.e. 
using the CRISPR-Cas system 67). Nonetheless, there are a number of crucial considerations 
which, if addressed would enhance the reported study in its current form and intended 
outcome. Firstly, quantitative data establishing the rate and extent of phage release from the 
nanoparticles would potentially provide an understanding of the fundamental properties of 
the current system. This may include insight into the responsiveness of the nanoparticles, the 
diffusion profile of the phage into the surrounding matrix and any inhibition of biological 
function as a result of polymeric confinement. The stability of the phage preparation within 
the nanoparticles should also be evaluated in order to establish the long term viability of the 
encapsulated phage. Finally, the precise mechanism of phage entrapment/ encapsulation 
within the PNIPAM nanoparticles should be investigated. Despite the observed success in the 
controlled release of phage, an understanding of the polymeric immobilisation may offer the 
potential for enhanced stability/ delivery.  
 
Alongside specific improvements to the research presented, further development of this 
technology, aimed at advancing the current study should focus on the following aspects in 
order to potentiate clinical implementation of such a system.  
 
4.5.1 Bacterial Resistance  
Owing to the selective pressure exerted as a result of phage predation, bacteria have evolved 
numerous strategies in order to resist infection. Some of the key evasion tactics include 
prevention of phage attachment (via modification of cell surface receptors, production of EPS 
or production of competitive inhibitors), degradation of phage DNA (via restriction-
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modification systems) and installation of abortive infection pathways (preventing phage 
multiplication by initiating ‘cell suicide’) 68. However, as co-evolutionary predators, phage 
have simultaneously evolved in order to overcome this resistance (largely via point 
mutations, arising as a result of complex phage-bacterium population dynamics) 69. A 
dynamic equilibrium exists between phage and their bacterial hosts, which has been 
described as an antagonistic-coexistence paradigm. The selection of evolved phage (present 
as a result of bacterial resistance mechanisms) therefore ensures the survival of the phage 
population, whilst influencing the genetic diversity of both phage and bacteria 70. The 
likelihood of bacteria becoming resistant to the therapeutic administration of phage is 
considered low, owing to the detrimental effects associated with the fitness of the host. 
Bacteria exhibiting resistance to phage demonstrate an increased susceptibility to other 
phage, an altered competitive ability and are subject to an enhanced cost of deleterious 
mutations 71. Despite this, any potential encouragement of resistance as a result of phage 
therapy must be avoided at all costs. A common strategy aimed at overcoming resistance 
focuses on the use of a phage cocktail. This requires a mixture of different phage, displaying 
unrelated modes of infection in order to ensure bacterial lysis, based on the extremely 
unlikely development of resistance to multiple (if not all) phage isolates within a cocktail. 
This has been previously demonstrated in a cocktail of modified phage K derivatives, capable 
of circumventing multiple resistance mechanisms exhibited by a number of clinical S. aureus 
strains 72. In addition, phage have exhibited synergy with antibiotics, offering the possibility 
of simultaneously reducing resistance to both 73. Utilisation of a phage cocktail or a 
phage/antibiotic cocktail within a thermoresponsive delivery platform may offer increased 
longevity of the therapeutic system.  
 
4.5.2 Phage Host Range  
The specificity of phage provides certain benefits with regards to targeted biocontrol (unlike 
broad-spectrum antibiotics, phage do not disrupt the commensal microflora of the host). 
However, when considering a polymicrobial infection (i.e. a mixed species biofilm within a 
chronic wound), a single phage preparation is not sufficient to effectively eliminate all 
pathogenic organisms. The use of polyvalent phage (as oppose to highly strain specific phage) 
provides a larger therapeutic window, especially if the pathogenic bacterial species has yet to 
be formally identified prior to clinical intervention. Polyvalent phage exhibit a broader host 
range, often targeting multiple strains within a species and, in some cases, multiple species 
within a genus. Phage K (used in the study in question), is a polyvalent phage, effective 
against both coagulase-positive and -negative staphylococci 74. Additionally, phage K lacks the 
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specific recognition site (GATC) for restriction modification by specific host endonucleases, 
thus exhibiting an effective counter-resistance strategy 75. However, in order to increase the 
therapeutic window further, a phage cocktail consisting of a number of different phage 
isolates should be employed. Expanding the host range of a phage cocktail provides an 
effective means of targeting multiple bacterial isolates, ranging from Gram-positive to –
negative species. This would be especially beneficial in the case of a mixed species wound 
infection.  
 
4.5.3 Biofilm Formation  
As discussed in Section 4.1.22, biofilm-associated infections are commonplace in SSTIs. In the 
current application, the increase in wound temperature as an indication of infection 
predominantly relates to chronic wounds, which are especially susceptible to the formation 
of biofilms. The use of phage to treat biofilm-associated infections has been widely 
investigated 76,77. Whilst biofilms are substantially more difficult to treat with conventional 
antibiotics and biocides (largely owing to the protective nature of the EPS and the presence of 
metabolically inactive persister cells), phage exhibit unique characteristics which have shown 
promise in the penetration and eradication of biofilms. The infectivity of phage and the 
production of EPS degrading enzymes has shown increased efficacy in the targeting of 
bacterial biofilms. In order to effectively model an infected wound scenario (and any 
temperature-associated effects) it would be beneficial to test the phage-PNIPAM system on a 
biofilm (preferably mixed-species). In addition, whilst phage are capable of producing EPS 
degrading enzymes, this occurs largely inside the bacterial cell prior to lysis, thus relying on 
initial penetration of the biofilm and the successful establishment of phage infection 78. 
Perhaps an additional consideration would be the incorporation of a biofilm disrupting agent 
(i.e. proteinase K), in order to facilitate rapid phage penetration into the biofilm in the first 
instance 79.  
 
4.5.4 Immune/ Cytotoxic Response  
An essential consideration regarding the potential implementation of any medical product/ 
device is the effect of the combined components on the host. As naturally occurring biological 
entities, phage are (in themselves) largely harmless to humans. There is some evidence to 
suggest the administration of therapeutic phage can result in the generation of antibodies via 
interaction with the adaptive immune system, however the clearance of phage (upon 
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intravenous administration), is thought to occur before the substantial production of 
antibodies. Furthermore, this phenomenon is largely associated with systemic phage therapy, 
topical application of phage has not shown any adverse effects and both animal and clinical 
trials have not demonstrated in any serious immunological effects 80,81.  
 
Perhaps a more concerning feature associated with the therapeutic administration of phage 
is the simultaneous lysis of numerous bacterial cells in vivo. The rapid release of endotoxins 
and liposaccharides from lysed pathogenic bacteria can produce a significant immune 
response and has been associated with cytokine cascades, potentially resulting in increased 
morbidity and mortality 82. Efforts to circumvent adverse immune reactions have focused on 
genetic engineering, aimed at retaining the bactericidal properties of phage whilst removing 
the requirement for bacterial lysis. This approach has been demonstrated for temperate 
phage via expression of lethal but non-lytic proteins, and for lytic phage resulting in non-lytic, 
non-replicative lethal variants 83. The gene encoding the endolysin (responsible for cellular 
lysis) was inactivated in a temperate S. aureus phage, which resulted in full retention of 
bactericidal activity and survival of all MRSA-infected mice in an in vivo study (n = 8) 84. This 
appears to be a promising strategy for the future development of phage technology, which, in 
light of the lengthy and complex regulatory framework associated with phage therapy, may 
potentially expedite approval pathways.    
 
Topical administration of phage has, thus far, failed to report any localised cytotoxic effects 
(although this may be a function of inadequate cytotoxicity studies rather than an absence of 
effect) 85. A study conducted recently has demonstrated promising results in the 
administration of a phage cocktail for treatment of S. aureus infection in the frontal sinus 
region of sheep. Safety data reported no inflammatory infiltration or tissue damage to the 
sinus mucosa, despite twice-daily phage application over a 20 day period 86. Nonetheless, 
owing to the wide variation in phage structure, activity and preparation (especially in the 
case of modified phage), all phage formulations should be fully characterised in terms of host 
response, regardless of previous studies.  
 
In addition to any immune or cytotoxic effects associated with the administration of phage, 
the current thermoresponsive system relies on the implementation of a polymeric delivery 
system, which may present additional host-associated effects. In-depth cytotoxicity studies of 
PNIPAM (formed by free radical polymerisation) and PNIPAM coated substrates have been 
conducted on a range of cell lines (it is well known that the NIPAM monomer is toxic). 
PNIPAM coated surfaces (using synthesised PNIPAM) were not cytotoxic to all 4 cell types 
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tested (fibroblasts, endothelial, epithelial and smooth muscle cells). Synthesised PNIPAM and 
commercially produced PNIPAM did not appear to affect cell viability. Of the cell lines tested, 
only endothelial cells demonstrated increased sensitivity to commercially available PNIPAM 
coated surfaces; however this was attributed to residual presence of the monomer 87.  This 
research highlights the importance of polymer purity and the choice of cell line. PNIPAM 
nanoparticles have been tested on a dermal cell line; results of this study indicated the 
nanoparticles were localised and internalised in lysosomes within 24 h and no cytotoxic or 
genotoxic responses were observed 88. Whilst these studies indicate promising results 
regarding the biocompatibility of PNIPAM as a drug delivery vehicle, the precise polymeric 
system (including the allylamine copolymer) reported in this study has yet to be tested. 
Furthermore, the stability of the nanoparticles on the non-woven fabric should be evaluated, 
in order to establish the degree of particle detachment from the plasma activated surface, 
which may affect the cytotoxicity of the system. There have been numerous studies 
conducted on the safety and tolerance of therapeutic nanoparticles detailing various complex 
biological interactions (including interaction with the innate immune system), which are 
largely dictated by the characteristics of the nanoparticles (size, shape, deformability etc.). A 
detailed review of some of the key considerations is presented by Boraschi et al 89.  
 
Additional studies aimed at optimising the research presented, focused on the 
aforementioned variables, could in theory, provide an effective means of controlling the 
release of an enhanced bacteriophage cocktail, from a fully biocompatible delivery system for 
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Chapter 5: Thermally Triggered Release of the Bacteriophage 
Endolysin CHAPK and the Bacteriocin Lysostaphin for the Control of 
Methicillin Resistant Staphylococcus aureus (MRSA) 
5.1 Introduction 
This research is presented as an extension of the previous study reported in Chapter 4; the 
utilisation of skin temperature as an indication of infection, in order to facilitate the delivery 
of an antimicrobial formulation from a thermoresponsive polymeric platform (Figure 1). 
Exploiting a formidable bacterial defence strategy (the production of bacteriocins), alongside 
utilisation of a key component involved in phage-mediated biocontrol of bacterial population 
dynamics (the production of phage-encoded endolysins), the potential to control infection 
has been investigated. This study details the formulation of an enzybiotic cocktail consisting 
of a phage-encoded endolysin (CHAPK) and a bacteriocin (lysostaphin). Cooperative effects in 
terms of synergistic interaction have been evaluated, with the intention of developing an 
effective cocktail, exhibiting greater antimicrobial efficacy than the sum of the individual 
components. The primary advantage associated with the use of bactericidal enzymes, 
surrounds avoiding the implementation of self-replicating biological agents, thus eliminating 
any potential transduction of genetic material. The aims of this research are largely based on 
those underpinning the previous publication, with the additional benefit of potentially 
circumventing some of the complex regulatory and approval issues surrounding the use of 











 Figure 1 Schematic illustrating the thermally triggered release of an enzybiotic cocktail, 
consisting of a bacteriophage-encoded endolysin (CHAPK) and a staphylococcal 
bacteriocin (lysostaphin) from PNIPAM-co-ALA nanospheres. 
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Phage-encoded endolysins have been the subject of considerable interest in recent years, 
owing to the rise in multi-drug resistance and the developmental decline of novel antibiotics. 
Endolysin classification, characterisation and clinical development are discussed in Chapter 
3. CHAPK, the truncated form of LysK exhibits a relatively broad lytic spectrum, which 
includes staphylococcal, micrococcal and streptococcal species. As a peptidoglycan hydrolase 
enzyme, CHAPK cleaves the bond between D-alanine and the first glycine in the pentaglycine 
cross-bridge of S. aureus peptidoglycan. However, in the case of streptococcal peptidoglycan, 
there are no glycine residues; instead, the cleavage site appears to be between D-alanine and 
L-alanine in the cross-bridge. It is therefore speculated that the absence of the cell wall-
binding domain (i.e. the SH3b domain found in LysK), may facilitate the recognition of a 
common moiety in the structure of the peptidoglycan cell wall of multiple bacterial species 1. 
This enhanced lytic activity (relative to the parent enzyme), offers an extended spectrum of 
antimicrobial activity against multiple Gram-positive species, including coagulase-negative 
strains, for example Staphylococcus epidermidis (S. epidermidis). CHAPK-mediated 
peptidoglycan bond cleavage involves a catalytic triad consisting of cysteine, histidine and 
glutamate (Figure 2 2). 
 
The proposed mechanism involves 2 sequential proton transfer steps: His117 (from the 
protonated imidazole ring) to Glu134, followed by Cys54 to His117. The deprotonation of 
Cys54 then facilitates nucleophilic attack on the peptide bond in the cell wall, resulting in the 
Figure 2 The catalytic triad of responsible for CHAPK–mediated peptidoglycan hydrolysis. 
The triad consists of Cys54, located on the second α-helix (bottom), His117, located on β-
strand C (middle) and Glu134, located on β-strand D (top). Distances are shown in Å. 
Reproduced from 2. Copyright © 2014 Sanz-Gaitero et al. 
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formation of an acyl-enzyme intermediate, which may be hydrolysed to release the newly 
cleaved peptidoglycan.  
 
CHAPK retains lytic activity over a broad pH range (6 – 11), a broad temperature range (5 – 40 
°C) and is stable for up to 1 month when stored at 4 °C and up to 1 year when stored at -80 °C 
3. The ability to withstand conditions which would otherwise inactive other phage endolysins 
and the ability to target multiple bacterial strains, regardless of their origin, antibiotic 
resistance profile or ability to form biofilms, makes CHAPK a promising candidate in the 
design of novel biotherapeutic antimicrobials.  
 
5.1.2 Bacteriocins 
Bacteriocins are highly specific, ribosomally synthesised antimicrobial peptides or proteins 
produced by both Gram-positive and -negative bacteria. In fact, over 99% of bacteria produce 
at least one type of bacteriocin 4. Microbial production of such proteinaceous species 
provides a means of out-competing neighbouring bacteria (for both space and resources), via 
cellular destruction of closely related competitor strains. The heterogeneous nature of 
bacteriocins gives rise to variation in their specific mode of action; the most common 
mechanisms involve the formation of pores in the cell membrane and dissipation of 
membrane potential, inhibition of nucleic acid synthesis and prevention of peptidoglycan 
synthesis 5. The producing strain remains unaffected by the presence of their synthesised 
bacteriocins, owing to the simultaneous expression of immunity proteins. This form of 
biocontrol is yet another crucial factor involved in controlling the complex ecology of 
bacterial communities. Recent studies have demonstrated promising results regarding the 
therapeutic potential of bacteriocins as protein antibiotics; a detailed review of the current 
state of research has been published by Behrens et al 6. 
 
In addition to their current development as therapeutic agents, bacteriocins have been 
widely investigated for use in the food industry. Nisin is produced by the bacteria Lactococcus 
lactis and is classed as a broad-spectrum bacteriocin (from the class lantibiotics, owing to the 
presence of the uncommon amino acid lanthionine). Nisin has been approved by the FDA for 
use in pasteurized processed cheese, for the control of lactic acid bacteria (known to spoil 
food preparations). Further discussion on the application of bacteriocins in the food industry 
is published elsewhere 7. However, recognition of the potent antimicrobial properties of 
certain bacteriocins by regulatory authorities is an encouraging first step for their future 
therapeutic development.  




Lysostaphin, first identified in 1964, is a bacteriocin (although may be referred to as a 
bacteriolysin), exhibiting potent and specific activity against clinically relevant 
staphylococcal species (predominantly S. aureus and S. epidermidis) 5.  Produced by a key 
environmental competitor of S. aureus (discussed further in Section 5.2), it has demonstrated 
efficacy against both MSSA and MRSA and is capable of killing both active and quiescent 
bacteria. Lysostaphin has been extensively investigated for the control of S. aureus both in 
vitro and in vivo, including biofilm associated infections 8. Additionally, this potent 
peptidoglycan hydrolase enzyme has shown greater antibiotic efficacy than vancomycin in 
vitro 9. Furthermore, enhanced antimicrobial effects have been demonstrated when using 
lysostaphin in conjunction with conventional antibiotics 10. Of particular relevance to this 
thesis is the development of a lysostaphin impregnated chitosan-collagen hydrogel for use in 
MRSA-infected burn wounds. The study, conducted by Cui et al, aimed to test the novel 
antimicrobial hydrogel formulation on MRSA-infected third degree burns in a rabbit model 11. 
The results showed 100% wound healing over a 2 week period and complete eradication of 
infection after 2 weeks, thereby demonstrating the promising potential of lysostaphin for 
treatment of burn wound infections.  
 
Lysostaphin initiates bacterial cell lysis via catalysis of cell wall hydrolysis, however it has a 
slightly different target site in the pentaglycine cross bridge compared to CHAPK. The 










Figure 3 Structure of the peptidoglycan cell wall of S. aureus, highlighting the cleavage 
site for lysostaphin relative to CHAPK. Adapted from 12. Copyright © 2010 Bastos et al. 
CHAPK Lysostaphin 
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As a member of the M23 metalloendopeptidase family, the active site of lysostaphin is 
centred around a Zn2+ ion, which is coordinated to histidine 279, aspartate 283, histidine 362 
and a water molecule (in the active form of the enzyme) 13. The proposed mechanism 
involves the abstraction of a proton from water by the first histidine residue, resulting in the 
formation of a nucleophilic hydroxide ion which attacks the carbonyl carbon in the 
peptidoglycan peptide bond. The second chelated-histidine is thought to stabilise the 
tetrahedral transition state 14.  
 
5.2 Extended Methodology 
5.2.1 Minimum Inhibitory Concentration 
A stock solution of the antimicrobial to be tested (i.e. antibiotic or enzyme) was made up to 
twice the starting concentration required (i.e. in order to start with 64 µg/ml in the MIC 
experiment, a 128 µg/ ml stock solution was prepared). Overnight bacterial cultures were 
subcultured 1:1000 in TSB. To a 96 well plate, 100 µl of TSB was added to columns 2 - 12 and 
100 µl of antimicrobial stock solution was added to columns 1 and 2. Using a multichannel 
pipette, 100 µl was taken from the wells in column 2 and serially diluted across the plate to 
column 10 (columns 11 and 12 were reserved for negative controls in the absence of 
antibiotic and bacteria respectively). The additional 100 µl in column 10 was discarded after 
dilution. 100 µl of bacterial subculture was added to every well except those in column 12. 
The plate was then incubated overnight at 37 °C and the MIC was determined the following 
day. The MIC was defined as the lowest concentration of antimicrobial capable of inhibiting 
the growth of bacteria (assessed as a function of OD at 600 nm using a microtitre plate 
reader). Each antimicrobial concentration was therefore tested 8 times (based on the number 
of rows in a 96 well plate).  
 
5.2.2 Checkerboard Assay 
Stock solutions of CHAPK and lysostaphin were made up to 4 times the starting concentration 
to be tested; in this case 256 µg/ml and 1 µg/ml respectively. Overnight bacterial cultures 
were subcultured 1:1000 in TSB. To a 96 well plate, 100 µl of TSB was added to each well 
except those in column 1. 100 µl of the lysostaphin stock solution was added to columns 1 
and 2. Using a multichannel pipette, 100 µl was taken from the wells in column 2 and serially 
diluted across the plate; the excess 100 µl in the final column was discarded after dilution. 
100 µl of the CHAPK stock solution was then added to each well in row A. Using a multichannel 
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pipette 100 µl was taken from the wells in row A and serially diluted down the plate; the 
excess 100 µl in the final row was discarded after dilution. 100 µl of bacterial culture was 
then added to each well (with the exception of those reserved for controls) and the plate was 
then incubated overnight at 37 °C.  Synergy was assessed visually the following day, 
demonstrated by an absence of bacterial growth and the calculation of inhibition 
concentrations (Section 5.3). 
 
5.2.3 Bradford Assay  
Bovine serum albumin (BSA) (Sigma Aldrich) was serially diluted 1:2 from stock (2 mg/ml) 
in DI water to create a range of BSA concentrations. 10 µl of each dilution was added to a 
microtitre plate in triplicate, alongside DI water (used as a blank sample). Coomassie Plus 
Reagent (Thermo Scientific™, ThermoFisher) was equilibrated to room temperature and 300 
µl was added to each well. The plate was mixed on a shaker plate at 600 rpm for 30 s at room 
temperature and held at room temperature for a further 10 min. The absorbance at 595 nm 
was then measured using a microtitre plate reader. The absorbance from the blank samples 
(DI water and Coomassie Plus Reagent), was subtracted from the sample measurements and 
the values were used to prepare a standard curve (BSA concentration vs. absorbance). The 
samples containing unknown concentrations of protein (in this case CHAPK), were then 
diluted 1:10 and 1:20 in DI water. 10 µl of each was added to a microtitre plate in triplicate, 
followed by 300 µl of Coomassie Plus reagent. The process was repeated as before and 
absorbance measurements were taken. The absorbance readings of the samples containing 
CHAPK were then correlated to the standard curve and the concentration was determined.  
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Staphylococcus aureus infections of the skin and soft tissue pose a major concern to public 
health, largely owing to the steadily increasing prevalence of drug resistant isolates. As an 
alternative mode of treatment both bacteriophage endolysins and bacteriocins have been 
shown to possess antimicrobial efficacy against multiple species of bacteria including 
otherwise drug resistant strains. Despite this, the administration and exposure of such 
antimicrobials should be restricted until required in order to discourage the continued 
evolution of bacterial resistance, whilst maintaining the activity and stability of such 
proteinaceous structures. Utilising the increase in skin temperature during infection, the 
truncated bacteriophage endolysin CHAPK and the staphylococcal bacteriocin lysostaphin 
have been co-administered in a thermally triggered manner from Poly(N-
isopropylacrylamide) (PNIPAM) nanoparticles. The thermoresponsive nature of the PNIPAM 
polymer has been employed in order to achieve the controlled expulsion of a synergistic 
enzybiotic cocktail consisting of CHAPK and lysostaphin. The point at which this occurs is 
modifiable, in this case corresponding to the threshold temperature associated with an 
infected wound. Consequently, bacterial lysis was observed at 37 °C, whilst growth was 
maintained at the uninfected skin temperature of 32 °C. 
 
Keywords: PNIPAM, Bacteriophage Endolysin, Bacteriocin, Thermal Release 





Staphylococcus aureus (S.aureus) is a frequent inhabitant of the human skin flora colonizing 
up to 30% of individuals at any given time, primarily through nasal carriage 15. Requiring a 
suitable portal of entry into the body, the skin normally provides such a barrier to 
progressive infection. However a breach in the skin, often as a result of a scratch, cut or burn 
provides a suitable infection point for the opportunistic bacteria. S.aureus is the leading cause 
of skin and soft tissue infections (SSTI) across all continents, thus resulting in both delayed 
wound healing and further systemic infections, such as sepsis, osteomyelitis and endocarditis 
16. With the discovery of staphylococcal drug resistance and the subsequent global epidemic 
that methicillin resistant S. aureus (MRSA) has become, the need to source alternative 
treatment has become paramount. Hospital acquired MRSA (HA-MRSA) has a mortality rate 
twice that of its methicillin susceptible counterpart, and is more than twice as expensive to 
treat 17. Furthermore, the isolation of these ‘super-bugs’ is not confined to the hospital 
setting. Indeed, community acquired MRSA (CA-MRSA) is proving an equal challenge to 
clinicians worldwide 18.  
 
Bacteriophage (phage), (the naturally occurring parasitic viruses of bacteria, able to infect 
and destroy bacterial cells) were first utilised as a treatment to infection in the 1930s within 
the former Soviet Union. Despite the continued development of phage products throughout 
the Cold War, bacteriophage therapy was largely disregarded in the West from under the 
relative comfort of the antibiotic blanket. However, the alarming rise in multi-drug resistance 
(MDR) in recent times has regenerated interest in phage therapy 19. One of the main 
disadvantages associated with the use of whole phage to treat infection is the viral nature of 
the phage itself. Containing a vast amount of genetic material, temperate phage have been 
known to increase the virulence of certain species of bacteria through transduction, an 
example of which includes the bacterial acquisition of the gene encoding the Panton 
Valentine Leucocidin toxin, causing ‘scalded skin syndrome’ 20. Whilst this is selected against 
when sourcing phage for treatment, the regulation and control of suitable virulent phage for 
clinical use is often timely and uncertain.      
 
Bacteriophage-encoded endolysins (peptidoglycan hydrolases synthesised by phage infected 
bacterial cells) are utilised in the end stages of phage infection. Lysins are capable of 
destroying the bacterial cell wall through digestion of the peptidoglycan polymer, resulting in 
cell death through osmolysis 21. The isolation of these hydrolases has the potential to 
overcome many issues surrounding the use of whole phage. As hydrolytic enzymes, they 
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retain specificity without affecting commensal flora, are capable of rapid bacterial lysis, are 
unlikely to encounter resistance owed to the essential bacterial binding sites and they do not 
contain transducible genetic information 22. The specific mechanism of action of these 
endolysins is discussed elsewhere 23. Endolysins demonstrating activity towards both Gram-
positive and Gram-negative bacteria have been isolated and characterised, including lysins 
active against Acinetobacter baumanni, Bacillus anthracis, Streptococcus pyogenes and in some 
cases active against both Gram-positive and –negative bacteria simultaneously 24-26. The 
phage endolysin designated LysK isolated from the staphylococcal bacteriophage K has been 
shown to have potent antimicrobial activity against a range of staphylococci including MRSA 
1. LysK has been truncated to its single catalytic domain, a cysteine, histidine-dependent 
aminohydrolase/peptidase (CHAPK). This single domain, 18.6 kDa antimicrobial enzyme has 
been fully characterised and has demonstrated retention of lytic activity in vitro, in vivo and 
against staphylococcal biofilms 3,27,28.  
 
Another class of potential alternative antimicrobials are bacteriocins. Lysostaphin, a 26.8 kDa 
metalloendopeptidase is produced naturally by Staphylococcus simulans 29. Consisting of a 
single lytic domain (glycyl-glycine M23 endopeptidase), lysostaphin demonstrates potent 
antistaphylococcal activity through cleavage of the pentaglycine cross-bridges within the 
peptidoglycan of the bacterial cell wall. Active against a multitude of antibiotic susceptible, 
intermediate and resistant strains of bacteria, lysostaphin exhibits synergistic behaviour with 
multitude of antibiotics, phage lysins and antimicrobial peptides 30-32. Successful application 
of lysostaphin has been demonstrated in cases of ocular infection, osteitis and endocarditis 33-
35.  
 
Despite the discovery and development of new potential antimicrobial candidates, the mode 
of delivery of any such pharmacologically active substance remains equally as important as 
the discovery itself. Ensuring activity, stability and dosage conditions are correct (especially 
when considering biological material), is crucial to successful administration in order to 
maximise the therapeutic benefit and to reduce any potential side effects. The triggered 
release of a therapeutic agent (small molecule, protein or virus) may rely on a variety of 
external stimuli in order to release the active cargo, including pH, temperature, ultrasound, 
magnetism or biomarker signals 36,37. Utilising the difference between the healthy and the 
diseased state may provide certain conditions whereby treatment can be administered in a 
controlled fashion. Consequently, high local concentrations are achieved only in the specific 
location required. When considering treatment of bacterial infection, preventing the 
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administration of unnecessary or sub-lethal concentrations of an antibiotic or antimicrobial 
agent is crucial in preventing the continued development of antibiotic resistance 38.  
 
Poly(N-isopropylacrylamide) (PNIPAM)  has been widely investigated as a triggered drug 
release vehicle 39. As a thermoresponsive polymer, PNIPAM undergoes a reversible, 
entropically driven phase transition at a lower critical solution temperature (LCST), resulting 
in the expulsion of water and a subsequent change in polymer volume. The LCST of PNIPAM 
and its associated structures (nanoparticles, micelles, nanogels etc.) can be manipulated 
through control of polymer concentration, copolymers and surfactants. Through adjusting 
the LCST to that of a clinically relevant temperature, PNIPAM has been extensively 
investigated in a wide range of biomedical applications including cancer therapy, wound 
healing, bioscaffolding and cell cultivation 40-43.  
 
In previous studies, PNIPAM nanoparticles were formulated with allylamine for the 
controlled release of Bacteriophage K,  which demonstrated potent antistaphyloccal activity 
through the thermally controlled collapse of the nanoparticles 44. However in this study, 
phage virions were replaced with a synergisitic enzybiotic cocktail. Allylamine was used in 
order to adjust the LCST to a biologically relevant temperature of 34 °C, which is indicative of 
an infected wound. A bacterial infection of a wound as been shown to present as an elevation 
in skin temperature of around 3.6 °C (demonstrated in infected leg ulcers), in comparision to 
the surface temperature of approximately 32 °C seen in healthy skin 45. PNIPAM 
nanoparticles were anchored to non-woven polypropylene to simulate a wound dressing 
using plasma deposited maleic anhydride and free amine groups from allylamine. Plasma 
based deposition strategies for surface activation have been well documented elsewhere 46-48. 
As a representative bacterial isolate, MRSA252 was chosen, which is a HA-MRSA bacterium 
belonging to the clinically relevant epidemic MRSA-16 clone (EMRSA-16), and considered 
endemic in the majority of UK hospitals 49.  
 




N-isopropylacrylamide, allylamine, ethylene-glycol diacrylate, sodium persulfate, sodium 
dodecylsulfate (SDS), phosphate buffered saline (PBS) tablets (pH 7.4), vancomycin 
hydrochloride from Streptomyces orientalis and maleic anhydride were all purchased from 
Sigma-Aldrich (Poole, Dorset, UK).  
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Lysostaphin from Staphylococcus simulans, Tryptic Soy Broth (TSB) and Tryptic Soy Agar 
(TSA) were purchased from Sigma-Aldrich (Poole, Dorset, UK). Coomassie (Bradford) Protein 
Assay Kit was purchased from Pierce Scientific. MRSA 252 was sourced from a bacterial 
strain collection belonging to the Biophysical Chemistry Research Group housed at the 




PNIPAM Nanoparticle Synthesis, Plasma Deposition and Surface Grafting  
 
Particles were synthesised via precipitation polymerisation and anchored onto of non-woven 
polypropylene (2 x 2 cm) squares via plasma deposited maleic anhydride as previously 
described 44, the only modification being an increase in the surface grafting duration from 1 
to 24 h. Following surface attachment, samples were washed in deionised (DI) water, air 
dried and kept under aseptic conditions prior to enzyme addition.  
 
Electron Microscopy  
 
Samples were prepared as above, freeze dried, sputter coated with gold and imaged via a 




Bacteria and Growth Conditions 
 
MRSA 252 was taken from freezer stock (stored as a 15% (v/v) glycerol at -80 °C), streaked 
across a TSA culture plate with a loop spreader and incubated at 37 °C overnight in order to 
obtain single colonies. Bacterial cultures were prepared by inoculating 10 ml TSB with a 
single colony and incubating at 37 °C with agitation overnight. 
 
CHAPK Production  
 
CHAPK production was performed as previously described 28. Briefly, the truncated lysin 
CHAPK was previously cloned and expressed using a pQE60 vector (Qiagen) in Escherichia 
coli (E. coli) XL1-Blue 50.  This recombinant E. coli was grown at 37 °C with shaking. Protein 
expression was achieved by inducing the cells with Isopropyl β-D-1-thiogalactopyranoside 
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(IPTG). After which, the cells were lysed and active CHAPK was purified to >90% homogeneity 
by cation exchange chromatography and quantified via the Bradford assay 51.  
 
Minimum Inhibitory Concentration (MIC) 
 
MICs for both CHAPK and lysostaphin were determined by the classical microdilution broth 
method, conducted according to the Clinical and Laboratory Standards Institute (CLSI) 
guidelines 52,53. Briefly, MRSA 252 cells at 7 x105 colony forming units per millilitre (CFU/ml) 
were added to wells containing varying concentrations of CHAPK (64 – 1 μg/ml) and 
lysostaphin (0.25 - 0.004 μg/ml) in a microtitre plate. The plate was then incubated for 18 h 
with shaking in a micro-plate reader (SPECTROstar Omega, BMG LABTECH) and bacterial 
growth monitored as a function of optical density (OD) at 600 nm. Experiments were 
conducted in triplicate both at 37 °C and 32 °C. DI water was used to make enzyme stock 
solutions and for control experiments.  
 
Turbidity Reduction Assays 
 
The in vitro activity of both CHAPK and lysostaphin was assessed according to the rate of 
bacterial cell lysis. MRSA 252 cells at 7 x105 CFU/ml were grown to an OD of 0.5, centrifuged 
at 4000 rpm for 20 min at 4 °C, washed twice and resuspended in PBS to reattain an OD of 
0.5. A range of CHAPK and lysostaphin solutions were prepared in DI water with 
concentrations relative to their MIC (0-16%) in order to assess enzyme activity in the 
presence of excess substrate: 100 μl of enzyme solution was added to 100 μl of bacterial 
solution in a microtitre plate in triplicate, the plate was shaken for 5 s to ensure sufficient 
mixing and the reduction in OD at 600 nm over 5 min was monitored using a micro-plate 
reader at either 37 °C and 32 °C. Control experiments were undertaken using DI water in 




Synergy was assessed according to the checkerboard assay 54. Briefly, 100 μl of 7 x105 
CFU/ml MRSA 252 was added to each well of an 8 x 8 section of a 96 well microtitre plate 
containing varying ratios of CHAPK: lysostaphin, ranging from 64 – 1 μg/ml CHAPK and 0.25 - 
0.004 μg/ml lysostaphin. The plate was incubated at 37 °C for 24 h without shaking and 
bacterial growth assessed visually. Synergy was confirmed by observation of wells with no 
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visible bacterial growth at enzyme concentrations lower than the MICs of the individual 
antimicrobials.  
 
Electron Microscopy  
 
Bacterial samples were grown on Melinex® film overnight in 5 ml TSB at 37 °C with minimal 
agitation (70 rpm). The volume of growth media was adjusted to 2 ml and exposed to either 
64 μg/ml CHAPK, 0.125 μg/ml lysostaphin, a combination of 8 μg/ml + 0.031 µg/ml 
lysostaphin or DI water (control) for 10 min at 37 °C. Samples were then fixed with 2.5% 
glutaraldehyde in 0.1 M sodium cacodylate buffer, postfixed in aqueous 1% osmium 
tetroxide, dehydrated in an acetone series (50 - 100%) and chemically dried in 
hexamethyldisilazane (HMDS). Samples were sputter coated with a thin layer of chromium 
and imaged using a Field Emission Scanning Electron Microscope (FESEM) (JEOL JSM6301F 
operating at 5 KV).  
 
Controlled Release Experiments 
 
Addition of CHAPK and Lysostaphin to Anchored Nanoparticles 
 
A cocktail consisting of 80 µg/ml CHAPK and 0.31 µg/ml lysostaphin (10 times the 
concentration shown to generate synergistic inhibition) was incorporated into the anchored 
gel matrix via soaking the dried gel modified polypropylene fabric in 500 µl of enzyme 
solution for 2 h at room temperature (20 °C). The fabric was washed in DI water and air 
dried. Control experiments were undertaken using DI water in place of enzyme solution. In 
order to estimate protein loading of the nanoparticles, the Bradford assay was used to 
quantify total protein concentration both in the soaking solution (as confirmation of synergy 
concentration) and in the solution in which the fabric swatches were washed post soaking. 
All experiments were performed in triplicate and corrected against control swatches (soaked 
in DI water) in order to eliminate any non-protein associated solution absorbance. An 
average blank reading was used to baseline correct all absorbance readings, using DI water 
only. The residual protein concentration post washing was subtracted from the initial soaking 




(total protein added - protein in washings)
total protein added
 × 100 
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Thermal Release of CHAPK/Lysostaphin Cocktail from Grafted PNIPAM Nanoparticles 
 
Polypropylene-nanoparticle swatches incorporating the enzybiotics were soaked individually 
in 250 µl of MRSA 252 of fixed concentration (1.2 x108 CFU/ml in PBS) at either 32 °C or 37 
°C for 30 min. Each square of fabric was then removed from solution and placed into 24.75 ml 
DI water (diluting the original solution volume 100-fold) alongside any residual liquid that 
had not been soaked up by the fabric. The 25 ml culture tube containing the fabric swatch 
was vortexed to remove any bacteria attached to the fabric and the solution from each tube 
was diluted and plated (in triplicate) on TSA plates and incubated at 37 °C overnight. Plates 
were assessed the following day for growth and any colonies counted. Control experiments 
were undertaken using the swatches without enzyme and each individual experiment was 
repeated 6 times.  
 
Results and Discussion 
 
Material Analysis  
 
PNIPAM Nanoparticle Characterisation and Surface Grafting 
 
The PNIPAM nanoparticles have been characterised by dynamic light scattering (DLS) and 
according to zeta potential analysis as reported in a previous study 44. The LCST of the 
nanoparticles was shown to be transitional but clearly definitive at 34 °C, manifesting as a 
change in the hydrodynamic radius from 400 nm ± 50 nm in the expanded state (< 33 °C), to 
170 nm ± 30 nm in the collapsed state (> 35 °C). Therefore the collapse of the nanoparticles 
and subsequent release of the enzybiotic cargo is targeted to occur only at a higher 
temperature associated with bacterial wound infection (around 36 °C), whilst remaining 
intact and preventing the release of the antimicrobial payload at temperatures indicative of 
an uninfected wound (around 32 °C). Successful deposition of maleic anhydride onto the non-
woven polypropylene as anchor points for the nanoparticles was confirmed by Fourier 
Transform Infrared Spectroscopy (FT-IR) (Figure 1, Supplementary Information) as 
previously described.  
 
Electron Microscopy  
 
SEM images indicated the incorporation of the PNIPAM nanoparticle solution to non-woven 
polypropylene following surface activation with plasma deposited maleic anhydride and 
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wash steps, as shown in Figures 4A and 4B. The large polymer webs (Figure 4B) seen 
throughout the fibre matrix, appear to consist of individual nanoparticles held together by 
the polymeric sheets (Figure 4C). The nanoparticles are of varying sizes encompassing both 
the swollen and the collapsed state, possibly as a result of the freeze drying during the sample 


























Minimum Inhibitory Concentration (MIC) 
 
The MIC was determined at both 32 °C and 37 °C as 64 µg/ml and 0.125 µg/ml, for CHAPK and 
lysostaphin, respectively, illustrating no change in the ability of either enzyme to prevent 






Figure 4 SEM images of non-woven polypropylene fabric (A) Untreated (B) 
Following PNIPAM nanoparticle attachment (C) Polymeric matrix seen dispersed 
within the fibre network (D) Nanoparticles attached to the surface of a 
polypropylene fibre. 
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Turbidity Reduction and Rate of Cell Lysis 
 
The rate at which both CHAPK and lysostaphin catalyse cell lysis was determined by assessing 
the reduction in turbidity (OD) of a bacterial suspension over the course of 60 s, defined as 
the initial rate of reaction (Figure 2 - Supplementary Information). This was investigated at 
32 °C (below the LCST of the nanospheres) and at 37 °C (above the LCST), and at low 
concentrations of enzyme in order to prevent substrate concentration from becoming a 
limiting factor. Initial rates were calculated by means of tangents and plotted as a function of 


















From these results it can be seen that CHAPK is capable of eliciting a rapid reduction in 
turbidity (associated with bacterial cell lysis) which follows a standard dose response at both 
temperatures, whilst slightly more linear at 32 °C. There is a small difference in the initial 
rate of reaction at the two temperatures, more noticeably at higher concentrations of CHAPK 
but not to such an extent that indicates enzyme activity is substantially hindered at the lower 
temperature. However it appears that lysostaphin is unable to initiate a substantial degree of 
cell lysis (even at the highest concentrations) in such a short timeframe despite having a very 
low overall MIC, with values being similar to that of the control and demonstrating little 
temperature associated effect. This is in keeping with previous studies whereby CHAPK 
B A 
Figure 5 Comparison of the initial rate of bacterial cell lysis by: (A) CHAPK   
 (B) lysostaphin. 
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exhibited a greater reduction in turbidity over a 5 min period when compared to lysostaphin 
of the same absolute concentration (independent of MIC) 3.  
 
Assessment of Synergistic Behaviour 
 
Synergy was assessed both visually (non-growth of bacteria in well plate) and via calculation 
of fractional inhibitory concentration (FIC), taking the value of the MIC of the enzymes in 
combination, divided by the MIC of the individual enzyme. To achieve strong synergy the sum 
of the two FICs (ΣFIC = FICA+FICB) must be less than 0.5 55. As shown in Figure 6, synergy is 
indicated across the microtitre plate, at a range of different concentrations and confirmed in a 
total of 11 wells with FICs ranging from 0.144 (well G5) to 0.378 (well C5). A combination of 
8 µg/ml CHAPK and 0.031 µg/ml lysostaphin was chosen as a concentration which 
demonstrates a strong synergistic combination (corresponding to a three-fold reduction in 
the MIC of lysostaphin and a four-fold reduction in the MIC of CHAPK), in order to utilise the 
ability of lysostaphin to inhibit bacterial growth at low concentration, together with an 
increased rate of cell lysis exhibited by CHAPK. 
Figure 6 Synergy analysis of CHAPK (MIC = 64 µg/ml) (ordinate) and lysostaphin 
(MIC = 0.125 µg/ml) (abscissa). 
 





Untreated MRSA cells exhibited uniformity in the presentation of their cell morphology as 
shown in Figure 7A, active cell division was also observed. Cells treated with vancomycin at 
twice the MIC (12.5 µg/ml) for 10 min as shown in Figure 7B, did not present any change in 
their surface morphology or exhibit any visible membrane damage.  
 
 
Cells treated with CHAPK (at the MIC) (Figure 8A) show some surface damage and slightly 
more extracellular debris when compared to the control (Figure 7A); however the majority of 
the cells appear unaffected. When evaluating cells exposed to lysostaphin at the MIC (Figure 
8B), they are comparable in appearance to those in the control group. This is in keeping with 
the established rate of lysis observed in solution, with CHAPK being much faster in eliciting a 
response. The synergistic effect of the cocktail of the two enzymes can be clearly observed in 
Figure 8C:  blebbing (protrusion of the plasma membrane) was seen (red arrow) and a high 






Figure 7 SEM images of untreated and antibiotic treated S. aureus MRSA 252 cells (A) cells 
exposed to DI water (control) (B) cells exposed to 2 x MIC (12.5 µg/ml) vancomycin. 10 
min incubation time. Cell division observed in both cases. 
 
A B 



























Controlled Release  
 
Fabric swatches with surface anchored PNIPAM nanoparticle gel were soaked in an enzyme 
solution consisting of 80 µg/ml CHAPK and 0.31 µg/ml lysostaphin (10 times the synergy 
MIC), this was confirmed using the Bradford assay. The unencapsulated, residual protein 
concentration in solution post soaking and washing was calculated (Table 1), thus giving an 
estimated loading concentration of 49.7 ± 23.4 µg/ml or approximately 56%. As the effective 
synergistic combination of the bactericidal enzymes equates to approximately 8 µg/ml, even 
at the lower limit of this estimate, this is over three times the concentration of the cocktail 




Figure 8 SEM images of  S. aureus MRSA 252 cells treated with antimicrobial enzymes (A) 
at MIC: 64 µg/ml CHAPK (B) at MIC 0.125 µg/ml lysostaphin (C +D) sub-individual MIC 8 
µg/ml CHAPK + 0.031 µg/ml lysostaphin. 10 min incubation time. 
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Table 1 Concentration of protein added to modified fabric, residual non-adsorbed protein 
and hence encapsulated protein concentration. 
 
Protein added g / ml Residual non-absorbed 
protein g / ml 
Encapsulated protein 
g / ml 
88.0 +/- 9.2 38.3 +/- 21.5 49.7 +/- 23.4 
 
PNIPAM nanoparticles are able to deliver an enzymatic formulation in a temperature 
controlled manner as shown by evaluating the difference in cell count post incubation at 
temperatures both above and below the LCST. Samples plated after incubation at 32 °C 
demonstrate very little difference in the number of colonies between the controls 
(nanoparticles without enzybiotic cocktail) (Figure 9A) and the samples containing the 
enzybiotic cocktail (Figure 9B). The control experiments also confirm that the nanoparticles 
alone do not affect the bacteria. Whereas samples tested at 37 °C indicate a drastic decrease 
in the number of viable cells post treatment (Figure 9D). Figure 9C confirms that the collapse 
of the nanoparticles above the LCST does not affect the survival of the bacteria, being 






















Figure 9 Plate analysis of S. aureus MRSA 252 survival and growth  
 (A) PNIPAM control at 32 °C (B) PNIPAM/CHAPK/lysostaphin at 32 °C (C) PNIPAM control 
at 37 °C (D) PNIPAM/CHAPK/lysostaphin at 37 °C. 
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Quantitative analysis (colony counting) showed a significant difference in the number of 
viable cells at the two temperatures (p ≤ 0.0001, Student’s t-test). Whilst there is a relatively 
small change in the number of CFU/ml between the control and the experimental sample at 
32 °C, this is not unreasonable when taking into account possible passive diffusion or 
leaching of the enzymes from the particles. Nonetheless, when compared to samples 
incubated at 37 °C there is a clear difference in survival, manifesting as a >4 log reduction in 




In summary this study demonstrates a new and previously unreported application of a novel 
enzybiotic cocktail for the thermally triggered control of Staphylococcus aureus. As potentially 
viable alternatives to antibiotic therapy, the use of enzybiotics may indicate a possible future 
treatment for drug resistant bacterial infection. Through exploitation of the ability of 
Figure 10 Comparison of bacterial survival at 32 °C and 37 °C for PNIPAM nanoparticle 
entrapped CHAPK/ lysostaphin cocktail, relative to PNIPAM nanoparticles without 
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lysostaphin to inhibit bacterial growth at very low concentration, and the fast acting nature of 
the bacteriophage-encoded endolysin CHAPK, the two antimicrobial enzymes have been 
shown to work synergistically in the inhibition and subsequent lysis of bacterial cells, 
demonstrating a faster response time when compared to the current antibiotic of choice for 
the treatment of MRSA. Moreover, restricting the administration of such antimicrobials by 
means of an external trigger (in this case an increase in skin temperature associated with 
infection), limits the possibility of the development of resistance through prevention of any 
sub-lethal selection pressure. Through exploitation of the thermoresponsive behaviour of 
PNIPAM, nanoparticles were employed as a drug delivery system capable of releasing their 
antimicrobial cargo at a biologically relevant temperature indicative of infection. Which, 
when compared to the same system containing whole phage, the use of an enzybiotic cocktail 
which is not self-replicating but relies solely on successful diffusion from the polymer matrix 
and full retention of stability, the results are a promising step forward in the controlled 
release of an alternative antimicrobial formulation, whilst avoiding any issues associated 
with the administration of whole phage 44. Although the clinical indication of our delivery 
system would be chronic wound infection via utilisation of a dressing/bandage concept, the 
technology presented here offers the possibility of infection control through use of 
enzybiotics for a range of conditions owing to the proven stability and retention of activity of 
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Supplementary Figure 1 FT-IR confirming addition of carbonyl functionality (peak at      
1782 cm-1) to non-woven polypropylene via plasma deposition of maleic anhydride. 
 
 
Supplementary Figure 2 Reduction in turbidity of planktonic MRSA 252 cells (measured as 
change in OD at 600 nm) over a 1 minute period as a function of CHAPK concentration. 
Tangents fitted in order to calculate initial rate of reaction. Each data point corresponds to 
the mean of three individual experiments and error bars represent the standard deviation. 
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5.4 Additional Results  
5.4.1 Lytic Spectrum of CHAPK 
In order to assess the lytic spectrum of CHAPK, numerous staphylococcal strains were 
screened and classified according to their susceptibility to the endolysin. Cultures were 
grown over an 18 hour period with the addition of 64 µg/ml of CHAPK (according to the 
methodology detailed in Section in 5.3.4). Of the 15 staphylococcal strains tested, 6 strains 
were classed as resistant (defined as the ability to sustain bacterial growth within 12 hours). 
The growth curves of the resistant isolates are shown in Figure 11, alongside growth media 
only (TSB) as the negative control.  
 
 
Additionally, five bacterial strains were classified as intermediate, indicating their ability to 
grow in the presence of CHAPK post 12 hour incubation (meaning growth is severely delayed 
rather than suppressed). A further four isolates were susceptible to CHAPK, illustrated by the 
complete suppression of bacterial growth over the full 18 hours. The growth curves of the 
intermediate and susceptible strains are shown in Figure 12 and the susceptibility of all 
strains tested is summarised in Table 2. 
















M R S A  7 1
M R S A  x
M R S A  4 J J
S . e p id e rm id is 1 2 2 2 8
S . e p id e rm id is  R P 2 6 A
S . a u re u s  B tn  7 2 6
T S B  O N LY
Figure 11 Growth of various resistant staphylococcal strains over 18 hours with the addition 
of 64 µg/ml of CHAPK. Each data point represents the mean of three individual biological 
replicates and the error bars represent the standard deviation. 






Table 2 Summary of the susceptibility of various staphylococcal strains to 64 µg/ml CHAPK 
following 18 hour incubation. Resistant (R) = Sustained bacterial growth within 12 hours. 
Intermediate (I) = Delayed bacterial growth, initiated after 12 hours. Susceptible (S) = 
Complete suppression of bacterial growth over 18 hours.  
 
Staphylococcal Strain Susceptibility to CHAPK 
MRSA 71 R 
MRSA x R 
MRSA 4JJ R 
EMRSA 1 I 
MRSA 252 S 
MSSA 476 I 
S. epidermidis ATCCA493 I 

















S . a u re u s  H 4 7 6
S . a u re u s  C 7 2 0
S . a u re u s  C 3 1 6
M R S A  2 5 2
S . e p id e rm id is
A T C C A 4 9 3
S . a u re u s  H 3 2 5
E M R S A  1
M S S A  4 7 6
S . a u re u s C 2 3 3
Figure 12 Growth of various intermediate and susceptible staphylococcal strains over 18 hours 
with the addition of 64 µg/ml of CHAPK. Each data point represents the mean of three 
individual biological replicates and the error bars represent the standard deviation. 
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S. epidermidis RP26A R 
S. epidermidis 12228 R 
S. aureus Btn 726 R 
S. aureus H325 I 
S. aureus H476 S 
S. aureus C720 S 
S. aureus C316 S 
S. aureus C233 I 
 
 
Of the four susceptible strains, MRSA 252 was chosen to take forward for further 
experiments, owing to its clinical relevance and drug-resistance profile.  
 
5.4.2 Effect of Temperature on Enzybiotic Activity  
The MIC of both CHAPK and lysostaphin was then determined for MRSA 252 at 32 °C and      
37 °C (as detailed in the publication), with the intention of assessing the lytic ability of the 
endolysins at a reduced temperature. This was an important parameter to establish in order 
to confirm that any observable effect on bacterial growth (when considering the 
thermoresponsive release of the enzybiotics), is indeed a function of controlled release as 
oppose to reduced enzymatic activity. The results for lysostaphin and CHAPK are shown in 
Figures 13 and 14 respectively. The variation in OD values between the left and right axes is 
purely a function of the spectrophotometer used. Whilst the absolute values differ, the 
increase in OD (or lack thereof) remains representative of the effect of the endolysins.  




Figure 13 Endpoint OD measurements of MRSA 252 as a result of the addition of varying 
concentrations of lysostaphin at 37 °C (pink - right axis) and 32 °C (blue - left axis). Each data point 
represents the mean of three independent replicates and error bars represent the standard 
deviation. The data is fitted to a standard sigmoidal dose-reponse curve. 
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Figure 14 Endpoint OD measurements of MRSA 252 as a result of the addition of varying 
concentrations of CHAPK at 37 °C (pink - right axis) and 32 °C (blue - left axis). Each data 
point represents the mean of three independent replicates and error bars represent the 
standard deviation. The data is fitted to a standard sigmoidal dose-reponse curve. 
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These data demonstrate no change in the MIC of lysostaphin at 32 °C, inhibition of bacterial 
growth occurs at 0.125 µg/ml of lysostaphin in both cases. For CHAPK, the degree of bacterial 
growth is reduced at 32 °C, at sub-MIC concentrations (i.e. 32 µg/ml); however, the MIC 
remains at 64 µg/ml as shown by complete inhibition of bacterial growth. The purpose of this 
study was to ensure that the endolysins are able to elicit bacterial lysis at a reduced 
temperature, which has been proven in both cases. In fact, the apparent increase in 
bacteriostatic activity of CHAPK at 32 °C may provide a more challenging evaluation of the 
thermoresponsive system employed, owing to the fact that a smaller proportion of CHAPK 
released from the nanoparticles at the lower temperature, compared to 37 °C, would 
potentially manifest as a reduction in bacterial cell count, thus reducing the observed 
thermoresponsive behaviour of the system.   
 
5.5 Conclusions and Future Work 
The research published in the preceding article describes the development of a novel 
enzybiotic cocktail, which has been employed in a stimuli-responsive, polymeric carrier 
matrix. To date, this is the first example (to the best of the author’s knowledge) of the 
incorporation of a phage-encoded endolysin into a triggered release system. The study builds 
on the research presented in Chapter 4 via the acquisition of quantitative data, 
demonstrating statistically significant bacterial lysis of MRSA from thermally responsive 
PNIPAM nanoparticles. Owing to time constraints it has not been possible to deduce the exact 
mechanism of enzyme immobilisation/ encapsulation. However, similar studies aimed at 
encapsulation of various drug molecules within PNIPAM polymer networks (including 
particles), have also demonstrated effective diffusion-mediated entrapment. PNIPAM 
nanoparticles copolymerised with allylamine and acrylamide have been successfully loaded 
with doxorubicin by means of physical entrapment over a 3 day period via continuous 
stirring in buffer solution 56. A possible explanation for the apparent immobilisation of both 
drugs and proteins within PNIPAM particles may involve electrostatic interactions between 
the drug/protein and the polymer chains 57. Proteins (in this case antimicrobial enzymes), 
consist of multiple amino acids which, depending on pH, may contain charged side chains. At 
physiological pH certain amino acids are protonated (such as lysine and histidine) and others 
are deprotonated (glutamate and aspartate). Whilst it is challenging to predict the overall 
charge on the surface of a protein from amino acid sequence alone (as pKa values of isolated 
amino acids differ to those in a folded protein), the variation in amino acid structure 
(resulting in the presence of both cationic and anionic groups), often results in areas of 
localised charge which can interact with the external environment. The synthesised PNIPAM 
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nanoparticles (designed to house the antimicrobial enzymes), are likely to contain 
protonated amine groups at pH 7 (as a result of copolymerisation with allylamine), which are 
able to facilitate electrostatic interactions with the anionic amino acid side chains located 
within the structure of the enzybiotics. Additionally, the use of a radical initiator during the 
precipitation polymerisation may result in the incorporation of carboxyl and sulphate groups 
within the polymer chains, providing small areas of localised negative charge 58. This may 
promote additional polymer-protein interactions, resulting in electrostatic retention of the 
immobilised proteins following diffusion into the carrier matrix. The collapse of the polymer 
chains above the LCST initiates in a change in polymer structure from a random coil to a 
hydrophobic globule. The contraction of the polymer chains then forces the expulsion of the 
hydrophilic proteins from within the polymeric matrix into the surrounding environment.  
 
Alongside deducing the mechanism of entrapment, the long term stability of the immobilised 
enzymes should be established in order to assess the clinical potential of the system, both in 
terms of longevity and storage requirements. Many of the factors associated with the 
development of this technology are in keeping with those discussed in Chapter 4, with some 
additional considerations.  
 
5.5.1 Bacterial Resistance 
As discussed in Chapter 3, there are currently no identified examples of resistance 
mechanisms towards phage-encoded endolysins. However, there is some concern 
surrounding the therapeutic use of lysostaphin. Lysostaphin-resistant S. aureus isolates have 
occasionally been reported in vitro and in vivo, potentially limiting the suitability of this 
particular peptidase for therapeutic treatment 59. Resistance towards lysostaphin is reported 
to occur as a result of mutations in the femA gene, which is responsible for the addition of the 
second and third glycine residues in the pentaglycine bridge of staphylococcal peptidoglycan, 
resulting in monoglycine cross bridges (thus removing the target site of lysostaphin). 
Interestingly, numerous studies documenting the occurrence of lysostaphin resistance also 
demonstrate restoration of methicillin susceptibility 60,61. Additionally, lysostaphin resistance 
is accompanied by a significant reduction in the fitness of the host, including decreased 
virulence and decreased growth rate. In one study this resulted in the resistant variants being 
outcompeted in cocultures by their wild-type parental strain 62.  Therefore, it has been argued 
that the emergence of resistant isolates during lysostaphin therapy would result in less 
virulent infections which are easily treatable with β-lactam antibiotics (removing the 
necessity to administer valuable, last-resort antibiotics in the first instance). Nonetheless, any 
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potential for the development of resistance (regardless of the mode of treatment: topical, 
systemic etc.), should be fully evaluated. The use of an enzybiotic cocktail may alleviate some 
of the concerns surrounding the development of resistance to lysostaphin; however this 
should be tested and quantified.  
 
5.5.2 Immunogenic Response 
In addition to any immune/cytotoxic response arising as a result of the surface anchored 
polymer particles (Chapter 4), any immunogenic effects of the enzybiotic cocktail should be 
established. There is limited experimental data surrounding the immunogenicity of phage-
encoded endolysins, however some studies have indicated that lysin administration can 
result in the formation of antibodies, yet the production of such immune complexes has thus 
far exhibited minimal effect on the efficacy of lysin treatment 63,64. A recent phase I clinical 
trial of the phage-encoded endolysin SAL-200 (based on a recombinant form of the phage-
encoded endolysin SAL-1, derived from the staphylococcal phage SAP-1), analysed anti-SAL 
antibody levels following intravenous administration. The results illustrated the presence of 
serum antibodies in 37% of the participants, however no serious adverse effects were 
observed and the endolysin retained clinical efficacy 65.  
 
In contrast, the immunogenic profile of lysostaphin as a potential therapeutic agent for the 
treatment of staphylococcal infection in animals and humans has been widely investigated. 
Consequently, there is a mounting body of evidence to suggest that lysostaphin elicits a 
potent immune response in animal models (small animal and non-human primates) and in 
humans 66. The formation of lysostaphin-antibody immune complexes in vivo (as a result of T 
cell activation and immunoglobulin G antibody production), has thus far hindered the 
therapeutic development of lysostaphin. However, recent efforts focused on mutagenic 
deletion of immunogenic T cell epitopes (responsible for antibody recognition), have 
demonstrated promising results in the production of deimmunised lysostaphin variants, 
exhibiting enhanced antimicrobial activity whilst evading immune surveillance 67,68. This may 
prove a promising strategy in the engineering of antimicrobial proteins with reduced 
immunogenic properties.  
 
Part B: Chapter 5 
215 
 
5.5.3 Increasing the Therapeutic Window 
The reported increase in skin temperature as a result of infection (and the corresponding 
polymeric release of antimicrobial enzymes), exists as a transitional process across a 
temperature gradient of approximately 4 °C. This relatively small therapeutic window may 
limit the use of such a system, owing to certain environmental factors which may contribute 
to an increase in skin temperature. Furthermore, the transitional collapse of the polymeric 
nanoparticles could potentially facilitate partial release of the therapeutic cargo at 
temperatures not associated with infection. A potential solution may involve raising the 
temperature at which the nanoparticles collapse, to a point which is irrespective of either 
healthy or infected skin temperature, but may be manually induced. For example, PNIPAM-
co-acrylamide-co-allylamine nanoparticles have been synthesised (of varying sizes depending 
on surfactant concentration), which exhibit a sharp phase transition at 40 °C 56. Subject to the 
positive diagnosis of infection (an indication of which could be achieved via co-incorporation 
of a diagnostic platform, as demonstrated by Thet et al 69), external application of a heating 
element such as a heat pad, would raise the external temperature of the dressing, forcing the 
nanoparticles to collapse, thereby releasing the antimicrobial cargo contained within.  
 
5.5.4 Increasing the Lytic Spectrum 
The enzybiotic cocktail presented in this research utilises two peptidoglycan hydrolase 
enzymes, both of which are ineffective against Gram-negative bacteria. The specificity of 
CHAPK and lysostaphin limit their application in polymicrobial infections. Predominantly 
effective against staphylococcal species, the utilisation of such an antimicrobial cocktail 
would rely on successful identification of the pathogens responsible for infection. However, 
as discussed in Chapter 3, protein engineering has provided a means of extending the 
antimicrobial spectrum of endolysins to include Gram-negative species 70. Utilisation of lysins 
active against both Gram-positive and –negative bacterial species would greatly enhance the 
versatility of this system, especially when considering chronic wound infections which may 
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“A conclusion is the place where you got tired thinking”. 
 
Martin H. Fischer – Physician, renowned for his teachings in the art and practice of medicine. 
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The Role of Biotechnology in the Prevention and Treatment of 
Infection 
 
The timely detection and effective treatment of hospital-associated infection will be of 
paramount importance in the future prevention of infectious disease. In the USA alone, 1 in 
25 hospitalised patients will develop an infection directly related to their medical care at any 
given time, resulting in over 1 million infections annually, costing over $30 billion 1. In 
Europe, over 4 million people acquire a healthcare-associated infection each year, ~37,000 of 
which result in death. As such, there has been a substantial increase in the number of global 
incentives aimed at combating such (arguably) avoidable infections. The significant 
investment and dissemination of global epidemiology surveillance data in recent years has, to 
some extent, alleviated certain aspects related to hospital-associated infections. For example, 
from 2011 – 2014 the number of HA-MRSA bacteraemia infections in the USA decreased by 
13% 2, and from 2009 – 2012 the number of death certificates citing MRSA as the underlying 
cause of death in England and Wales decreased by 32% 3. However, a recent report published 
by the WHO (September 2017), highlights a significant lack of novel antibiotics under 
development, especially for infections posing the greatest threat to health 4. Furthermore, of 
the 51 antibiotics and 11 biologics in clinical trials, it is estimated that only 10 will be granted 
approval over the next 5 years, suggesting a distinct void in the developmental pipeline for 
treatment of priority resistant organisms.       
 
There can be little doubt that efficient monitoring of potentially pathogenic microorganisms 
will play a crucial role in retaining the efficacy of current treatment options. The successful 
clinical detection of infectious agents (prior to the onset of various disease states), will not 
only reduce the ever-increasing burden on healthcare services worldwide, but will also 
prevent the unnecessary administration of increasingly valuable ‘last-line’ treatment 
strategies, thus controlling the spread of both infection and microbial resistance. The 
specificity of biological entities (such as enzymes or antibodies) has facilitated their 
development as efficient biosensors for proteinaceous contamination (including both viral 
and microbial). For example, there are currently a number of clinical biosensors for the 
detection of the causative agents responsible for a range of infectious diseases, including 
influenza, HIV, malaria, tuberculosis, various E. coli and Group A and B streptococcal 
infections and of course, residual surface contaminants responsible for a range of spongiform 
encephalopathies 5. The development of biosensor technology is an encouraging prospect in 
the prevention of infection, especially in the healthcare setting where time is of the essence 
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and conventional diagnostics (i.e. PCR) are often time consuming, expensive and require 
specialist equipment and skills beyond those of the primary care clinician.        
 
The implementation of biological therapeutics for the treatment of infection has undergone 
significant development in recent years. Advances in genetic and protein engineering have 
paved the way for enhancing the activity, stability, and clinical application of various 
biologically-inspired antimicrobials. Indeed, of the new antimicrobial candidates currently 
undergoing clinical trials, all of the biologics are considered innovative, owing to their unique 
MOA, which is in direct contrast to the meretricious antibiotics also undergoing clinical 
assessment. Amongst the developmental biotherapeutics (predominantly consisting of 
monoclonal antibodies), two phage endolysins; CF-301 (discussed in Chapter 3) and SAL-200 
(discussed in Chapter 5), are in currently in phase II trials, both of which have demonstrated 
potent activity against priority pathogens (as defined by the WHO). The utilisation of 
biological therapeutics in order to expand the seemingly limited arsenal of effective 
antimicrobial treatment options (especially those effective against MDR infections), is a 
promising strategy, albeit still very much in its infancy. However, the utilisation of nature’s 
own evolutionary-defined antimicrobials (potentially exhibiting some modifications, courtesy 
of modern synthetic biology), alongside conventional antibiotics as an adjunctive therapy, 
may hold the key for the future of antimicrobial therapy.  
 
Whilst it cannot be denied that new and novel treatment options are desperately required for 
future infection control; the translation of such technology from bench to bedside will 
undoubtedly rely on global collaboration in order to meet the current clinical standards 
required. Such collaboration, not only from scientists, but also from regulatory/ approval 
bodies, clinicians and governments worldwide will be of the utmost importance in the 
successful implementation of viable and effective alternative treatment options. The potential 
advancement of biological therapeutics will depend heavily on securing investment for the 
often lengthy clinical approval process. Nonetheless, this is an exciting time for the 
development of antimicrobial biotechnology which, in light of the relentless increase in 
antibiotic resistance, may be the difference between progression into the future of infection 
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